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ABSTRACT 
Bacterial infections are a leading cause of mortality and morbidity. Many species of 
pathogenic bacteria secrete pore-forming toxins to damage eukaryotic cells and 
facilitate pathogen invasion. Although cells can repair this damage, little is known 
about the intrinsic protection of cells against these toxins. Side-chain oxysterols and 
steroids can reduce the severity of bacterial diseases by suppressing immunity. Here 
we tested the hypothesis that oxysterols and steroids might also enhance the intrinsic 
protection of eukaryotic cells against pore-forming toxins. We first used the 
cholesterol-dependent cytolysin pyolysin, which forms pores in bovine endometrial 
cells. We found that 25-hydroxycholesterol or 27-hydroxycholesterol treatment 
protected bovine endometrial cells against pyolysin, and that these oxysterols are 
present in the reproductive tract. The oxysterols reduced pyolysin-induced leakage of 
potassium and lactate dehydrogenase by > 65%, limited changes to the actin 
cytoskeleton, and prevented cytolysis. The oxysterols also protected human cervical, 
lung, and liver epithelial cells against pyolysin damage, and protected cells against 
Staphylococcus aureus α-hemolysin. Mechanistically, oxysterol cytoprotection was 
partially dependent on activating acetyl-coenzyme A acetyltransferase and liver X 
receptors. The steroids, progesterone, oestradiol, or hydrocortisone were not protective 
in bovine endometrial cells. However, hydrocortisone and dexamethasone protected 
several types of human cells against pyolysin, reducing cytolysis from > 75% to < 
25%, via a glucocorticoid receptor dependent mechanism. Treatment with these 
glucocorticoids also protected human cells against α-hemolysin and another 
cholesterol-dependent cytolysin, streptolysin O. However, glucocorticoid 
cytoprotection was reversibly blocked by the presence of ≥ 4% serum, which led to 
the discovery that glucocorticoid cytoprotection depended on the rate limiting enzyme 
of cholesterol biosynthesis, 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase. In 
conclusion, side-chain oxysterols and glucocorticoids enhance the intrinsic protection 
of eukaryotic cells against pore-forming toxins. These findings imply that oxysterols 
and glucocorticoids could help limit the severity of disease caused by pathogens that 
secrete pore-forming toxins.  
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1 INTRODUCTION 
1.1 GENERAL INTRODUCTION 
Pore-forming toxins perforate eukaryotic cell plasma membranes resulting in target 
cell lysis, the release of molecules that bacteria can use as nutrients, as well as enabling 
the delivery of additional bacterial virulence factors. In this way, pore-forming toxins 
promote pathogen growth, facilitate dissemination through host tissues, and cause 
tissue pathology (Peraro and van der Goot, 2016). The most common family of pore-
forming toxins are cholesterol-dependent cytolysins, which bind to cholesterol in the 
plasma membrane of target cells (Tweten, 2005). These cytolysins form stable pores 
that cause the leakage of potassium ions within minutes, changes in cell shape and 
structure, and leakage of cytosolic proteins within 2 h, ultimately resulting in cytolysis 
(Gonzalez et al., 2011).  
Increasing the tolerance of cells to pore-forming toxin damage can limit the severity 
of disease without decreasing the pathogen burden (Schneider and Ayres, 2008, 
Medzhitov et al., 2012). Changes in cytosolic molecular concentrations in response to 
pore formation trigger a variety of secondary reparative responses to improve cell 
survival, such as mitogen-activated protein kinase (MAPK) activation and cytoskeletal 
remodelling (Gonzalez et al., 2011, Brito et al., 2019). However, tolerance can also be 
achieved through damage prevention. Treating cells with certain chemical compounds, 
such as statins and cyclodextrins, can reduce cellular cholesterol and increase the 
intrinsic protection of cells against pore-forming toxins in a process termed 
cytoprotection (Amos et al., 2014, Griffin et al., 2017). 
Oxysterols, the ovarian sex steroid hormones, oestradiol (estra-1, 3, 5 (10) -triene-3, 
17β-diol) and progesterone (pregn-4-ene-3, 20-dione), and glucocorticoids are thought 
to act via their cognate nuclear receptors to modulate the risk of diseases caused by 
bacteria that secrete pore-forming toxins (Abrams et al., 2020, Reboldi et al., 2014, 
Lewis, 2003, Stern et al., 2017). Therefore, we wondered whether steroids and 
oxysterols might alter intrinsic cell protection against pore-forming toxins. 
This thesis will focus on intrinsic protection against pyolysin, a cholesterol-dependent 
cytolysin secreted by Trueperella pyogenes that damages the bovine endometrium 
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contributing to the severity of uterine disease. We will examine the effect of 
progesterone, oestradiol, glucocorticoid, and oxysterol treatment on the pyolysin-
induced cytolysis of bovine endometrial cells. We will then explore the extent of 
cytoprotection in a range of human cell types and investigate the mechanisms 
involved. Identifying protective mechanisms can inform strategies to prevent or limit 
the severity of disease caused by pathogens that secrete pore-forming toxins.  
The present chapter will review current literature, commencing with an overview of 
bacterial pore-forming toxins before focusing on cholesterol-dependent cytolysins and 
the toxins used throughout this thesis (pyolysin, streptolysin O, and α-hemolysin). 
Subsequently, we will outline the consequences of membrane pore formation and 
mechanisms of damage repair. We will then discuss strategies to reduce disease 
severity by increasing cell tolerance and outline the rationale behind exploring the 
effect of oxysterols and steroids on cell protection.  
1.2 PORE-FORMING TOXINS 
Bacterial infections are a leading cause of global mortality and morbidity, particularly 
impacting the world’s most vulnerable populations (Diseases and Injuries, 2020). For 
example, lower respiratory tract infections accounted for over 2 million deaths in 2016, 
with > 1 million attributed to Streptococcus pneumoniae (Khang and Collaborators, 
2018). Additionally, a review in 2005 identified more than 750 million Streptococcus 
pyogenes infections globally per annum, with over 500,000 deaths caused by severe 
disease (Carapetis et al., 2005). Infection of domesticated animals with bacteria such 
as T. pyogenes and Staphylococcus aureus also impacts human well-being through loss 
of food security, treatment/prevention costs, or sustaining and expanding the 
prevalence of drug-resistant strains (Ribeiro et al., 2015, Wulf and Voss, 2008).   
Pore-forming toxins are proteins with an ability to transform from a water-soluble form 
to a membrane-inserted form thereby perforating membranes, killing target cells, 
releasing nutrients, and facilitating the delivery of additional bacterial toxins (Parker 
and Feil, 2005, Geny and Popoff, 2006). Pore-forming toxins are commonly associated 
with majorly pathogenic and even drug-resistant bacterial strains (Los et al., 2013). 
They account for around one third of all toxins released across both Gram-positive and 
Gram-negative bacteria, making them the most common bacterial virulence factor 
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(Los et al., 2013). Furthermore, without pore-forming toxins the virulence of many 
bacterial species is reduced (Kho et al., 2011, Amos et al., 2014, Limbago et al., 2000).  
Various host cell receptors have been identified as the target for toxin binding such as 
glycosylphosphatidylinositol-anchored proteins, a disintegrin and metalloprotease 10 
(ADAM10), C-C chemokine receptor type 5, glycans, cholesterol, and other lipids 
(Wilke and Bubeck Wardenburg, 2010, Alonzo III et al., 2013, Giddings et al., 2003, 
Shewell et al., 2020).  Once bound, pore formation begins with the organisation of 
proteins into a pre-pore oligomeric structure. Following a complex conformational 
change, membrane spanning residues insert into the lipid bilayer. The resulting pores 
range from 0.5 to 100 nm in diameter depending on the toxin (Parker and Feil, 2005).  
Pore-forming toxins can be characterised into two large groups; α-pore-forming toxins 
and β-pore-forming toxins, split according to the secondary structure of their pore-
forming domain as demonstrated in Fig 1.1 (Dal Peraro and van der Goot, 2016, 
Gouaux, 1997). In most α-pore-forming toxins, α-helices are inserted into the 
membrane during pore formation and the pore-forming domain consists of a 
hydrophobic helical hairpin buried between two amphipathic layers of α-helices 
(Cosentino et al., 2016). The α-pore-forming domain typically contain many residues 
that have a large hydrophobic content. Hydrogen bonds keep the helical structure 
stable in the membrane. α-pore-forming toxins can permeate membranes in their 
monomeric form, resulting in pores that are formed in a more dynamic and less defined 
manner than those formed by β-pore-forming toxins  (Cosentino et al., 2016). In β-
pore-forming toxins, oligomerization generates a transmembrane β-barrel that lines the 
pore. Each oligomer subunit comprises of 1 to 2 β-strands that contribute to the overall 
cylindrical structure in the lipid membrane (Bischofberger et al., 2012). Not all pore-
forming toxins can be perfectly classified into α and β subfamilies. The repeats-in-
toxin family are not always categorised in this manner due to difficulties in 
crystallographic analysis (Dal Peraro and van der Goot, 2016). Further characterisation 
is provided by the Transporter Classification Database, which separates pore forming 
toxins into over 100 separate subfamilies. The major families and their classification 
are outlined in Table 1.1. Whilst there are many pore-forming toxins, to study 
cytoprotection in the present thesis we challenged cells with pyolysin and streptolysin 
O, members of the large cholesterol-dependent cytolysin family of pore-forming 
4 
 
toxins. We also examined protection against S. aureus α-hemolysin, a toxin that does 
not specifically rely on cholesterol for cytolysis and forms pores of a smaller diameter.  
 
Figure 1.1 The two major classes of pore-forming toxins  
(A) α-helical pore-forming toxin oligomer exemplified by the cytolysin A from 
Escherichia coli. (B) β-barrel pore-forming toxin oligomer exemplified by the anthrax 
toxin protective antigen pore from Bacillus anthracis (Omersa et al., 2019). 
Table 1.1 Classification of pore-forming toxin families 
The major families of pore forming toxins. Toxins used in this project are highlighted 
in bold (adapted from Dal Peraro and van der Goot (2016). 
Family  Class Example toxins 
Colicins α Colicin E1, Colicin A, Colicin N 
Actinosporin α Equinatoxin II, Sticholysin II, 
Fragaceatoxin C 
Cytolysin A  α Cytolysin A, Non-haemolytic tripartite 
enterotoxin, Haemolysin BL 
Hemolysin β α-hemolysin, γ-hemolysin, leukocidins 
Aerolysin β Aerolysin, α-toxin, ε-toxin, Enterotoxin 
Cholesterol-dependent 
cytolysins 
β Perfringolysin O, Pneumolysin, 
Streptolysin O, Pyolysin 
Membrane attack complex 
component/ perforin 
(MACPF) 
β Plu-MACPF, Bth-MACPF 
Repeats-in-toxin ? Bifunctional haemolysin-adenylyl 
cyclase toxin 
A B 
5 
 
1.3 CHOLESTEROL-DEPENDENT CYTOLYSINS 
Cholesterol-dependent cytolysins are mainly produced by pathogenic Gram-positive 
bacteria (Heuck et al., 2010). Over twenty species of the genera Clostridium, 
Streptococcus, Listeria, Bacillus and Arcanobacterium (including T. pyogenes and S. 
pyogenes) synthesise cholesterol-dependent cytolysins to disrupt target cell plasma 
membranes and facilitating bacterial invasion via the formation of pores with a 
diameter of 30 to 50 nm (Tweten, 2005). Like the name suggests, membrane 
cholesterol is important for cholesterol-dependent cytolysin function, as first reported 
by Hewitt and Todd (1939), where preincubation of streptolysin O with free 
cholesterol inhibited hemolytic activity.  
1.3.1 Plasma membrane cholesterol 
Plasma membrane structure 
Eukaryotic cells are encapsulated in a protective plasma membrane that protects the 
intracellular contents from the surrounding environment (Fig 1.2). To understand how 
cholesterol-dependent cytolysins interact and perforate the plasma membrane, it is 
important to understand plasma membrane structure. A bilayer composed of four 
major phospholipids: phosphatidylcholine, phosphatidylethanolamine, 
phosphatidylserine, and sphingomyelin provides the structural integrity of the plasma 
membrane (Cooper, 2000). This bilayer is draped over a cytoskeleton that consists of 
actin, septin and other microtubule networks and provides a scaffold for various 
membrane components (Koster and Mayor, 2016, Bezanilla et al., 2015).   The external 
surface of the membrane predominantly consists of phosphatidylcholine and 
sphingomyelin, whereas the inner layer mainly contains phosphatidylethanolamine 
and phosphatidylserine (van Meer et al., 2008, Cooper, 2000). The interior of the 
bilayer contains the hydrophobic fatty acid chains of the phospholipids creating a 
membrane that is impermeable to water-soluble molecules (van Meer et al., 2008).   
The phospholipid bilayer also contains glycolipids and cholesterol. Glycolipids are 
lipids with a carbohydrate attached by a glycosidic bond found exclusively on the 
external membrane surface (Curatolo, 1987). They are relatively minor membrane 
component that contributes to cell stability and recognition (Yamakawa and Nagai, 
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1978). On the other hand, cholesterol is the most abundant plasma membrane lipid and 
must be present in the target cell membranes for cholesterol-dependent cytolysin pore-
formation (Giddings et al., 2003).  Cholesterol orientates in the biological membrane 
perpendicular to the lipid bilayer. The hydroxyl group at the 3β position of the 
cholesterol molecule is positioned where water meets the membrane and the 
cholesterol side chain points towards the hydrophobic interior of the bilayer (Yeagle, 
1985).  
Plasma membrane lipids are organised into a variety of different sub compartments, 
as specific lipids interact preferentially with one another (Singer and Nicolson, 1972, 
Simons and Vaz, 2004, Sezgin et al., 2017). For example, cholesterol preferentially 
associates with saturated lipids, such as sphingomyelin (Slotte, 1999, Barenholz and 
Thompson, 1980). These cholesterol and sphingomyelin-enriched nanodomains range 
from 10 to 200 nm in diameter and are termed lipid rafts (Pike, 2006, Sezgin et al., 
2017).  
Whilst lipids provide the structural integrity of the eukaryotic cell plasma membrane, 
proteins are bedded within the phospholipid bilayer to carry out specific cellular 
functions. Transmembrane proteins span the membrane, typically functioning as a 
transport gateway. Additionally, a different variety of proteins are anchored to the 
plasma membrane via covalently attached lipids (Ray et al., 2017). These attachments 
range from simple fatty acids to complex glycosylphosphatidylinositol (GPI) anchors. 
The lipid modifications control a diverse range of critical cell functions including 
membrane signalling and trafficking (Resh, 2006).   
 
Figure 1.2 Structure of the plasma membrane 
Diagram of a eukaryotic cell plasma membrane displaying key structures of interest. 
Created with BioRender.com. 
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Interaction between cholesterol-dependent cytolysins and membrane cholesterol 
The 3β-hydroxy group, the stereochemistry of the sterol ring system, and the side-
chain stemming from carbon 17 are thought to be the key features of the cholesterol 
molecule that interact with cholesterol-dependent cytolysins (Prigent and Alouf, 
1976). However, the 3β-hydroxy group is small relative to the head groups of 
phospholipids, remaining relatively hidden and complexed in the membrane in the 
presence of excess phospholipids. When the concentration of cholesterol exceeds 35 
mol% (molar percentage) of total membrane lipids there is increased surface exposure 
of the cholesterol molecule, permitting cholesterol-dependent cytolysin binding (Das 
et al., 2013). Conversely, depleting cellular cholesterol reduces the accessibility of 
plasma membrane cholesterol to cholesterol-dependent cytolysins.  
Using a mutant version of perfringolysin O labelled with 125I, that binds but does not 
form pores in mammalian cells, Das et al. (2014) identified three separate ‘pools’ of 
plasma membrane cholesterol. The cholesterol that accumulates in the presence of 
excess cholesterol, allowing cholesterol-dependent cytolysin binding was termed the 
‘labile pool’ and is referred to as accessible cholesterol throughout the present thesis. 
The cholesterol in-accessible to the mutant perfringolysin O was then split into two 
further ‘pools’.  The first of these ‘pools’, termed the ‘sphingomyelin-sequestered 
pool’, refers to the cholesterol that is typically sequestered in complexes with 
sphingomyelin and only became available for cholesterol-dependent cytolysin binding 
after sphingomyelin was destroyed by sphingomyelinase (Das et al., 2014, Endapally 
et al., 2019, McConnell and Radhakrishnan, 2003). Finally, a ‘residual pool’ of 
cholesterol was not available for cholesterol-dependent cytolysin binding even after 
sphingomyelinase treatment. The ‘residual pool’ of cholesterol is vital formembrane 
stability and depleting it compromises cell morphology and viability (Das et al., 2013).  
Although the importance of membrane cholesterol in cholesterol-dependent cytolysin 
function is clear, there are indications that additional cellular receptors may exist. 
Intermedilysin, a cholesterol-dependent cytolysin secreted by Streptococcus 
intermedius, uses cluster of differentiation 59 as a binding receptor (Dowd et al., 
2012). When cholesterol-depleted human red blood cells were exposed to 
intermedilysin, the initial membrane interaction and pre-pore assembly could occur 
without the presence of cholesterol, though cholesterol is required for pore insertion 
(Hughes et al., 2009). Additionally, a recent study by Shewell et al. (2020) 
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demonstrates that cholesterol-dependent cytolysins also use glycans such as 
glycolipids, glycoproteins and GPI-anchored glycoproteins as cellular receptors in an 
independent mechanism to cholesterol.  All the cholesterol-dependent cytolysins 
screened bound to glycans, although with varying specificity. For example, 
lectinolysin bound to a single structure, whereas streptolysin O and perfringolysin O 
interacted with a broad range of glycans (Shewell et al., 2020). 
1.3.2 Pore formation 
The cholesterol-dependent cytolysin molecule typically consists of four distinct 
domains (Fig 1.3A). Domain 4 consists of two four-stranded beta-sheets that are 
interconnected into four loops: three short loops and a longer highly conserved 
tryptophan-rich undecapeptide loop. These loops insert into the membrane upon 
binding and are responsible for cholesterol-toxin interaction that stimulates pore 
formation (Ramachandran et al., 2002, Farrand et al., 2010). A recent study by Shewell 
et al. (2020) has proposed that domain 4 initially interacts with glycoconjugate 
receptors to direct and accumulate the toxin monomers on the target cell surface. A 
pre-pore oligomer is developed via the lateral diffusion and association of cholesterol-
dependent cytolysin monomers linked by hydrogen bonding (Soltani et al., 2007). The 
entire cholesterol-dependent cytolysin oligomer assembly takes place in the pre-pore 
state, with oligomerization halted before pore insertion (Leung et al., 2014, Hotze and 
Tweten, 2012). Once the pre-pore oligomer is formed, there is a disengagement with 
the glycoconjugate receptors (Shewell et al., 2020), and the vertical collapse of domain 
1 and the buckling of domain 2 support the insertion of both transmembrane helices in 
domain 3 into the plasma membrane (Hotze and Tweten, 2012).  
Individual toxin monomers contribute to the overall β-barrel that inserts into the lipid 
bilayer (Rosado et al., 2008). However, a fully enclosed β-barrel is not necessary for 
the insertion of the transmembrane helices, and arcs formed from the incomplete 
oligomerization of cholesterol-dependent cytolysin monomers can still perforate the 
plasma membrane (Leung et al., 2014, Sonnen et al., 2014).   
Regardless of the extent of oligomerization, the inserted transmembrane helices 
compromise the integrity of the plasma membrane. The hydrophilic inner surface of 
the β-barrel destabilizes the lipid membrane encapsulated by the cholesterol-dependent 
cytolysin oligomer (Leung et al., 2014). As a result, lipids are expelled generating a 
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pore in the lipid bilayer (Leung et al., 2014). The consequences of this pore formation 
will be discussed in section 1.5.  
 
Figure 1.3 Cholesterol-dependent cytolysin membrane insertion 
(A) A crystal structure of perfringolysin O (B) Schematic representation of 
cholesterol-dependent cytolysin pore formation.  Binding is carried out through the tip 
of domain (D) 4. This initiates a conformational change of domain 2 that facilitates the 
insertion of the transmembrane helices (TMH) (Reboul et al., 2014). 
1.3.3 Thiol-activation 
Most crude cholesterol-dependent cytolysins are only active in a chemically reduced 
state. Activity is reversibly lost by oxidation (Billington et al., 2000). To restore 
activity, a thiol group (or other reducing agent) can be added (hence the term thiol 
activation). A thiol is an organosulfur compound that contains a carbon-bonded 
sulfhydryl (R-SH) group (R represents an organic substitute such as an alkyl). The 
necessity to become thiol activated is derived from a cysteine residue that is located 
within the conserved undecapeptide sequence (location shown in Fig 1.3). It is the 
oxidation of this residue that leads to the reduced activity, possibly by impairing of 
other crucial amino acids such as the three tryptophan residues that are found in the 
same location (Iwamoto et al., 1987). 
The need to be thiol-activated is not a characteristic of all cholesterol-dependent 
cytolysins. Pyolysin does not show any requirement for thiol activation and is not 
susceptible to any thiol blocking agents (Billington et al., 1997). It is clearly still a 
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cholesterol-dependent cytolysin though as it exhibits the same amino acid homology 
as other cholesterol-dependent cytolysins. However, in the afore mentioned 
undecapeptide sequence Alanine is substituted for the typical cysteine residue 
(Billington et al., 2000). 
1.3.4 Pyolysin and Trueperella pyogenes 
Pyolysin is a useful toxin for examining cholesterol-dependent cytolysins that forms 
pores in many types of mammalian cells. As thiol activation is not required, pyolysin 
is spontaneously active in vitro, easing experimental use. Pyolysin is secreted by 
Trueperella pyogenes; a Gram-positive, nonmotile, anaerobic species of bacteria that 
commonly resides in the urogenital, gastrointestinal, and upper respiratory tracts of 
cattle, goats, horses, musk deer, pigs, and sheep (Ribeiro et al., 2015). Trueperella 
pyogenes is an opportunistic pathogen that causes mastitis, abscesses, pneumonia, and 
endometritis (Jost and Billington, 2005). For example, T. pyogenes contributes to 
uterine disease in cattle. Reduced milk yield and infertility are resulting complications 
and cost the United States and European dairy industries a combined $2 billion 
annually (Sheldon et al., 2009). 
Parturition disrupts the protective endometrial epithelium of the bovine reproductive 
tract, exposing the underlying sensitive stromal cells (Amos et al., 2014). There is an 
upsurge in bacteria in the uterine lumen surrounding birth, with T. pyogenes, E. coli, 
and S. aureus commonly isolated from diseased animals (Bonnett et al., 1991, Sheldon 
et al., 2002). However, of all the bacteria located within the uterus following 
parturition, T. pyogenes is most associated with the severity of pathology (Bonnett et 
al., 1991, Westermann et al., 2010).  
Trueperella pyogenes secretes several virulence factors including neuraminidases, 
fimbriae, and collagen-binding proteins (Jost and Billington, 2005). However, most of 
the pathology and tissue damage surrounding uterine disease is associated with the 
secretion of pyolysin (Ribeiro et al., 2015). Indeed, it has been shown that a pyolysin-
deleted T. pyogenes mutant does not trigger bovine endometrial cell cytolysis (Amos 
et al., 2014). The biological significance of the interaction between pyolysin and the 
bovine endometrium in uterine disease informed the decision to use this as a model 
system to explore cell protection. 
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Pyolysin is a 55 kDa protein encoded by a gene that consists of 1,605 base pairs 
(Billington et al., 1997). A sequence based structural model demonstrates that pyolysin 
also consists of the typical four domains demonstrated by cholesterol-dependent 
cytolysins (Fig 1.4A), showing clear similarity with the structure of perfringolysin O 
(Fig 1.3A), the archetypal cholesterol-dependent cytolysin (Pokrajac et al., 2012). The 
isolated domain 4 of pyolysin binds to target cell membranes but also forms oligomers 
with itself (Pokrajac et al., 2013). Electron micrographs demonstrate that oligomerized 
pyolysin monomers form typical ring-shaped structures (Fig 1.4B).  
               
Figure 1.4 Pyolysin structure and oligomerization 
(A) Structural model of pyolysin based on the crystal structure of perfringolysin O. 
(B) Electron microscopy of pyolysin oligomers on cholesterol crystals; scale bar = 100 
nm (Pokrajac et al., 2013).  
1.3.5 Streptolysin O and Streptococcus pyogenes 
Streptococcus pyogenes is a Gram-positive bacterium that commonly colonises the 
skin and throat, causing a wide range of disease that significantly contributes to global 
morbidity and mortality (Wannamaker, 1970). Pathology takes the form of cellulitis, 
impetigo, scarlet fever, bacterial pharyngitis, and pneumonia, with severe invasive 
infections progressing to necrotizing fasciitis and streptococcal toxic shock syndrome 
(Cunningham, 2000).   
Streptolysin O is one of over twenty proteins secreted by Streptococcus pyogenes to 
enhance virulence (Alouf, 1980, Sierig et al., 2003, Bhakdi et al., 1985). Streptolysin 
O is a typical thiol-activated cholesterol-dependent cytolysin that interacts with 
cholesterol and multiple glycans in target bilayers (Shewell et al., 2020), and is 
regularly utilised to investigate cholesterol-dependent cytolysins (Babiychuk et al., 
A B 
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2009, Turner et al., 2020). Purified streptolysin O is lethal to mice and rabbits within 
minutes when injected intravenously (Barnard and Todd, 1940, Howard and Wallace, 
1953). Furthermore, mice infected with a mutant streptolysin O deleted Streptococcus 
pyogenes had a significantly higher survival rate than those infected with wild-type 
bacteria (Limbago et al., 2000). 
1.4 STAPHYLOCOCCUS AUREUS ALPHA-HEMOLYSIN 
Staphylococcus aureus is an opportunistic pathogen that is one of the leading causes 
of human bacterial infection, infecting the skin and soft tissues, the bloodstream and 
the respiratory tract (Lowy, 1998). Production of α-hemolysin (the archetypal toxin of 
a distinct family of pore-forming toxins; see Table 1.1) is key to the pathogenesis of 
sepsis, pneumonia, and severe skin infections (Bubeck Wardenburg and Schneewind, 
2008, Kennedy et al., 2010). Expression of α-hemolysin contributes directly to S. 
aureus virulence (Patel et al., 1987).  
A disintegrin and metalloprotease 10 is required for the cytolytic activity of α-
hemolysin, as the toxin interacts directly with ADAM10 in plasma membrane lipid 
rafts (Wilke and Bubeck Wardenburg, 2010). Seven α-hemolysin monomers 
oligomerize on the membrane surface to form a mushroom shaped complex as shown 
in Fig 1.5 (Song et al., 1996). The stem of the complex is initially folded and located 
within the cap, but is then dynamically inserted into the cell forming a transmembrane 
pore (Menestrina et al., 2001).  Pores vary in diameter from 1.4 to 2.8 nm throughout 
various points of the ‘stem’, and are selectively permeable for monovalent ions, 
excluding calcium (Song et al., 1996). Deoxyribonucleic acid (DNA) fragmentation 
and apoptosis are induced as a result (Bantel et al., 2001). However, at high 
concentrations, the toxin will bind non-specifically to the lipid bilayer of most 
eukaryotic cells (Hildebrand et al., 1991), forming larger pores that permit calcium ion 
influx in some cell types (Walev et al., 1993). 
13 
 
 
Figure 1.5 Staphylococcus aureus α-hemolysin oligomer 
(A) Side and (B) top views of the crystal structure of S. aureus α-hemolysin (Song et 
al., 1996, Berube and Bubeck Wardenburg, 2013). 
1.5 CONSEQUENCES OF PORE FORMATION 
Perforation of the plasma membrane by pore-forming toxins leads to an increase in 
membrane permeability, allowing the leakage of cytosolic content (Fig 1.6). The 
primary consequence of compromised membrane integrity is a change in cytoplasmic 
ion composition and a loss of membrane potential (Bischofberger et al., 2009). 
However, different pore-forming toxins form pores of varying sizes, triggering 
different responses in target cells (Bischofberger et al., 2012). The large pores formed 
by cholesterol-dependent cytolysins permit rapid calcium ion entry and potassium 
efflux as well as the leakage of molecules such as lactate dehydrogenase (LDH) and 
adenosine triphosphate (ATP) within 2 h (Hotze and Tweten, 2012, Gonzalez et al., 
2011, Bonfini and Buchon, 2016). Several secondary consequences are triggered by 
the changes in cytosolic molecular concentrations, promoting recovery and cell 
survival, and these will be described in detail in the next section (Gonzalez et al., 
2011). 
A 
B 
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Plasma membrane damage by pore-forming toxins can also trigger changes in cell 
shape within 15 min, such as the formation of large blebs (Keyel et al., 2011). As 
cellular structure declines, the internal hydrostatic pressure causes the actin 
cytoskeleton to decouple from the plasma membrane and individual bulges of the 
intracellular matrix protrude from the cell (Fackler and Grosse, 2008). 
Ultimately, a major consequence of pore-forming toxins is target cell cytolysis. 
Excessive pore formation leads to necrosis, partly due to the decreased intracellular 
ATP and potassium deregulating mitochondrial activity (Kennedy et al., 2009, Knapp 
et al., 2010). Lower toxin concentrations can activate a range of programmed cell death 
pathways such as apoptosis, pyroptosis (both caspase dependent), and necroptosis 
(caspase independent) (Lin et al., 2010). 
 
Figure 1.6 Consequences of pore-forming toxin pore formation 
A visual representation of the consequences of eukaryotic cell membrane perforation 
by bacterial pore-forming toxins. 
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1.6 CELL REPAIR 
Although high concentrations of pore-forming toxins can cause rapid cell cytolysis, 
throughout infection many cells are exposed to sublytic concentrations that initiate 
pro-survival responses in response to the changes in cytosolic molecular 
concentrations (Gonzalez et al., 2011, Bischofberger et al., 2012). Though several of 
these processes are described below and summarised in Fig 1.7, it is likely that more 
remain to be characterised.  
1.6.1 Membrane remodelling 
The influx of extracellular calcium ions following cholesterol-dependent cytolysin 
pore-formation activates cytoskeletal remodelling to reduce tension, facilitate vesicle 
recruitment, and promote membrane repair (McNeil and Steinhardt, 1997, Jimenez and 
Perez, 2017). Sustained cytosolic calcium concentrations activate various 
cytoskeleton-modulating enzymes, such as Ras-related C3 botulinum toxin substrate 
1, Ras homolog family member A and calpains, to break down actomyosin structures 
(Iliev et al., 2007, Ono and Sorimachi, 2012). Activated calpains break down 
interactions between actin and actin-binding proteins, separating the cytoskeleton from 
the plasma membrane (Redpath et al., 2014). Rab3 promotes continued actin 
remodelling, assisting lysosomes to bind and fuse to the plasma membrane 
(Encarnacao et al., 2016). Endoplasmic reticulum (ER) proteins translocate to the 
plasma membrane. The ER chaperone Gp96 interacts with the actin motor protein non-
muscle myosin II and the actin adaptor filament A regulating non-muscle myosin IIA 
cortical bundles and stabilizing the remodelling (Mesquita et al., 2017). 
Prolonged elevation of intracellular calcium can be toxic. Activated intracellular 
proteinases and phospholipases cause irreversible damage to the phospholipid bilayer 
and cytoskeleton (Geeraerts et al., 1991).   Therefore, mediating calcium ion influx 
appears crucial to determining cell fate and repairing the compromised membrane 
allows cells to recover from the disruption triggered by pore formation (McNeil and 
Kirchhausen, 2005). Indeed, streptolysin O permeabilization of THP-1 monocytes was 
shown to be reversible, with membrane resealing dependent on the presence of 
calcium; recovering cells remained viable for several days after the challenge and 
maintained their ability to proliferate (Walev et al., 2001). Several mechanisms 
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coalesce to  regulate calcium-dependent plasma membrane repair, in response to pore-
forming toxin damage and these are described below (Andrews and Corrotte, 2018).   
Calcium influx depolarises cortical actin and recruits components such as annexin A1 
to stabilize and repair damaged and blebbing membranes (McNeil et al., 2006). 
Annexin A1 links membrane either side of protruding blebs, generating a ‘plug’ or 
‘patch repair’. In this way, the compromised, pore containing membrane is separated 
from the rest of the cytoplasm, preventing further efflux of cytosolic content (Romero 
et al., 2017, Babiychuk et al., 2011). Blebbing cells appear more likely to recover from 
streptolysin O damage and inhibiting plasma membrane blebbing with blebbistatin 
increased the likelihood of cell lysis (Babiychuk et al., 2011, Keyel et al., 2011). 
Repaired blebs isolate surplus intracellular calcium and might be removed from the 
plasma membrane to spare the rest of the cell from further damage, though this is 
disputed (Babiychuk et al., 2009, Babiychuk et al., 2011). Andrews and Corrotte 
(2018) suggest that these large blebs do not detach from the membrane and simply 
reflect actin cytoskeleton disassembly. Much smaller vesicles (around 50 nm) can be 
shed in the process of membrane repair, but these are generated by the endosomal 
sorting complexes required for transport (ESCRT) pathway (Jimenez et al., 2014, 
Andrews and Corrotte, 2018, Wolfmeier et al., 2016).  
Endocytosis is another calcium-dependent reparative mechanism (Idone et al., 2008). 
Calcium sensors such as synaptotagmin VII, dysferlin, and N-ethylmaleimide-
sensitive factor attachment protein receptors trigger lysosomal exocytosis in response 
to pore formation (Rodriguez et al., 1997, Chakrabarti et al., 2003, Defour et al., 2014).  
Lysosomes release enzymes, such as acid sphingomyelinase. Sphingomyelin tends to 
cluster near cholesterol and so is likely to be adjacent to pore-forming toxin 
(specifically cholesterol-dependent cytolysin) pores (Truman et al., 2011). Acid 
sphingomyelinase hydrolyses sphingomyelin, forming ceramide rich plasma 
membrane invaginations termed caveolae (Corrotte et al., 2013). These caveolae 
promote pore-removal via endocytosis (Corrotte et al., 2012). Pore-containing 
endosomes undergo ubiquitination and interact with components of the ESCRT 
pathway as they enter the lumen of multivesicular bodies and are degraded (Corrotte 
et al., 2012).  
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Following the shedding or internalisation of pores, cells can return to original 
cytoskeletal organisation and establish normal cytosolic calcium concentrations. 
1.6.2 Mitogen-activated protein kinases 
The MAPK family, comprised of over 50 different proteins in mammals are involved 
in intracellular regulation in response to extracellular signals (Porta et al., 2011). They 
largely respond to stress, coordinating host cell survival, metabolism and proliferation 
(Cargnello and Roux, 2011). Activation of the MAPK pathways is augmented by the 
potassium efflux caused by pore-formation, triggering membrane repair and cell 
survival mechanisms (Porta et al., 2011, Kloft et al., 2009). Activated MAPKs can 
translocate to the nucleus and function as an enzyme, phosphorylating and activating 
transcription factors (McCain, 2013). Phosphorylation of p38 occurs imminently in 
response to a range of toxins including S. aureus α-hemolysin, streptolysin O, and 
pneumolysin, and wanes after several hours (Ratner et al., 2006, Husmann et al., 2006). 
Phosphorylation of the extracellular signal-regulated kinases 1 and 2 (ERK1/2) and c-
Jun (N)-terminal kinase (JNK) are also commonly identified (Stassen et al., 2003, 
Aguilar et al., 2009). Pyolysin challenge induces the phosphorylation of all three of 
these MAPKs in both bovine endometrial stromal and HeLa cervical cells (Preta et al., 
2015, Pospiech et al., 2021). Thus, the phosphorylation of p38, ERK1/2, and JNK will 
be examined in the present thesis.   
Activated p38 facilitates the recovery of original potassium ion concentrations 
following proaerolysin or listeriolysin O challenge, promoting cell survival (Gonzalez 
et al., 2011). Additionally, p38 up-regulates genes involved in the activation of the 
unfolded protein response (UPR) and the expression of cation efflux proteins (Bischof 
et al., 2008). Activation of the UPR by listeriolysin O stimulates lipid synthesis, 
potentially enhancing membrane repair and increasing the movement of vesicles 
between the ER and the Golgi (Cassidy and O'Riordan, 2013).  
The JNK pathway has been viewed as a key regulator of cellular defence to pore-
forming toxins, up-regulating innate immune signalling and p38 specific pathways via 
the activating protein-1 (AP-1) transcription factor (Kao et al., 2011).  Loss of either 
the p38 or JNK pathway can lead to a hypersensitivity to pore-forming toxins 
(Huffman et al., 2004).  
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Activation of ERK1/2 in response to insult by pore formation also contributes to cell 
survival by inducing the shedding of cell adhesion and intracellular-contact molecules, 
potentially assisting in the shedding of pores (Brito et al., 2019). Additionally, ERK 
activation contributes to the recovery of cellular ion homeostasis (Gonzalez et al., 
2011).  
1.6.3 Inflammasome activation and autophagy 
The decrease in intracellular potassium caused by a multitude of pore-forming toxins 
such as aerolysin, pneumolysin and S. aureus α-hemolysin can also trigger 
inflammasome assembly (Gurcel et al., 2006, McNeela et al., 2010, Soong et al., 2012, 
Witzenrath et al., 2011). Specifically, the Ipaf and Nalp3 inflammasomes are 
assembled in response to aerolysin pore formation and proceed to activate caspase-1 
and the sterol responsive element binding proteins (SREBPs) (Gurcel et al., 2006). The 
caspase-1 dependent SREBP activation results in an increase in cellular cholesterol 
that may improve cell survival (Gurcel et al., 2006). Downstream targets of caspase-1 
also include interleukin (IL)-1β and IL-18, pro inflammatory cytokines that play 
essential roles in innate and adaptive immunity (Dinarello, 1998), and both are secreted 
from cells in response to pore-forming toxin challenge (Walev et al., 1995, 
Meixenberger et al., 2010, Dunne et al., 2010).  
Autophagy is another defence mechanism against pore-formation, triggered by a drop 
in the cytosolic ATP / adenosine monophosphate (AMP) ratio that prompts AMP-
activated protein kinase phosphorylation. Phosphorylated AMP-activated protein 
kinase then initiates autophagy by inhibiting the target of rapamycin receptor complex 
1 (Stanfel et al., 2009), triggering the formation of autophagosomes (Gutierrez et al., 
2007). These autophagosomes interact with the endocytic pathway, forming 
autophagolysosomes by fusing with lysosomes, and degrade bacterial toxins 
promoting cell survival (Saka et al., 2007). Cells that cannot generate autophagic 
vacuoles in response to pore-forming toxins demonstrate a poorer prognosis, 
confirming a link between autophagy and cell survival (Gutierrez et al., 2007). 
Additionally, autophagy contributes to ER remodelling and helps remove and detect 
organelles damaged by pore-formation (Brito et al., 2019). 
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Figure 1.7 Mechanisms repairing the damage caused by pore-forming toxins 
Changes in cytosolic ion concentrations trigger a variety of pro-survival responses. (1) 
Calcium influx triggers cytoskeletal remodelling to reduce plasma membrane tension 
by activating cytoskeleton-modulating enzymes and triggering lysosome secretion. (2) 
Acid sphingomyelinase (ASM) released from lysosomes hydrolyses sphingomyelin to 
form ceramide-rich domains which facilitate the endocytosis of pores. Toxins are then 
trafficked to multivesicular bodies and degraded by lysosomes. (3) Increased calcium 
ion concentrations recruit annexins to damage sites clogging pores. The recruitment of 
ESCRT subunits facilitates the budding and release of pore-forming toxin containing 
vesicles. (4) Potassium ion efflux activates MAPK signalling, which controls the UPR 
and other protective responses. (5)  Decreased cytosolic potassium concentrations also 
trigger inflammasome assembly and caspase-1 activation. Downstream effects of 
caspase-1 include SREBP activation the secretion of IL-1β and IL-18. Created with 
BioRender.com. 
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1.7 PROTECTION AGAINST PORE-FORMING TOXIN DAMAGE 
The reparative processes discussed in section 1.7 can react to pore-formation and 
mediate cell damage, however, increasing toxin concentrations ultimately results in 
cell cytolysis. Alternatively, increasing intrinsic cell protection in advance of toxin 
challenge might reduce the severity of disease caused by pathogens that secrete pore-
forming toxins.  
1.7.1 Cell tolerance 
It is commonly assumed that resilience to infection is achieved by combatting invading 
pathogens directly (Medzhitov et al., 2012). Activation of the innate and adaptive 
immune response kills invading microbials and limits the number of pathogenic 
bacteria, though these pathways, termed resistance mechanism (McCarville and Ayres, 
2018). The innate immune response provides an immediate defence to pathogens that 
does not depend on prior exposure (Takeuchi and Akira, 2010). Cells use pattern 
recognition receptors to recognise pathogen-associated molecular patterns and trigger 
the secretion of inflammatory mediators that induce vasodilation, attract and activate 
immune cells, and induce the production of acute phase proteins and reactive oxygen 
species (Medzhitov and Janeway Jr, 2000). Adaptive immunity relies on prior 
exposure of T and B cells to specific antigens. Antigen presenting cells process 
pathogenic antigens and present them to T-cells triggering T cell activation. 
Subsequently, T cells detect and destroy infected cells, secrete cytokines, and activate 
B cells to commence antibody production (Bonilla and Oettgen, 2010). However, an 
immune response can be energetically expensive, requiring a 15% to 30% increase in 
resting metabolic rate (Lochmiller and Deerenberg, 2000). 
Avoidance mechanisms limit pathogen exposure with minimal metabolic cost and 
include intrinsic behaviours to maintain hygiene and avert diseased animals, possibly 
by identifying the odour of pathogens or infection (Curtis, 2007, Curtis, 2014). 
However, the effectiveness of avoidance mechanisms can depend on pathogen 
transmissibility and population density. 
Alternatively, survival can be achieved by limiting the consequential effects of an 
invasive microorganism. Cell tolerance (not immunological tolerance) is the ability to 
restrict the damage caused by pathogenic invasion without decreasing the pathogen 
burden (Schneider and Ayres, 2008, Read et al., 2008, Medzhitov et al., 2012). While 
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there is extensive knowledge about resistance mechanisms, research in the field of 
tolerance is still developing. Examples of tolerance mechanisms against bacterial 
pathogens include damage repair (including the pathways described in section 1.6) to 
help restore the integrity of compromised tissues and reprogramming cellular 
responses to help generate energy and substrates for tissue repair (Sheldon et al., 2020, 
Escoll and Buchrieser, 2018). Additionally, protecting cells against bacterial toxins is 
a mechanism of improving tissue tolerance that increases resilience. Protection implies 
defending or guarding against attack, injury, or damage. Protective mechanisms 
include physical barriers such as epithelial and mucus layers and neutralising toxins 
with antimicrobial peptides, acute phase proteins, and mucosal glycoproteins (Hein et 
al., 2002, Gruys et al., 2005, Epand and Vogel, 1999, Linden et al., 2008).  
Collectively these resistance, avoidance, and tolerance mechanisms combine to 
increase the resilience to bacterial infection and prevent or restrict the severity of 
disease (Fig 1.8) (Schneider and Ayres, 2008, Read et al., 2008).  
 
Figure 1.8 Mechanisms of achieving resilience to bacterial infection 
Resilience to infection is a product of the complementary strategies of avoidance, 
tolerance, and resistance. This cartoon displays the concept for each strategy (Sheldon 
et al., 2020). 
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1.7.2 Cell protection 
As mentioned above, protecting cells against pore-forming toxin damage is a potential 
method of increasing tissue tolerance to bacterial infection and reducing disease 
severity, though there is currently limited research in this field.  
Protection can be achieved by impairing pore-forming toxin function. Small molecules 
can bind to specific regions of toxin monomers, preventing pore-formation. For 
example, amentoflavone and verbascoside can bind between domains 3 and 4 on 
pneumolysin monomers inhibiting oligomerization (Zhao et al., 2017, Zhao et al., 
2016). Additionally, editing the availability of toxin binding receptors can prevent 
membrane interaction. Indeed, inhibiting ADAM10 (required for S. aureus α-
haemolysin binding) with GI254023X improves pathology (Kennedy et al., 2010).  
Pore-forming toxins can be neutralized by molecules with a high affinity to them; 
examples include β-sitosterol (a cholesterol mimic) and allicin (Li et al., 2015, 
Arzanlou and Bohlooli, 2010). Synthetic plasma membranes (termed liposomes) have 
been developed to draw cholesterol-dependent cytolysins away from their cellular 
targets, however, they suffer from a variety of drawbacks such as in vivo stability, 
immune clearance, and the need to alter their composition depending on the toxin 
(Henry et al., 2015). Stealth coatings have been used to disguise liposomes from 
immune cell clearance, however, these can result in off target immune effects 
(Immordino et al., 2006). 
Finally, protection can be achieved by treating cells with chemical compounds that 
increase intrinsic cell protection against pore-forming toxin damage, thereby 
improving tissue tolerance. This process is termed cytoprotection. Current research 
screening for cytoprotective agents has focused on reducing cellular cholesterol, as 
cholesterol is essential for cholesterol-dependent cytolysin pore-formation and most 
of the other molecules that act as pore-forming toxin binding receptors are located in 
cholesterol-rich lipid rafts (Fivaz et al., 2000, Fivaz et al., 1999). Treating cells with 
cyclodextrins depletes total cellular cholesterol, decreasing cholesterol-dependent 
cytolysin binding and pore formation (Giddings et al., 2003). For example, a 24 h 
treatment with > 0.1 mM methyl-β-cyclodextrin (MβCD) protected bovine 
endometrial cells against the cytolytic activity of pyolysin (Amos et al., 2014).  
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Statins also provide cytoprotection against cholesterol-dependent cytolysin damage by 
decreasing cholesterol synthesis through the inhibition of 3-hydroxy 3-methylglutaryl 
coenzyme A reductase (HMGCR) (Maron et al., 2000). Specifically, simvastatin 
confers bronchial and alveolar epithelial cells with resistance to pneumolysin damage 
and atorvastatin protected bovine endometrial stromal cells against pyolysin challenge 
(Statt et al., 2015, Griffin et al., 2017, Griffin et al., 2018). Additionally, inhibiting 
farnesyl diphosphate farnesyltransferase 1 (also known as squalene synthase) with 
zaragozic acid or bisphosphonates and treating cells with the isoprenoids farnesyl and 
geranylgeranyl pyrophosphate reduces cell cholesterol and provides protection against 
pyolysin damage (Griffin et al., 2017, Griffin et al., 2018, Pospiech et al., 2021). 
1.8 CHOLESTEROL 
As described above, cholesterol is an important focus of cell protection against pore-
forming toxins (particularly cholesterol-dependent cytolysins). The abundance of 
cellular cholesterol partially depends on cholesterol biosynthesis via the mevalonate 
pathway (Bloch, 1992).  Exogenous cholesterol can also be obtained through the LDL 
receptor mediated endocytosis of circulating plasma lipoproteins. These lipoproteins 
are then hydrolysed by endosomal lysosomes to provide free cholesterol (Brown and 
Goldstein, 1976, Brown and Goldstein, 1986).  Finally, cholesterol can be obtained 
from the cholesterol esters stored in lipid droplets via cholesterol ester hydrolase 
(Brown and Goldstein, 1976, Goldstein and Brown, 1990, Hu et al., 2010). 
Intracellular cholesterol is tightly controlled by feedback mechanisms involving 
SREBPs, the liver X receptors, and the enzyme acetyl-coenzyme A acetyltransferase 
(ACAT) (Brown and Goldstein, 1997, Edwards et al., 2002, Gill et al., 2008). 
1.8.1 Cholesterol biosynthesis 
The mevalonate pathway incorporates a series of enzymes that regulate cellular 
cholesterol biosynthesis (Goldstein and Brown, 1990, Bloch, 1965). Initially 
acetoacetyl-coenzyme A (CoA) is formed by condensing two acetyl-CoA molecules 
(synthesized from cytosolic acetate), and then converted to 3-hydroxy-3-methyl-
glutaryl-CoA (HMG-CoA) by HMG-CoA synthase (Fig 1.9). Mevalonate is then 
produced by HMGCR in the rate limiting step of cholesterol biosynthesis, before it is 
metabolised to isopentenyl pyrophosphate and subsequently dimethylallyl 
pyrophosphate. Farnesyl pyrophosphate is formed by a series of condensation 
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reactions catalysed by farnesyl pyrophosphate synthase (Miziorko, 2011). 
Specifically, dimethylallyl pyrophosphate and isopentenyl pyrophosphate condense to 
form geranyl pyrophosphate, which reacts with an additional unit of isopentenyl 
pyrophosphate yielding farnesyl pyrophosphate. This is a branch point of the pathway 
with subsequent reactions leading to the production of various end products. For 
example, geranylgeranyl pyrophosphate synthase converts farnesyl pyrophosphate to 
geranylgeranyl pyrophosphate, leading to the production of prenylated proteins. 
However, in the first specific step in cholesterol biosynthesis, squalene synthase 
converts farnesyl pyrophosphate to squalene, and subsequently lanosterol is produced 
by lanosterol synthase. A further series of reactions convert lanosterol to 7-
dehydrocholesterol, which is then reduced to form cholesterol (Bloch, 1965). Newly 
synthesised cholesterol and its precursors contribute to many biological pathways. 
Significantly, cholesterol is a precursor for vital metabolites such as bile acids, 
steroids, fat soluble vitamins, and oxysterols. 
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Figure 1.9 The mevalonate pathway  
A stepwise illustration of cholesterol synthesis from acetyl-CoA via the mevalonate 
pathway. The enzymes involved are labelled in red. 
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1.8.2 Cholesterol homeostasis 
Cells must avoid an excess accumulation of cholesterol as it can form toxic crystals 
and trigger apoptotic signalling pathways (Tabas, 2002). Although cholesterol itself 
plays the pivotal role, oxysterols feedback as auxiliary regulators functioning to 
maintain appropriate cellular cholesterol concentrations through several pathways (Fig 
1.10) (Gill et al., 2008).  
Intracellular cholesterol concentrations can be transcriptionally regulated by the ER-
bound SREBPs (Brown and Goldstein, 1997). There are three known isoforms of 
SREBP: SREBP-1a, SREBP-1c (are involved in fatty acid metabolism) and SREBP-
2 (involved in cholesterol and lipid synthesis). Initially residing in the ER, SREBPs 
are escorted to the Golgi apparatus by the SREBP cleavage-activating protein (SCAP) 
(Goldstein et al., 2006). The SREBP cleavage-activating protein contains a binding 
site for coat protein II (COPII) proteins which cluster the SCAP-SREBP complex into 
COPII coated vesicles that bud from the ER and fuse with the Golgi. In the Golgi, 
SREBPs undergo sequential proteolysis by the transmembrane enzymes Site-1 and 
Site-2 protease, yielding active fragments that enter the nucleus (Goldstein et al., 2006, 
Brown and Goldstein, 1999). Activated SREBPs control HMGCR along with the 
majority of the downstream mevalonate pathway enzymes (Sakakura et al., 2001). 
Additionally, SREBPs can increase LDL receptor transcription boosting exogenous 
cholesterol uptake (Brown 1990). The LDL receptor activity is inversely proportional 
to cellular cholesterol and so its synthesis is suppressed as sterols over accumulate 
(Brown and Goldstein, 1986). Cholesterol and oxysterols inhibit cholesterol synthesis 
by blocking SREBP activation. Cholesterol binds to SCAP, promoting the binding of 
SCAP to the ER anchor protein Insig (Radhakrishnan et al., 2004). Oxysterols bind to 
Insig-2 (Fig 1.10, 1), inducing Insig-SCAP binding (Radhakrishnan et al., 2007). As a 
result of Insig binding, the COPII proteins can no longer bind to SCAP and the SCAP-
SREBP complex can no longer move to the Golgi. 
The liver X receptors (LXRs) also contribute to maintaining cholesterol homeostasis 
and are activated by oxysterols to initiate cholesterol clearance (Fig 1.10, 2) (Willy et 
al., 1995). The two liver X receptor isoforms, LXRα (NR1H3) and LXRβ (NR1H2) 
share a 77% identity at the amino acid level and differ primarily on expression 
(Farnegardh et al., 2003). While LXRα is predominantly expressed in the liver, there 
are also high levels in the ovary and uterus; LXRβ is ubiquitously expressed (Mouzat 
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et al., 2013). The liver X receptors bind to oxysterols, form heterodimers with retinoid 
X receptor α, and bind to direct repeat-4 elements in target genes to control expression 
(Janowski et al., 1996). Target genes include the ATP-binding cassette transporter 
super-family (such as ATP binding cassette subfamily A member 1 (ABCA1) and ATP 
binding cassette subfamily G member 1 (ABCG1)), that facilitate cholesterol efflux 
(Edwards et al., 2002). Additionally, LXRs increase fatty acid synthesis by enhancing 
SREBP-1c transcription (Schultz et al., 2000), and  promote the inducible degrader of 
the LDL receptor (Idol), reducing exogenous cholesterol uptake by restricting the 
endocytosis of LDL (Zelcer et al., 2009). 
Newly synthesised cholesterol leaves the ER. It is transported to the plasma membrane 
via non-vesicular mechanisms, to other sites such as endosomes (Baumann et al., 
2005), or can be converted to cholesterol esters for storage as cytosolic lipid droplets 
by ACAT (Chang et al., 2009). Oxysterols can increase ACAT-dependent cholesterol 
esterification within minutes (Fig 1.10, 3) (Lange et al., 1999). Resulting cholesterol 
esters are stored as neutral lipid droplets, decreasing the amount of free cholesterol in 
the plasma membrane (Du et al., 2004). Oxysterols also promote the movement of 
membrane cholesterol to the endoplasmic reticulum for storage in a pool accessible to 
ACAT (Lange and Steck, 1997).  
Finally, oxysterols can rapidly control cell cholesterol by regulating HMGCR (Fig 
1.10, 4) (Lange et al., 2008, Song et al., 2005). Oxysterols such as 25-
hydroxycholesterol (Cholest-5-ene-3β,25-diol) and 27-hydroxycholesterol ((25R)-
Cholest-5-ene-3 β,26-diol) promote the binding of HMGCR to Insig, triggering 
ubiquitination and proteasome-dependent degradation. This decreases the half-life of 
HMGCR from ~12 h to less than 1 h, reducing the synthesis of mevalonate from HMG-
CoA (Jo and Debose-Boyd, 2010).  
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Figure 1.10 Oxysterol regulation of cholesterol homeostasis 
Certain oxysterols modulate cholesterol homeostasis through several molecular 
mechanisms including (1) suppression of SREBP activation, (2) liver X receptor 
activation, (3) increased storage of cholesterol as esters, (4) accelerated degradation of 
HMGCR. Created with BioRender.com. 
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1.9 OXYSTEROLS  
1.9.1 Oxysterols and disease 
As well as controlling cholesterol homeostasis, oxysterols also regulate immunity and 
suppress the inflammation caused by bacterial infection (Joseph et al., 2003, Cyster et 
al., 2014, Bauman et al., 2009, Reboldi et al., 2014, Ito et al., 2015). Liver X receptor 
activation by oxysterols can suppress the inflammatory response by promoting the 
synthesis of anti-inflammatory polyunsaturated fatty acids and suppressing genes 
under the control of pro-inflammatory transcription factors such as nuclear factor κ-
light-chain-enhancer of activated B cells (NF-κB), AP-1, nitric oxide synthase and 
cyclooxygenase (Spann and Glass, 2013, Joseph et al., 2003). Lipopolysaccharide 
(LPS) from E. coli  (an endotoxin derived from the outer bacterial membrane) induces 
cholesterol 25-hydroxylase (CH25H) to produce 25-hydroxycholesterol in 
macrophages, negatively regulating the adaptive immune response by suppressing B 
cell proliferation and class switching to immunoglobulin A (Bauman et al., 2009, 
Reboldi et al., 2014). Macrophages unable to produce this oxysterol overproduce the 
interleukin 1 family of inflammatory cytokines (Reboldi et al., 2014). Additionally, 
the interferon stimulated production of 25-hydroxycholesterol provides immunity to 
several bacterial species such as Listeria monocytogenes and Shigella flexneri 
infection by mobilising plasma membrane cholesterol (Abrams et al., 2020).  
1.9.2 Oxysterol structure 
Oxysterols are 27-carbon oxidised forms of cholesterol, formed enzymatically or via 
cholesterol autoxidation, and are commonly produced as intermediates in pathways 
converting cholesterol to steroid hormones or bile acids (Schroepfer, 2000). The 
addition of extra oxygen substitutes, such as hydroxyl, carbonyl, epoxy, hydroperoxyl 
or carboxyl groups, form molecules with diverse biological effects (Olkkonen and 
Hynynen, 2009). Oxysterols can be classified according to the location of the 
additional oxygen group (Fig 1.11). Oxidation of the cholesterol at various points on 
the side-chain forms ligands that regulate cholesterol homeostasis through LXR 
binding, inhibiting the processing of SREBP-2 and cholesterol esterification through 
ACAT (Lehmann et al., 1997, Radhakrishnan et al., 2007, Du et al., 2004). Ring-
modified oxysterols have markedly different functions; demonstrating little activity 
with the LXRs and with several ligands, such as 7-ketocholesterol and 7β-
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hydroxycholesterol possessing potent cytotoxic and pro-apoptotic properties, 
therefore, this thesis has focused on side-chain oxysterols (Lordan et al., 2009).  
 
Figure 1.11 Oxysterol structure  
The structures of commonly occurring side-chain and ring-modified oxysterols 
(Bielska et al., 2012). 
1.9.3 Oxysterol synthesis 
Many oxysterols are produced from cholesterol in the mitochondria or endoplasmic 
reticulum by cholesterol hydroxylases that belong to the cytochrome P450 (CYP) 
family (Russell, 2000). The oxysterols 27-, 24(s)-, 7α-, and 4β-hydroxycholesterol are 
the physiologically important products of this pathway most abundant in human serum 
(Fig 1.11). The enzymes CYP7A1 and CYP27A1 produce 7α- and 27-
hydroxycholesterol respectively as the first step of classic and alternative bile acid 
synthesis (Bjorkhem and Eggertsen, 2001). Excess cholesterol is eliminated from the 
brain across the blood brain barrier by the production of the more polar 24(S)-
hydroxycholesterol catalysed by CYP46A1 (Bjorkhem et al., 2019), and 4β-
hydroxycholesterol is the product of CYP3A4, an enzyme involved in xenobiotic and 
steroid hormone metabolism (Bodin et al., 2002). Additionally, 25-hydroxycholesterol 
is produced by CH25H, a microsomal enzyme not in the P450 family (Lund et al., 
1998). Cholesterol autoxidation occurs through non-enzymatical reactions initiated by 
free radical species or reactive oxygen species attack (Fig 1.12), producing 
endogenous oxysterols commonly modified at the 7-carbon position (Zerbinati and 
Iuliano, 2017). 
Side-chain oxysterols Ring-modified oxysterols 
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Figure 1.12 Endogenous oxysterol synthesis 
The synthetic pathway of commonly occurring endogenous oxysterols. The names of 
enzymatically derived molecules are presented in green and the cholesterol 
autoxidation products are in red (Olkkonen et al., 2012). 
1.9.4 Oxysterol membrane organisation 
The structural modifications to cholesterol make oxysterol molecules more 
hydrophilic and alter lipid packing properties, enabling several products to transfer 
through membranes at a much faster rate than cholesterol itself (Olkkonen and 
Hynynen, 2009). The orientation of oxysterols in membranes is often studied in model 
monolayers and differs significantly from cholesterol (Fig 1.13). Side chain oxysterols 
have polar groups at each end of the molecule and favour a horizontal orientation in 
the membrane, only positioning perpendicularly under high surface pressure. Ring 
modified oxysterols are angled in the membrane under low pressure, positioning both 
polar groups close to the bilayer exterior (Kauffman et al., 2000).  The additional 
oxygen groups mean that oxysterols do not condense in the membrane as effectively 
as cholesterol, and can increase membrane permeability (Theunissen et al., 1986). 
Decreased membrane integrity is thought to be a causative factor in the underlying 
cytotoxic effects of some oxysterols (O'Callaghan et al., 2001).  
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Figure 1.13 Oxysterol membrane organisation 
Schematic representation of the organisation of cholesterol (black) and the oxysterols 
7-ketocholesterol (blue) and 25-hydroxycholesterol (green) in a model phospholipid 
monolayer; adapted from (Olkkonen and Hynynen, 2009).   
1.9.5 Other functions of oxysterols  
Oxysterols also bind to the retinoic acid receptor-related receptor (ROR) family, that 
includes three subtypes RORα, RORβ, and RORγ (Ma and Nelson, 2019). Several 
oxysterols including 22R-hydroxycholesterol, 24S-hydroxycholesterol, 25-
hydroxycholesterol and 27-hydroxycholesterol are ligands for both RORα and RORγ 
(Mutemberezi et al., 2016), acting as  agonists or inverse agonists to either activate or 
repress transcription respectively (Wang et al., 2010). For example, 20S-
hydroxycholesterol, 22R-hydroxycholesterol, and 25-hydroxycholesterol have been 
shown to activate RORγ promoting the recruitment of co-activators, whereas 24S-
hydroxycholesterol supresses the constitutive activity of both RORα and RORγ (Jin et 
al., 2010, Wang et al., 2010). As of yet, no oxysterols have demonstrated binding with 
RORβ (Mutemberezi et al., 2016). Activated RORs contribute to cholesterol 
metabolism. For example, CYP7B1 (the gene coding for oxysterol 7α-hydroxylase) is 
a downstream target of RORα and regulates the metabolism of 25-hydroxycholesterol 
and 27-hydroxycholesterol to bile acids (Wada et al., 2008). Additionally, RORγ plays 
a key role in Th17 cell differentiation (Soroosh et al., 2014).  
Oxysterols also have some oestrogenic activity. Several oxysterols demonstrate 
oestrogen receptor α activation in transfected HeLa cells (Sato et al., 2004), and 
oxysterols including 22R-hydroxycholesterol, 24S-hydroxycholesterol, 25-
hydroxycholesterol and 27-hydroxycholesterol inhibit the oestradiol activation of 
oestrogen receptor α and β (Umetani et al., 2007). In particular, 27-hydroxycholesterol 
has been described as a selective oestrogen receptor modulator (DuSell et al., 2008), 
promoting the proliferation of oestrogen receptor positive breast cancer cells (Nelson 
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et al., 2013, Wu et al., 2013), and inhibiting the oestrogen-dependent production of 
nitric oxide by vascular cells, reducing oestrogen-induced vasorelaxation (Umetani et 
al., 2007).  
1.10 STEROIDS 
1.10.1 Steroids and disease 
Like oxysterols, cholesterol-derived steroids also modulate immunity and the risk of 
disease caused by bacterial infection. Glucocorticoid treatment suppresses the 
inflammation and immunopathology associated with bacterial infection, and 
concentrations of the ovarian sex steroids progesterone and oestradiol affect the 
susceptibility of the bovine endometrium to bacterial infection. 
Ovarian sex steroids and disease 
The ovarian cycle can affect the risk of bacterial infection in the bovine endometrium. 
To prepare for pregnancy, significant physical changes occur in response to the ovarian 
sex steroids progesterone and oestradiol (Wira et al., 2005, Lewis, 2003). In the 
follicular phase of the oestrus cycle, oestradiol concentrations are elevated, and the 
endometrium is more resistant to infection. On the contrary, the high progesterone 
concentrations experienced during the luteal phase can predispose the endometrium to 
infection (Lewis, 2003, Lewis, 2004, Rowson et al., 1953). Although the ovarian cycle 
has demonstrated clear effects on uterine disease progression, the role of oestradiol 
and progesterone remains unclear. Cells collected from the bovine uterine lumen at 
different points of the oestrous cycle secrete differing amounts of cytokines and 
chemokines (Fischer et al., 2010). However, treating endometrial cells with oestradiol 
or progesterone, or inhibiting their cognate nuclear receptors, did not alter the secretion 
of IL-1β, IL6 or IL8, and the gene expression of IL1β, IL6, CXCL8 and CCL5 (Saut et 
al., 2014). As ovarian steroids do not appear to modulate disease severity by 
manipulating the innate immune response, then perhaps they alter the intrinsic 
protection of cells to bacterial pathogens. 
Glucocorticoids and disease 
Glucocorticoids can be included in the effective treatment of a variety of infections 
caused by bacteria that secrete pore-forming toxins, such as sore throats, pneumonia, 
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tuberculosis, meningitis, and septic shock (Marik et al., 2008, Hayward et al., 2012, 
Meijvis et al., 2011). Host tissues secrete cytokines and other inflammatory mediators 
as a mechanism of eliminating invading pathogens. Excessive cytokine release can be 
harmful and glucocorticoids function to regulate the inflammatory response (Rhen and 
Cidlowski, 2005). However, glucocorticoid therapy poses potentially harmful side-
effects including immunosuppression, hypertension, osteoporosis, weight gain and 
Cushing’s syndrome (Yasir et al., 2018). The potentially therapeutic benefits of 
glucocorticoid treatment must be weighed against the side-effects they might cause. 
To ensure that the benefits outweigh the consequences, trials commonly investigate 
patient outcomes. For example, in a review examining 17 randomised control trials 
comprising 2,264 participants, glucocorticoid therapy reduced the mortality and 
morbidity of adults with severe community acquired pneumonia (Stern et al., 2017). 
Furthermore, glucocorticoid treatment can improve the outcome of patients with acute 
bacterial meningitis (de Gans et al., 2002, van de Beek, 2009). The benefits of 
glucocorticoid therapy are typically attributed to mediation of the inflammatory 
response. However, we wondered if it is possible that  glucocorticoids  increase the 
intrinsic protection of cells to invading bacterial pathogens, thereby preventing 
damage.  
In a study by Jamieson et al. (2010), influenza infection triggered a generalized stress 
response in mice elevating serum glucocorticoid concentrations and suppressing the 
immune response. The virus-induced glucocorticoid production was necessary to 
reduce the mortality of a secondary bacterial infection with Listeria monocytogenes 
(Jamieson et al., 2010). As mentioned above, benefits were attributed to the mediation 
of the inflammatory response and the effects of glucocorticoids on the intrinsic 
protection of cells to invading bacterial pathogens were not considered. Additionally, 
in red-winged blackbirds, higher endogenous glucocorticoid concentrations were 
associated with a greater resilience to infection (Schoenle et al., 2018). Though in a 
subsequent study by the same group, supplying exogenous glucocorticoids was 
associated with reduced tolerance and resistance to infection (Schoenle et al., 2019).  
1.10.2 Steroid synthesis 
Steroids are biologically active organic compounds, typically comprised of 17 carbon 
atoms fused into four ring structures with varying functional groups stemming from 
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the fourth core ring. Steroidogenic cells do not typically store steroid hormones, 
instead they are synthesized as required in a pathway consisting of a series of 
cytochrome P450 enzymes, hydroxysteroid hydrogenases and steroid reductases 
(Miller, 1988, Parker and Schimmer, 1995). The cholesterol side-chain cleavage 
enzyme (CYP11A) commences steroid synthesis by catalysing the conversion of 
cholesterol to pregnenolone (Hanukoglu, 1992). The cholesterol side-chain cleavage 
enzyme is located on the inner mitochondrial membrane and is found in all 
steroidogenic tissues (Miller, 1988). Pregnenolone is then converted to progesterone 
by 3β-hydroxysteroid dehydrogenase. Progesterone and pregnenolone form the 
precursors for all other steroid hormones (Fig 1.14). Steroid hormones can be further 
classified by their target nuclear receptor, outlined in Table 1.2. Secreted steroids pass 
through target cell membranes, exerting genomic and non-genomic effects through 
receptor binding.  
 
Figure 1.14 Steroid biosynthesis 
The synthesis of the three endogenous steroids examined in this thesis (highlighted in 
green). The hydroxysteroid dehydrogenase (HSD) and the cytochrome P450 (CYP) 
enzymes involved are labelled in red.  
  
36 
 
Table 1.2 Nuclear Receptor Subfamily 3 
Receptor Gene Target hormone 
(Ligand) 
Group A: Oestrogen Receptors 
Oestrogen Receptor-α NR3A1 Oestradiol 
Oestrogen Receptor-β NR3A2 Oestradiol 
Group B: 3-Ketosteroid Receptors 
Glucocorticoid Receptor NR3C1 Cortisol 
Mineralocorticoid Receptor NR3C2 Aldosterone 
Progesterone Receptor NR3C3 Progesterone 
Androgen Receptor NR3C4 Testosterone 
 
1.10.3 Oestrogens 
Oestrogens are the primary female sex hormones and are responsible for the 
development and regulation of the female reproductive system and secondary sex 
characteristics. Genomic effects are exerted through the two forms of the oestrogen 
receptor, α and β, located on the sixth and fourteenth chromosome (6q25.1 and 
14q23.2) respectively (Giguere et al., 1998). The receptors interact with oestrogen 
response elements in the promoters of target genes and recruit various co-activators to 
mediate transcriptional regulation (McDonnell and Norris, 2002). Oestrone, oestradiol 
and oestriol are three endogenous oestrogens found in women. Oestetrol is a fourth 
major oestrogen found exclusively in pregnant women. Oestradiol is the major 
oestrogen in fertile women, demonstrating higher serum concentrations and superior 
oestrogenic activity. Oestradiol is around eighty times more potent than oestriol and 
12 times more potent than oestrone (Thomas and Potter, 2013). It is responsible for 
the development of female reproductive characteristics along with the regulation of 
the menstrual and oestrous reproductive cycles (Hall et al., 2001). Production mainly 
occurs within the ovarian follicles, but small amounts are also formed in the testicles, 
the adrenal glands, fat, the liver, the breasts, and the brain (Findlay et al., 2010).  
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1.10.4 Progesterone 
Progesterone, along with 17α-hydroxyprogesterone and 17α-hydroxypregnenolone, is 
a precursor for the synthesis of other endogenous steroids, and so it is produced by a 
variety of tissues including the adrenal glands, testes, and ovaries (Taraborrelli, 2015).  
Progesterone functions through the progesterone receptor and is essential for the 
reproductive process, aiding fetal growth through many pathways (Di Renzo et al., 
2016). For example, progesterone in the myometrium counteracts the stimulatory 
activity of prostaglandins and oxytocin to reduce uterine contractility and decrease the 
risk of premature labour (Fanchin et al., 2000). Progesterone modulates the maternal 
immune response suppressing inflammation and permitting fetal acceptance (Schwartz 
et al., 2009). Additionally, progesterone prevents lactation during pregnancy, with 
milk production occurring when progesterone concentrations fall after parturition 
(Spencer and Bazer, 2002).  
Overall, it is generally accepted that progesterone and oestradiol exert opposing effects 
on steroid nuclear receptors with menstruation and ovulation controlled by the 
rhythmic regulation of ovarian hormone concentration. Specifically, in the bovine 
uterus, high follicular oestrogen increased the abundance of oestradiol and 
progesterone receptors. In turn, progesterone and oestrogen receptor levels were low 
at cycle stages associated with higher progesterone concentrations (Kimmins and 
MacLaren, 2001).   
1.10.5 Glucocorticoids 
Cortisol 
Cortisol (11β, 17α, 21-Trihydroxypregn-4-ene-3, 20-dione) is the principal 
endogenous glucocorticoid hormone (referred to as hydrocortisone when supplied as 
a medication) and is primarily produced by the zona fasciculata of the adrenal cortex 
(Chrousos, 2009). The release and production of cortisol is regulated by the 
hypothalamus-pituitary axis (Kadmiel and Cidlowski, 2013). Cortisol and other 
glucocorticoids modulate genomic effects through glucocorticoid receptor binding. 
Secreted cortisol affects most organ systems because the glucocorticoid receptor is 
expressed in almost every tissue in the human body and contributes significantly to the 
metabolic, cardiovascular, and immunological systems (Kadmiel and Cidlowski, 
2013).  
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Physiological stress such as burns and in extreme cases septic shock, are well 
associated with activating the hypothalamic-pituitary-adrenal axis, leading to an 
increase in cortisol that helps with the maintenance of vascular tone, endothelial 
integrity, cardiac contractility, and potential catecholamine actions (Arafah, 2006, 
Munck et al., 1984). Septic shock can elevate basal cortisol to an average of 880 
nmol/litre compared with a control level of 352 nmol/litre (Ho et al., 2006). However, 
in general the reported range of cortisol in stress varies and the optimum 
concentrations are not known (Sam et al., 2004). This variation in cortisol affects 
vulnerability to further infection.  
In dairy cattle transportation and hot conditions induce stress. Complications include 
decreased milk production, reduced fertility, and increased susceptibility to disease 
(Buffington et al., 1983, Chirase et al., 2004, Crowe and Williams, 2012, Kadzere et 
al., 2002). Both heat and transport induced stress can trigger a short-term increase in 
plasma cortisol concentrations (Alvarez and Johnson, 1973, Christison and Johnson, 
1972, Nanda et al., 1990). As a stress hormone, cortisol suppresses immune function 
by down-regulating key inflammatory transcription factors, increases blood sugar 
concentrations through gluconeogenesis and assists in fat, protein, and carbohydrate 
metabolism (Heck et al., 1997, Jonat et al., 1990), though its impact on intrinsic cell 
protection is unknown.  
Dexamethasone 
The anti-inflammatory properties of glucocorticoids are the basis for the 
pharmaceutical development of drugs, such as dexamethasone, that are used in the 
treatment of many inflammatory disorders, such as rheumatic problems, skin diseases, 
asthma, chronic obstructive pulmonary disorder and brain swelling (Rhen and 
Cidlowski, 2005). Dexamethasone (1-dehydro-9-fluoro-16-methylhydrocortisone) is 
a synthetic pregnane (a C21 steroid derivative with carbons present at positions 1 
through 21) and derivative of cortisol. The binding affinity of dexamethasone to the 
glucocorticoid receptor was found to be four times greater than that of cortisol 
(Kontula et al., 1983). 
The glucocorticoid receptor 
Glucocorticoids exert effects though binding to the widely expressed glucocorticoid 
receptor (Hollenberg et al., 1985). The human glucocorticoid receptor is derived from 
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a single gene, NR3C1, that contains nine exons.  Alternative splicing at exon 9 
generates two main glucocorticoid receptor isoforms (α and β) (Bamberger et al., 
1995). Glucocorticoid receptor α is ubiquitously expressed and mediates the classic 
glucocorticoid effects, whereas the β isoform has a more selective distribution, is 
typically found at lower concentrations than glucocorticoid receptor α, and does not 
bind to glucocorticoid agonists due to its altered binding domain (Oakley et al., 1996). 
Several other glucocorticoid receptor isoforms have been detected in tissues and 
certain cancer cells (Krett et al., 1995, Beger et al., 2003). Differing abundance of the 
individual glucocorticoid receptor isoforms regulating independent sets of genes might 
partly explain the cell and tissue-specific response to glucocorticoid treatment 
(Kadmiel and Cidlowski, 2013, Oakley and Cidlowski, 2011).  
Glucocorticoids readily cross cell membranes to combine with the glucocorticoid 
receptor in designated tissues. Unbound glucocorticoid receptor, located in the cytosol 
of cells, are attached to chaperone proteins such as the heat shock proteins 90, 70 and 
40 (Dittmar and Pratt, 1997, Schneikert et al., 1999). When a ligand/hormone binds to 
the glucocorticoid receptor, the connected heat shock protein releases, and the receptor 
translocates into the nucleus (Isohashi and Okamoto, 1993). The liganded 
glucocorticoid receptor dimers then slot into the glucocorticoid response elements in 
the DNA helix, leading to the enhancement and/or repression of gene transcription, 
typically within a few hours (Duma et al., 2006, Ratman et al., 2013, Wang et al., 
2004). However, global glucocorticoid recruitment assays indicate that only a small 
portion of glucocorticoid response elements are occupied by the receptor and these 
sites vary in cell-specific manner due to differences in the chromatin landscape that 
alters response element exposure (John et al., 2011). Alternatively, the glucocorticoid 
receptor can also regulate transcription by physically interacting with other 
transcription factors without tethering directly to DNA; examples include the Jun 
subunit of AP-1 and the p65 subunit of the nuclear factor κ-light-chain-enhancer of 
activated B cells (NF-κB) (Nissen and Yamamoto, 2000, Yang-Yen et al., 1990). 
Reported membrane bound glucocorticoid receptors potentially allow cortisol to 
trigger alternative fast acting non-genomic actions on target cells (Strehl et al., 2011).  
Glucocorticoid receptor genomic effects regulate the transcription of a variety of genes 
controlling development, signal transduction, transport, metabolism, and immune 
response  (Wang et al., 2004). Most of the glucocorticoid receptor anti-inflammatory 
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effects stem from interactions with NF-κB and AP-1. Repression of the NF-κB 
pathway reduces the expression of pro-inflammatory cytokines (i.e.: IL-1α and tumour 
necrosis factor α) and genes that contribute to T-cell developmental pathways, 
mediated by the glucocorticoid-induced leucine zipper (Beaulieu and Morand, 2011, 
Ayroldi and Riccardi, 2009). Glucocorticoids suppress a variety of AP-1 driven genes 
involved in inflammation and immune dysregulation such as IL-6, and also suppress 
proliferative genes such as c-Jun (Wei et al., 1998). Additionally, glucocorticoids 
upregulate genes such as the dual specificity protein phosphatase (decreasing MAPK 
phosphorylation) and the IL-1 receptor protein kinase 3, repressing Toll-like receptor 
and IL-1 receptor signalling (Ayroldi et al., 2012).  
There is not total specificity between steroid hormones and their target receptors, and 
many steroid hormones can bind to several different nuclear receptors. Oestradiol, 
aldosterone, and progesterone, alongside cortisol, are all chemically similar molecules 
that can still fit into the glucocorticoid receptor binding site (Kontula et al., 1983). 
However, structural differences prevent necessary contacts, and could suggest an 
explanation for the selectivity of the glucocorticoid receptor for the endogenous ligand 
cortisol (von Langen et al., 2005). 
Side-effects of glucocorticoid treatment  
Although glucocorticoids can have substantial therapeutic benefits, prolonged use, 
particularly at high concentrations, can have severe adverse effects (Schacke et al., 
2002). Metabolic disorders include the development of Cushingoid features, 
hyperglycaemia, adrenal suppression (Barnes and Adcock, 2009, Hoes et al., 2011). 
Skin atrophy stems from reduced keratinocyte and dermal fibroblast proliferation 
(Oikarinen and Autio, 1991, Oikarinen et al., 1998). Glucocorticoid-induced 
osteoporosis increases the risk of fractures and long-term treatment in children can 
impair growth and delay puberty (Dykman et al., 1985, Reid, 2000, Skoner et al., 
2000).  
Another complication of glucocorticoid therapy is the reduced sensitivity or even 
resistance that can develop in patients treated for chronic diseases (Ramamoorthy and 
Cidlowski, 2013). This increases the vulnerability of patients to exaggerated 
inflammatory responses (Rodriguez et al., 2016).  
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1.11 AIMS AND HYPOTHESES   
Protecting cells against damage can increase the tolerance of tissues to bacterial 
pathogens. The present thesis aimed to explore methods of increasing the intrinsic 
protection of eukaryotic cells against the damage caused by pore-forming toxins. Side-
chain oxysterols, the ovarian sex steroids oestradiol and progesterone, and 
glucocorticoids are thought to modulate the risk of disease caused by bacteria that 
secrete pore forming toxins (Abrams et al., 2020, Lewis, 2003, Stern et al., 2017). With 
this in mind, the present thesis tests the hypothesis that side-chain oxysterols and 
steroids alter the intrinsic protection of eukaryotic cells against pore-forming toxins.  
We used pyolysin as a model toxin to study cytoprotection because it does not require 
thiol activation and forms pores in many types of mammalian cells (Jost and 
Billington, 2005, Amos et al., 2014). In the first experimental chapter of this thesis 
(Chapter 3) we focused on cells from the bovine endometrium, a target tissue of 
pyolysin. There we tested the hypothesis that progesterone, oestradiol, glucocorticoids, 
and side-chain oxysterols, alter bovine endometrial cell protection against 
pore-forming toxins. The first objective was to determine whether treatment of primary 
bovine endometrial cells with the steroids or oxysterols reduced the damage caused by 
a subsequent challenge with pyolysin.  Cytoprotection was assessed by measuring the 
leakage of potassium ions and LDH into cell supernatants, by evaluating toxin-induced 
changes to the actin cytoskeleton, and by assessing cell viability. The second objective 
was to determine whether oxysterol cytoprotection extended beyond pyolysin to 
protection against α-hemolysin from another endometrial pathogen, S. aureus 
(Sheldon et al., 2002). The third objective was to examine the mechanisms of side-
chain oxysterol cytoprotection in bovine endometrial cells. We examined whether 
cellular cholesterol abundance, ACAT activity, and LXR expression contributed to 
side-chain oxysterol cytoprotection. The final objective was to explore the type and 
abundance of oxysterols in the ovary and uterus using mass spectrometry.  
Having examined the protection of bovine endometrial cells against pore-forming 
toxins, we then aimed to explore the protection of human tissue cells. In Chapter 4 we 
tested the hypothesis that treatment with side-chain oxysterols would protect human 
epithelial cells against pore-forming toxin damage. The first objective was to 
determine whether side-chain oxysterol treatment protected several types of human 
epithelial cells against pyolysin or S. aureus α-hemolysin. Again, cytoprotection was 
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assessed by measuring the leakage of potassium ions and LDH into cell supernatants, 
and changes in cell viability and the cytoskeleton. The subsequent objective was to 
examine the protective mechanisms involved in side-chain oxysterol cytoprotection 
and we investigated ion flux, MAPK activation, liver X receptor expression and ACAT 
activity.  
Chapter 5 challenged the hypothesis that glucocorticoids increase the intrinsic 
protection of human cells against pore-forming toxins. The first objective was to 
establish whether glucocorticoid treatment would protect human tissue cells against 
pyolysin, streptolysin O, or S. aureus α-hemolysin. Cytoprotection was assessed as in 
Chapters 3 and 4. The second objective was to determine the role of the glucocorticoid 
receptor in cytoprotection. The final objective was to examine potential mechanisms 
for glucocorticoid cytoprotection. We investigated the involvement of MAPKs, ion 
flux, cellular cholesterol, and specific gene activation.  
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2 GENERAL MATERIALS AND METHODS 
2.1 GENERAL APPROACH TO EXAMINING CYTOPROTECTION 
The present thesis used a consistent approach to examine the cytoprotective properties 
of oxysterols and steroids. We first challenged cells with a range of concentrations of 
pyolysin to determine a suitable challenge for use in experiments exploring 
cytoprotection. We evaluated the consequences of pore formation by measuring the 
leakage of lactate dehydrogenase (LDH), the leakage of potassium, and cell cytolysis. 
Cells were then treated with a range of concentration of steroids or oxysterols to 
investigate their effect on cell protection to determine effective treatment 
concentrations. The treatments and vehicles used throughout the present thesis are 
listed in Table 2.1. Cytoprotection was attributed to treatments that reduced the toxin-
induced leakage of LDH, leakage of potassium, cell cytolysis and cytoskeletal 
changes. We examined the extent of cytoprotection, by repeating experiments in 
multiple cell lines and with several toxins. Finally, we investigated cytoprotective 
mechanisms. We explored the effect of treatment on cellular cholesterol, as 
manipulating cholesterol homeostasis is an effective method of protecting cells against 
cholesterol-dependent cytolysins (Amos et al., 2014, Statt et al., 2015). Additionally, 
we used synthetic agonists, short interfering ribonucleic acid (siRNA) and inhibitors 
to target genes or receptors that might be involved in cytoprotection (Table 2.1). 
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Table 2.1 Treatments and inhibitors used throughout this thesis and the vehicles 
used to reconstitute them 
Compound  Use in thesis Product code and 
supplier 
Vehicle 
Progesterone  Treatment #P8783; Merck, 
Gillingham, UK 
Ethanol 
Oestradiol Treatment #E2758; Merck Ethanol 
Hydrocortisone Treatment #H0888; Merck Ethanol/ dimethyl 
sulfoxide (DMSO, 
#6768-51; Merck) 
Dexamethasone Treatment #D4902; Merck DMSO 
25-hydroxycholesterol  Treatment #700019P; Avanti 
Polar Lipids, 
Alabama, United 
States 
Methanol 
27-hydroxycholesterol Treatment #LM4114; Avanti 
Polar Lipids 
Methanol 
Methyl-β-cyclodextrin 
(MβCD) 
Treatment #C4555, Merck Phosphate-buffered 
saline (PBS, 
#10010023; 
Thermo Fisher 
Scientific). 
Sphingomyelinase Treatment #S8633, Merck Buffered aqueous 
glycerol solution 
Cholesterol Treatment #C3045, Merck Ethanol 
T0901317 Synthetic 
agonist 
#2373; Tocris, 
Abingdon, UK 
DMSO 
GW3965 Synthetic 
agonist 
#2474; Tocris DMSO 
Fluticasone propionate Synthetic 
agonist 
#2007; Tocris DMSO 
SZ58-035 Inhibitor #S9318; Merck DMSO 
RU486 Inhibitor #M8046; Merck DMSO 
Cycloheximide Inhibitor #01810; Merck DMSO 
Actinomycin D Inhibitor #A9415; Merck DMSO 
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2.2 PORE-FORMING TOXIN PREPARATION 
2.2.1 Pyolysin 
Pyolysin was selected as the model cholesterol-dependent cytolysin to explore the 
cytoprotective properties of oxysterols and steroids as it is spontaneously active in 
vitro and has successfully been utilised to explore protection against cholesterol-
dependent cytolysins in the past (Billington et al., 1997, Amos et al., 2014, Griffin et 
al., 2018). Trueperella pyogenes secretes pyolysin, damaging endometrial cells and 
contributing to the progression of uterine disease in cattle (Billington et al., 1997, 
Sheldon et al., 2006), therefore we used a model system of bovine endometrial cells 
challenged with pyolysin to explore cytoprotection.  
Protein expression 
Recombinant pyolysin was generated from a plasmid (pGS59) containing 6xHis-
linked pyolysin, generously provided by Prof B.H. Jost (University of Arizona). For 
this project, pyolysin was purified from a 1 g Escherichia coli pellet provided by Dr 
S. Owens that was generated as previously described (Billington et al., 1997). Briefly, 
5 µl plasmid deoxyribonucleic acid (DNA) was added to 50 µl BL21 (DE3) E. coli 
(#BIO-85032; Bioline, London, UK) in 17 x 100 mm polypropylene tubes (#2059; 
Thermo Fisher Scientific, Paisley, UK), mixed by swirling, and placed on ice for 30 
min. The tube was incubated in a water bath at 42⁰C for 45 s and returned to ice for 2 
min, thereby triggering heat-shock driven plasmid DNA internalisation. The plasmid 
E. coli mixture was then transferred to a 1 ml reaction tube containing 950 µl Luria-
Bertani (LB) broth (#L3022; Merck). The tube was placed horizontally in a shaking 
incubator set at 180 rpm and incubated at 37⁰C for 1 h. Warm 1.5% LB agar plates 
containing 100 µg/ml ampicillin (#A0166; Merck) were prepared and 100 µl plasmid 
E. coli mixture was added after the incubation period was complete. The remaining 
900 µl was centrifuged at 6,000 x g for 5 min. After centrifugation, the supernatant 
was discarded, and the pellet was resuspended in 100 µl fresh LB broth and plated on 
a separate LB agar ampicillin plate. Plates were incubated at 37⁰C overnight. 
The next day, a single colony was selected from the transformation plates, inoculated 
into 10 ml LB broth (100 µl/ml ampicillin), and incubated at 37⁰C overnight again. 
The following morning, 5 ml of this culture was incubated in 500 ml LB broth (100 
µl/ml ampicillin) at 37⁰C and shaken at 180 rpm until the OD600 reached 0.6. Protein 
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expression was induced by adding 1 mM isopropyl-β-D-thiogalactopyranoside 
(#BP1755-10; Thermo Fisher Scientific) for 3 h. Incubation temperature was then 
reduced to 25⁰C and agitation to 150 rpm overnight. The following morning, cultures 
were centrifuged at 5,000 x g for 10 min (4⁰C). The supernatant was then discarded, 
and the pellet was divided into 1 g portions ready for protein purification.  
Protein purification 
Pyolysin protein purification was carried out in a cold room at 4⁰C. A 1 g E. coli cell 
pellet was resuspended in 20 ml of HisTALON xTractor buffer (#635651; Clontech, 
California, US), with 10 µl benzonase (#E8263-5KU; Merck). The solution was 
centrifuged at 10,000 x g for 20 min and clarified supernatant was collected and stored 
on ice (10 µl of the supernatant, later referred to as the soluble fraction, was aliquoted 
for sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
analysis). Equilibration and elution buffer (#635651; Clontech) were filtered through 
a 0.22 µM vacuum filter (#99250; TPP, Trasadingen, Switzerland), then 8 ml of 
equilibration buffer was ran through a 1 ml cobalt resin FPLC cartridge for His-tagged 
protein purification (#635655; Clontech). We ran clarified supernatant through the 
column and the 6xHis tag on the recombinant protein bound to the cobalt irons in the 
column resin bed. The column was washed with 8 ml of equilibration buffer then 7 ml 
of wash buffer (0.66 ml elution buffer added to 9.34 ml equilibration buffer). The 
recombinant pyolysin was eluted by running 8 ml of elution buffer through the column 
and 1 ml fractions were collected in 1.5 ml reaction tubes (#616201; Greiner Bio-One, 
Gloucester, UK). The elution buffer displaced the His-tagged recombinant protein as 
the 150 nM imidazole competitively binds to the cobalt ions in the column allowing it 
to flow through the column and be collected. The concentration and abundance of 
pyolysin was determined using a DC assay and SDS-PAGE analysis. 
DC assay  
A Bio-Rad DC protein assay (#5000111; Bio-Rad, Hercules, California, United States) 
is a colorimetric assay used to distinguish the concentration of protein via the 
solubilisation of a detergent. The protein interacts with an alkaline copper tartrate 
solution, reducing the fiolin reagent and giving rise to characteristic colour changes. 
A protein standard curve was attained by using 0.5, 1.0, 1.5, 2.0 and 2.5 mg/ml 
concentrations of bovine serum albumin (BSA, #A7906; Merck). Five µl of standard 
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or sample were added in duplicate into the wells of a clear flat bottom 96 well plate 
(#437958; Thermo Fisher Scientific). The assay was performed using the reagents 
provided by the Bio-Rad DC protein assay kit (reagent A, B and S). Working reagent 
was prepared by combining 60 µl reagent S and 3 ml reagent A. To start the reaction, 
25 µl working reagent and 200 µl reagent B were added to each well. The plate was 
incubated at room temperature on a shaker for 15 min. Absorbance was read at 750 
nm using a POLARstar Omega microplate reader (POLARstar Omega; BMG Labtech, 
Aylesbury, UK). The inter- and intra-assay coefficients of variation for the DC assay 
were < 6% and < 5% respectively. The protein concentrations from the first 4 eluted 
fractions are shown below (Table 2.2). As expected, fraction 2 contained the majority 
of protein.  
Griffin et al. (2017) determined that the activity of pyolysin was 628,338 hemolytic 
units (HU)/mg protein by using a hemolysis assay carried out with horse red blood 
cells. Therefore, the concentration of pyolysin used in the experiments in the present 
thesis is reported in HU.  
Table 2.2 Recombinant pyolysin protein concentrations from eluted fractions 
Fraction  1 2 3 4 
Protein concentration mg/ml  0.09 
 
3.87 0.62 0.01 
 
SDS-PAGE 
We used SDS-PAGE analysis to confirm that fraction 2 contained the majority of the 
recombinant pyolysin protein. A 12% acrylamide running gel and the stacking gel 
were prepared as shown in Table 2.3. Eluted fractions 1 to 5 and the soluble fraction 
were combined with 2X Laemmlli sample buffer (#161-0737; Bio-Rad) and boiled at 
95⁰C for 10 min to prepare for SDS-page analysis. Five µl of each sample were loaded 
onto the gel. Electrophoresis was carried out at room temperature and ran for 40 min 
at 200 volts. Gels were stained overnight in Coomassie stain (50% distilled water, 40% 
methanol, 10% acetic acid and 0.5% Coomassie blue R250 (#1610436; Bio-Rad), and 
destained with destain solution (50% dH2O, 40% methanol and 10% acetic acid) until 
clear. Figure 2.1 confirms that the majority of the recombinant pyolysin eluted in 
fraction 2, and therefore this fraction was used for the experiments throughout the 
present thesis.  
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Table 2.3 Ingredients for SDS-PAGE gel 
Reagent  Product code 
and supplier 
12% Running 
gel 
Stacking gel 
Distilled water N/A 3.5 ml 1.75 ml 
Separating buffer 4x Solution  #7732-18-5; 
Melford 
Laboratories, 
Ipswich, UK 
2.5 ml 0.75 ml 
30 % Acrylamide #A374; Merk 4 ml 0.5 ml 
Ammonium persulfate (APS; 
10% solution) 
#A3678; 
Merck 
100 µl 50 µl 
TEMED (N, N, N’, N’-
tetramethylethylenediamine) 
#161-0800; 
Bio-Rad 
10 µl 3 µl 
 
 
 
Figure 2.1 SDS-PAGE analysis of recombinant pyolysin fractions 
L = All protein blue standard. S = soluble fraction: (BL21 (DE3) E. coli cell lysate 
with over-expressed recombinant pyolysin, 1 to 5 refer to the 1 ml eluted protein 
fractions. Most of the protein was eluted in fraction 2. Smaller bands possibly reflect 
breakdown products of pyolysin or histidine rich E. coli proteins. 
75 kDa  
50 kDa 
L  S  1  2  3  4  5  
Recombinant 
pyolysin 
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2.2.2 Streptolysin O 
Streptolysin O was purchased from Merck (#S5265) and stored according to the 
manufacturer’s instructions. A storage buffer consisting of 10 ml Dulbecco’s 
phosphate-buffered saline (DPBS, #14190250; Thermo Fisher Scientific), 10 mg BSA, 
and 15.4 g (10 mM) dithiothreitol was prepared in a 20 ml universal tube (#201170; 
Greiner Bio-One) and gently rotated for 10 min. The streptolysin O was reconstituted 
in the storage buffer (1 mg/ml) by gently rotating at room temperature for 1 h. After 
reconstitution, 200 µl aliquots were stored at -20⁰C. Prior to use, aliquots were 
incubated at 37 ⁰C for 30 min.  
2.2.3 Staphylococcus aureus α-hemolysin 
Staphylococcus aureus α-hemolysin (#H9395; Merck) was reconstituted, according to 
the manufacturer’s instructions, in deionized water to yield a 0.5 mg/ml solution that 
was stored at 4⁰C.  
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2.3 CELL CULTURE  
2.3.1 Bovine endometrial cell culture 
Anatomy of the bovine uterus 
The bovine uterus consists of a body and two horns suspended in the pelvic cavity. An 
ovary resides at the end of each horn and produces a single ovum per oestrus cycle 
(Fig 2.2). The walls of the uterus are comprised of the perimetrium, myometrium and 
the endometrium.  
 
Figure 2.2 Anatomy of the bovine reproductive tract 
The bovine female genital tract as received from the St Merryn Abattoir  (Cronin et 
al., 2014). 
The endometrium lines the inside of the uterus and consists of a single layer of 
columnar epithelial cells covering underlying stromal cells (Fig 2.3). Blood vessels are 
located between the endometrium and myometrium, and monocytes migrate into the 
stromal cell layers maturing into macrophages. The endometrial surface has protruding 
caruncles, that interact with the fetal placenta during pregnancy, and is covered in a 
protective layer of mucus.  
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Figure 2.3 The bovine endometrium 
A cross section of the bovine endometrium, displaying the individual layers from the 
uterine lumen to the myometrium. Created with BioRender.com. 
Tissue collection 
Bovine endometrial epithelial and stromal cells were isolated from uteri as described 
previously (Cronin et al., 2012, Turner et al., 2014). Bovine female genital tracts were 
collected from post-pubertal, non-pregnant, mixed breed beef cattle that demonstrated 
no sign of infection or disease. The cattle were slaughtered as part of the daily work at 
the St Merryn Abattoir, Merthyr Tydfil. Approval was granted by the United Kingdom 
Department for Environment, Food and Rural Affairs under the animal by-products 
registration (EC) No. 1069/2009 (registration number U1268379/ABP/OTHER). 
Immediately following collection, uteri were individually bagged and placed in a cool 
box filled with ice ready for transport.  
Tissue processing 
In preparation for dissection, all work surfaces were cleaned with 70% ethanol and 
covered in aluminium foil. The uteri were rinsed with 70% ethanol. An incomplete 
transverse incision was made across the ipsilateral horn just above the interconual 
ligament (Fig 2.2). The endometrium was then opened by cutting vertically towards 
the ovary. Endometrial wash solution comprising DPBS and 1% antibiotic antimycotic 
(ABAM, #A5955; Merck) was used to thoroughly wash the endometrium. The 
endometrium was then separated from the myometrium in thin strips (Fig 2.4) and 
placed directly into 60 ml pots (#219270; Greiner Bio-one) containing 25 ml Hank’s 
balanced salt solution (HBSS, #14175095; Thermo Fisher Scientific) with 1% ABAM. 
The tissue was washed by swirling, transferred to a second pot containing 25 ml HBSS, 
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and gently swirled again. The tissue was dissected into 5 mm2 pieces, placed in a 50 
ml tube (#210261; Greiner Bio-One) containing 25 ml HBSS, and then incubated at 
37⁰C for 10 min.  
 
Figure 2.4 Dissection of the bovine endometrium 
Visual representation of the endometrium being separated from the myometrium in 
thin strips using sterile forceps and scissors (Cronin et al., 2014). 
Tissue digestion  
A sterile digestive solution was freshly prepared consisting of 250 ml HBSS, 125 mg 
Collagenase II (#C6885; Merck), 250 mg BSA (#A9418; Merck), 600 µl 4% DNAse 
I (#DN25; Merck) and 600 BAEE units’ trypsin ethylenediaminetetraacetic acid 
(#T4049; Merck).  After incubation, the supernatant was decanted from the tissue and 
the digestive solution was added to reach a total volume of 40 ml. Tubes containing 
digestive solution were incubated in a shaking water bath for 1 h. Digested supernatant 
was sieved through a 70-μm mesh cell strainer to remove debris, and then through a 
40-μm mesh cell strainer (pluriStrainer®, Cambridge Bioscience, Cambridge, UK) 
into 5 ml of warm stop solution comprising of HBSS with 10% fetal bovine serum 
(FBS, #FB-1550/506; Biosera, East Sussex, UK).  
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Media preparation 
Cells were cultured in complete medium comprising Roswell Park Memorial Institute 
(RPMI)-1640 medium (#31870-025; Thermo Fisher Scientific), 10% FBS, 1% 
ABAM, and 1% L-glutamine (#25030-024; Thermo Fisher Scientific). 
Epithelial cell culture 
The larger epithelial cells were collected by back-flushing the 40-μm mesh cell 
strainers with complete culture medium. The resulting cell suspension was transferred 
to 25 cm2 flasks (#391-3143; VWR, Lutterworth, UK) and incubated at 37⁰C in 
humidified air with 5% CO2 for at least 48 h to allow time for the epithelial cells to 
adhere. Contaminating stromal cells were removed thanks to their selective attachment 
properties (Fortier et al., 1988). Medium was discarded and cells were washed with 5 
ml sterile warm (37⁰C) PBS (#10010023; Thermo Fisher Scientific). The PBS was 
discarded, and cells were incubated with 2 ml warm accutase for 2 to 5 min whilst the 
stromal cells detached from the culture surface. Progress was closely monitored 
through a microscope to determine when the stromal cells had detached. Accutase 
containing detached stromal cells was discarded and replaced with fresh culture 
medium.  Flasks were incubated under humidified air containing 5% CO2 at 37⁰C. 
Medium was replenished every 48 h and once confluency was achieved, cells were 
maintained in 75 cm2 flasks (#734-2705; VWR). Microscopy was used to determine 
that cell populations were > 95% pure (Fig 2.5) (Fortier et al., 1988). For experiments 
cells were used from passage 1 and 2.  
Stromal cell culture 
To isolate stromal cells, the digestive filtrate collected in the stop solution was 
centrifuged at 700 x g for 7 mins. The supernatant was discarded, 5 ml of sterile water 
was added to the pellet, and the suspension was vortexed to lyse contaminating red 
blood cells. Fresh warm (37⁰C) stop solution (45 ml) was added, and the suspension 
was centrifuged at 700 x g for a further 7 mins. The supernatant was decanted, the cell 
pellet was resuspended in 15 ml complete culture medium, and the suspension was 
then transferred to 75 cm2 flasks. Stromal cells adhered to culture flasks within 18 h, 
at which time the culture supernatant containing contaminating epithelial cells was 
discarded, stromal cells were washed with 5 ml warm PBS, and fresh culture medium 
was added. Flasks were incubated under humidified air containing 5% CO2 at 37⁰C 
with medium was replenished every 48 h. (Greiner Bio-One). Microscopy was used to 
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determine that cell populations were > 95% pure (Fig 2.5) (Fortier et al., 1988). 
Alternatively, cells can be distinguished by prostaglandin production, with epithelial 
cells producing significantly more than stroma cells (Fortier et al., 1988). For 
experiments cells were used from passage 1 and 2.   
 
Figure 2.5 Epithelial and stromal cell populations 
Representative phase contrast microscopy images of purified bovine endometrial 
epithelial and stromal cell populations. 
2.3.2 HeLa cell culture 
Immortal HeLa cervical cells (#CCL-2) were purchased for this thesis (#93021013; 
Public Health England, Salisbury, UK) and cultured in complete medium comprising 
Dulbecco’s Modified Eagle Medium (DMEM, #41965039; Thermo Fisher Scientific), 
10% FBS and 1% ABAM. Cells were maintained in 75 cm2 flasks and cultured under 
humidified air containing 5% CO2 at 37⁰C. Medium was replenished every 48 to 72 h. 
For experiments, cells were used from passage 5 to 30 and seeded in 1 ml/well 
complete media at a density of 4 × 104 cells/well using 24-well tissue culture plates 
unless otherwise stated.  
2.3.3 A549 cell culture  
A549 alveolar epithelial cells were purchased from American Type Culture Collection 
(#CCL-185; ATCC, Manassas, Virginia, United States) were cultured in complete 
medium comprising RPMI-1640, 10% FBS, 1% ABAM and 1% L-Glutamine. Cells 
were incubated in 75 cm2 flasks at 37⁰C under humidified air containing 5% CO2 and 
medium was replenished every 48 to 72 h. For experiments, cells were used from 
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passage 8 to 35 and seeded in 1 ml/well complete media at a density of 4 × 104 
cells/well using 24-well tissue culture plates unless otherwise stated.  
2.3.4 H441 cell culture  
NCI-H441 lung cells (#HTB-174; ATCC) were cultured in complete medium 
comprising RPMI-1640, 10% FBS, 1% ABAM and 1% L-glutamine. Cells were 
incubated in 75 cm2 flasks at 37⁰C under humidified air containing 5% CO2 and 
medium was replenished every 48 to 72 h. For experiments, cells were used from 
passage 20 to 30 and seeded in 1 ml/well complete media at a density of 4 × 104 
cells/well using 24-well tissue culture plates.  
2.3.5 Hep-G2 cell culture 
Hep-G2 liver cells (#HB-8065; ATCC) were cultured in complete medium comprising 
DMEM, 10% FBS and 1% ABAM. Cells were incubated in 75 cm2 flasks at 37⁰C 
under humidified air containing 5% CO2 and medium was replenished every 48 to 72 
h. For experiments, cells were used from passage 15 to 30 and seeded in 1 ml/well 
complete media at a density of 4 × 104 cells/well using 24-well tissue culture plates. 
2.3.6 Normal dermal human fibroblasts cell culture  
Primary normal dermal human fibroblasts (NDHF) primary cells were purchased from 
Promocell (#C-12302; Heidelberg Germany). Cells were cultured in Fibroblast 
Growth Medium 2 with Supplement Mix (#C23020; Promocell) and incubated in 75 
cm2 flasks under humidified air containing 5% CO2. Cells were grown to 95% 
confluence and were passaged every 2 to 3 days up to 10 passages. For experiments, 
cells were seeded in 1 ml/well complete media at a density of 1.4 × 104 cells/well using 
24-well tissue culture plates. 
2.3.7 Passaging cells  
The passaging of cells was carried out in a sterile class 2 hood. Spent medium was 
discarded from flask, and cells were washed with 5 ml sterile warm (37⁰C) PBS. The 
PBS was discarded, and flasks were incubated with 2 ml accutase (#A6964; Merck) 
at 37⁰C for at least 5 min. Once a single cell suspension had been achieved, 8 ml of 
complete culture medium (as specified above) was used to deactivate the accutase. 
Prior to experiments, a Z1 Coulter Particle Counter (Beckman Coulter, High 
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Wycombe, UK) was used to count the number of cells per ml in the suspension 
according to the manufacturer’s instructions.  
2.4 EVALUATING THE CONSEQUENCES OF PORE FORMATION 
2.4.1 Lactate dehydrogenase assay 
The release of LDH into cell supernatants was quantified by the LDH-dependent 
conversion of lactate to pyruvate via the reduction of β-Nicotinamide adenine 
dinucleotide sodium salt (NAD+) to β-Nicotinamide adenine dinucleotide sodium salt 
hydrate (NADH), which is detected by the NADH-dependent reduction of a 
tetrazolium salt to red formazan (Decker and Lohmann-Matthes, 1988). A 1.25 mM 
NADH standard stock solution was prepared in serum-free medium and used to 
generate a 0 to 20 nmol NADH standard curve (Table 2.4). Then 20 µl of standard 
curve or cell supernatant and 30 µl Tris(hydroxymethyl)aminomethane (Tris) 
hydrochloride (Tris-HCL) buffer pH 8.2 (Merck) were added in duplicate to a half-
area 96-well plate (#675061; Greiner Bio-One). 
Table 2.4 NADH standard curve 
NADH (nmol) Standard stock solution (µl) Media (µl) 
0 0 20 
5 4 16 
7.5 6 14 
10 8 12 
12.5 12 8 
15 14 6 
17.5 16 4 
20 20 0 
An assay mix consisting of 54 mM sodium L-lactate (#L7022; Merck), 0.66 mM 2-p-
iodophenyl-3-p-nitrophenyl tetrazolium (INT, #I8377; Merck), 0.28 mM phenazine 
methosulfate (#P9625; Merck) and 1.3 mM NAD+ (#N0632; Merck) was prepared in 
Tris-HCL buffer pH 8.2 (from the stock solutions shown in Table 2.5) as shown in 
Table 2.6, and 50 µl was added to each well of the 96-well plate.   
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Table 2.5 LDH assay mix stock solutions  
Solution Concentration Mass (mg) Dissolved in: 
Lactate 54 mM (10X stock) 605 10 ml assay buffer 
INT 0.66 mM (100X stock) 33.3 1 ml DMSO 
Phenazine 0.28 mM (100X stock) 8.5 1 ml PBS 
NAD+ 1.3 mM (10X stock) 89 10 ml assay buffer 
Table 2.6 LDH assay mix recipe 
Solution Volume (ml) 
Lactate 1 
INT 0.1 
Phenazine 0.1 
NAD+ 1 
LDH assay buffer 7.8 
Optical density (OD570) was measured using a POLARstar Omega micro plate reader 
before and after a 30 min incubation at 37.5⁰C. The difference in optical density 
represented the amount of NADH generated in each supernatant. Lactate 
dehydrogenase activity is defined as the amount of enzyme that catalyzes the 
conversion of lactate to pyruvate with the generation of 1 µmole of NADH per minute 
at 37.5⁰C and so the amount of LDH in each supernatant was calculated through the 
following equation: LDH Activity [nmole/min/ml] = (NADH × dilution factor) / 
(reaction time × volume of sample added to well [ml]. The inter- and intra-assay 
coefficients of variation for the LDH assay were < 2% and < 4% respectively. 
2.4.2 MTT assay  
A 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, #M2128; 
Merck) assay was used to assess viable cells after pore-forming toxin challenge as 
validated previously for the use of bovine endometrial cells challenged with pyolysin 
(Amos et al., 2014). The assay measured the reduction of MTT into an insoluble 
formazan product by the mitochondria of viable cells (Mosmann, 1983). At the end of 
each experiment medium was discarded and replaced with 250 µl cell specific serum-
free medium containing 1 mg/ml MTT and incubated in the dark for 2 h at 37⁰C. After 
2 h, the MTT solution was discarded, and formazan crystals were dissolved in 300 μl 
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DMSO in a shaker in the dark. The resulting solution was transferred to a clear flat 
bottom 96-well plate (#437958; Thermo Fisher Scientific), with 100 µl samples added 
in duplicate. Absorbance was read at 570 nm using a POLARstar Omega micro plate 
reader. 
2.4.3 CyQUANT assay  
The CyQUANT® Cell Proliferation Assay Kit (#C7026; Thermo Fisher Scientific) 
was used to quantify DNA as a measure of viable NDHF cells following pore-forming 
toxin challenge according to the manufacturer’s instructions. An MTT assay was not 
used because of the low metabolic activity of NDHF cells.  Immediately following the 
conclusion experiments, cell supernatants were removed, and cells were frozen at -
80⁰C overnight. The CyQUANT GR dye/cell lysis buffer was prepared by diluting the 
concentrated cell-lysis buffer stock 20-fold in distilled water, and then diluting the 
CyQUANT GR stock solution 400-fold in diluted cell lysis buffer. Plates were thawed 
to room temperature and 250 µl of CyQUANT GR dye/cell lysis buffer solution was 
added to individual wells and incubated in the dark at room temperature for 5 min. 
Samples (100 µl) were added in duplicate to black 96-well half area clear bottom plates 
(#734-4155; VWR). Fluorescence was measured with a POLARstar Omega micro 
plate reader using 480 nm excitation and 520 nm emission. 
2.4.4 Potassium leakage 
The leakage of potassium from cells was measured by flame photometry as described 
previously (Turner et al., 2020). A potassium-free choline buffer was prepared by 
adding the ingredients shown in Table 2.7 to 500 ml distilled water and adjusted to pH 
7.4 with 2 M NaOH. 
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Table 2.7 Potassium assay buffer recipe 
Ingredient Product code and 
supplier 
Mass (mg) Concentration 
(mM) 
Ammonium 
chloride 
#213330; Merck 267.5 10 
Calcium chloride #10043-52-4; 
Thermo Fisher 
Scientific 
83.3 1.5 
Choline chloride #C1879; Merck 9000 129 
Citric acid #C0759; Merck 480.3 5 
D-(+)-glucose #G5767; Merck 500 5.6 
Magnesium 
chloride 
#M8266; Merck 38 0.8 
Phosphoric acid #79622; Merck 245 5 
In preparation for experiments, cells were seeded for 24 to 48 h in complete medium 
at 1.5 x 105 cells per well in 6-well culture plates (#92006T; TPP) and treated in serum-
free medium for a further 24 h. Supernatants were discarded, and cells were washed 
three times with the potassium assay buffer. Cells were challenged with control 
medium or pyolysin for 5 min, or α-hemolysin for 15 min at 37⁰C. A 15 min α-
hemolysin challenge was selected as no potassium leakage was detected from bovine 
endometrial stromal cells or HeLa cells after a 5 min challenge period (Fig 2.6). 
Supernatants were collected after the challenge period. Cells were then washed three 
times in ice-cold potassium assay buffer and lysed with 0.5% Triton X-100 (#T9284; 
Merck) in dH2O for 20 min on a rocker at room temperature. All samples were 
centrifuged at 11,000 x g for 5 min to separate cell debris.  Potassium was measured 
in supernatants and lysates using a Jenway PFP7 flame photometer (Cole-Parmer, 
Stone, Staffordshire, UK) according to the manufacturer’s instructions.  Distilled water 
was aspirated through the flame photometer for 15 min to reach operating temperature, 
before the readout was set to zero.  A 500 ppm potassium stock solution was prepared 
by dissolving 95.4 mg potassium chloride (KCL; equating to 50 mg/ potassium) in 100 
ml distilled water. A 0 to 25 ppm potassium standard curve was prepared by diluting 
the KCL stock solution as shown in Table 2.8. 
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Figure 2.6 Potassium leaks from cells challenged with α-hemolysin for 15 min  
Extracellular and intracellular potassium from (A, B) bovine endometrial stromal and 
(C, D) HeLa cervical challenged for 5 min or 15 min with control medium or 8 µg α-
hemolysin. Dots represent the values from 4 independent experiments; data were 
analysed by t-test, **P < 0.01. 
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Table 2.8 Potassium standard curve 
Potassium (ppm) KCL stock (ml) Distilled water (ml) 
25 2.5 47.5 
20 2 48 
15 1.5 48.5 
10 1 49 
5 0.5 49.5 
 A 25 ppm potassium standard was aspirated, and the fuel settings were adjusted to 
obtain a peak reading. Once a peak reading was reached, the readout was set to 25. 
The other standards were read without adjusting the readout value and a standard curve 
was plotted. Samples were then aspirated, and readouts were recorded. Distilled water 
was continually aspirated between samples and the top standard (25 ppm) was 
periodically checked to ensure the readout remained consistently at 25 ppm. The 
standard curve was then used to adjust the readout values to ppm. The inter- and intra-
assay coefficients of variation were < 4%.  
Although supernatants and lysates were measured to obtain extracellular and 
intracellular potassium readouts for each sample, only data for extracellular potassium 
is reported in Results as the pyolysin-induced potassium leakage was represented 
equally by both data sets (Fig 2.7). Additionally, as the control challenge did not cause 
potassium leakage in cells treated with side-chain oxysterols (Fig 2.7A), LXR agonists 
(Fig 2.7B), or glucocorticoids (Fig 2.7C), only pyolysin challenge data is reported for 
treatments in Results.  
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Figure 2.7 Control challenge does not cause potassium ion leakage in treated cells 
Extracellular and intracellular potassium from HeLa cells treated for 24 h with vehicle, 
(A) 10 ng/ml 25-hydroxycholesterol (25-HC), 10 ng/ml 27-hydroxycholesterol (27-
HC), 1 mM MβCD, (B) 25 nM T0901317, 125 nM GW3965, (C) 10 µM 
dexamethasone, or 10 µM hydrocortisone and then challenged for 5 min with control 
medium or 100 HU pyolysin. Dots represent individual values from 4 independent 
experiments; statistical significance was determined using one-way ANOVA with 
Dunnett’s post hoc test; pyolysin challenge effects cellular potassium, ***P < 0.001. 
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2.5 CELL MICROSCOPY  
2.5.1 Phase contrast microscopy  
To visually quantify the damage caused by pore forming toxins transmitted light 
micrographs of cells were captured as described previously (Turner et al., 2020). Cells 
were cultured in 24-well plates (#92024, TPP) and after the specified duration of toxin 
challenge, an Axiovert 40C inverted microscope and Axiocam ERc5s microscope 
camera (Zeiss, Jena, Germany) were used to capture images. 
2.5.2 Immunofluorescence 
To examine the cytoskeleton, cells were stained with the actin dye phalloidin as 
described previously (Turner et al., 2020, Pospiech et al., 2021). Cells were seeded in 
complete medium on glass cover slips (#631-0150; VWR) in 24-well culture plates for 
24 to 48 h. Relevant treatments were applied for 24 h in serum-free medium, and cells 
were challenged with control medium or medium containing pyolysin for 2 h, or α-
hemolysin for 24 h. At the end of the challenge period, cells were washed with 500 µl 
PBS, fixed with 200 µl PBS containing 4% paraformaldehyde (#158127; Merck), 
washed twice again with PBS, and then permeabilized for 10 min in 250 µl PBS 
containing 0.2% Triton X-100. The cells were blocked for 30 min in 250 µl PBS 
containing 0.5% BSA and 0.1% Triton X-100 and then incubated for 1 h with 200 µl 
Alexa Fluor 555-conjugated phalloidin (1:1000 dilution in PBS, #A34055; Thermo 
Fisher Scientific). Cells were washed with 0.1% Triton X-100 in PBS three times, and 
then mounted onto microscope slides using Vectashield with 4,6-diamidino-2-
phenylindole (DAPI, #H-1200-10; Vector Laboratories Inc., Burlington, CA, USA) to 
visualize cell nuclei. The cells were examined using an Axio Imager M1 fluorescence 
microscope and images were captured using an AxioCamMR3 (Zeiss). 
Cells were stained with CellMask Deep Red plasma membrane stain (#C10046; 
Thermo Fisher Scientific) to investigate cell shape following pyolysin challenge 
according to the manufacturer’s instructions. Cells were cultured on glass cover slips 
in 24-well culture plates in complete medium for 24 h, treated for 24 h in serum-free 
media and challenged for 2 h with control medium or medium containing pyolysin. At 
the end of the challenge period, cells were washed twice with 500 µl PBS, incubated 
with 250 µl CellMask Deep Red (diluted 1:2000 in PBS) for 10 min at 37⁰C, washed 
again with PBS, and fixed with 200 µl PBS containing 4% paraformaldehyde. 
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Coverslips were mounted onto microscope slides using Vectashield with DAPI to 
visualize cell nuclei, and the cells were examined using an Axio Imager M1 
fluorescence microscope and images captured using an AxioCamMR3. 
2.5.3 Confocal microscopy  
To visualize changes in cellular cholesterol content, cells were stained with the 
cholesterol dye filipin III, as described previously (Turner et al., 2020). Cells were 
seeded at a density of, 5 x 104 cells/well in complete medium on glass cover slips in 
24-well culture plates for 24 h then treated in serum-free medium for 24 h. Coverslips 
were washed with 500 µl PBS, fixed with 200 µl PBS containing 4% 
paraformaldehyde, and washed twice again with PBS. Cells were stained with 50 
μg/ml filipin III from Streptomyces filipinensis (stock diluted 1:160 in 200 µl PBS 
#F4767; Merck) for 45 min at room temperature before a final three PBS washes. 
Cover slips were mounted using polyvinyl alcohol mounting medium with 1,4-
diazabicyclo-(2,2,2)-octane (#10981; Merck). A LSM710 confocal microscope (Zeiss) 
with the Zeiss Zen 2010 software was used to examine cellular cholesterol and images 
captured using a 40× oil objective and a 410 to 476 nm channel range. All coverslips 
were subjected to identical exposure times and conditions. 
2.6 CHOLESTEROL MEASUREMENT  
Cellular cholesterol was quantified from cells seeded at 1.5x105 cells/well in 6-well 
plates using the Amplex Red Cholesterol Assay Kit, according to the manufacturer’s 
instructions (#A12216; Thermo Fisher Scientific). At the end of the treatment period, 
cells were washed twice with 500 µl DPBS and then collected in 250 µl 1X Reaction 
Buffer and stored at -20⁰C. Samples were defrosted at room temperature and sonicated 
for 10 min, ensuring the absence of a pellet. The assay was carried out on a black 96-
well half-area plate (#734-1626; VWR). A standard curve was creating by diluting the 
5.17 mM cholesterol reference standard provided in 1X Reaction Buffer to give 
concentrations from 0 to 20 µM and 25 µl was added in duplicate to the 96-well plate. 
Samples were diluted appropriately in 1X Reaction Buffer and 25 µl was added in 
duplicate to the plate. An assay mix was prepared as shown in Table 2.9 and 25 µl was 
added to each well that contained standard or sample. The plate was incubated in the 
dark at 37⁰C for 30 min before fluorescence was measured by a POLARstar Omega 
micro plate reader using excitation in the range of 530 nm and emission 590 nm. The 
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inter- and intra-assay coefficients of variation for the cholesterol assay were < 5%. 
Protein abundance was also measured in the samples using a DC protein assay and 
cholesterol concentrations were normalized to protein (Nicholson and Ferreira, 2009). 
Table 2.9 Amplex Red working solution recipe  
Material Volume required for 100 assays (µl) 
Amplex® Red reagent stock solution 37.5 
Horseradish peroxidase 25 
Cholesterol oxidase, from Streptomyces 25 
Cholesterol esterase, from Pseudomonas 2.5 
1X Reaction Buffer 2.41 
2.7 WESTERN BLOTTING  
Protein isolation and Western blotting was performed as described previously, with 
minor modifications (Bromfield and Sheldon, 2011, Griffin et al., 2018). To extract 
protein for Western blotting, cells were washed with 500 μl of ice-cold PBS and lysed 
with 100 μl of PhosphoSafe extraction reagent (#71296; Merck). Protein concentration 
was quantified using a DC assay as described in section 2.2.1. Acrylamide gels were 
constructed as shown in Table 2.10, left to polymerize for 30 min, and 10 µg of protein 
or 10 μl Precision Plus All Blue Protein Standard (#1610373; Bio-Rad) were added to 
individual lanes. Proteins were separated in a mini trans-blot PROTEAN 
electrophoresis cell (Bio-Rad) for 40 min at 180 V (PowerPac Basic, Bio-Rad).   
Table 2.10 In-house acrylamide gel recipe (for 1 gel) 
Reagent 7.5 % Gel 10 % Gel 12 % Gel Stacking Gel 
Water 5 ml 4.2 ml 3.5 ml 1.75 ml 
4 x Tris & SDS 
(Separating buffer) 
2.5 ml 2.5 ml 2.5 ml 0.75 ml 
(stacking buffer) 
30 % Acrylamide 2.5 ml 3.3 ml 4 ml 0.5 ml 
APS (10% 
solution) 
100 μl 100 μl 100 μl 50 μl 
TEMED 10 μl 10 μl 10 μl 3 μl 
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Proteins were transferred onto polyvinylidene difluoride membranes (GE Healthcare, 
Chalfont, St Giles, UK) by semi-dry transfer for 25 V for 30 min in a Trans-Blot Turbo 
Transfer System (Bio-Rad). Membranes were then blocked with a 1 h room 
temperature incubation in Tris-buffered saline containing 0.1% Tween 20 (TBST, 
#P7949; Merck) with 5% BSA, before being probed overnight at 4⁰C with the relevant 
antibody of interest (Table 2.11). 
After incubation, membranes were washed five times for 5 min in TBST before 
secondary antibodies were added in TBST with 5% BSA for an hour at room 
temperature. Membranes were then washed a further five times with TBST. Protein 
reactivity was visualized using enhanced chemiluminescence (Clarity Western 
enhanced chemiluminescence substrate, #1705061; Bio-Rad) and captured with a 
ChemiDoc XRS System (Bio-Rad) using Quantity One software (Bio-Rad). After 
imaging, membranes were stripped for 7 min with Restore Western Blot Stripping 
Buffer (#21059; Thermo Fisher Scientific) and reprobed to detect another primary 
antibody, or with α-tubulin or β-actin to normalize protein loading. A representative 
whole blot image for each of the antibodies used in the present thesis is displayed in 
Fig 2.8. The average peak density of bands was quantified using Fiji and target proteins 
were normalized to α-tubulin or β-actin; phosphorylated proteins were normalized to 
their cognate total protein (Schindelin et al., 2012). 
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Table 2.11 List of antibodies used in this study 
Antibody target Species 
raised in 
and 
clonality 
Predicted 
molecular 
weight 
(kDa) 
Supplier Product 
code 
RRID 
Primary antibodies 
LXRα Rabbit 
monoclonal 
50 Abcam ab176323 AB_2877144 
LXRβ Rabbit 
polyclonal 
51 Abcam ab28479 AB_776097 
ABCA1 Mouse 
monoclonal 
254 Abcam ab18180 AB_444302 
diphosphorylated 
ERK1/2 
Mouse 
monoclonal 
44/42 Merck M8159 AB_477245 
ERK1/2 Rabbit 
polyclonal 
44/42 Abcam ab17942 AB_2297336 
phospho-p38 Rabbit 
monoclonal 
43 Cell 
Signaling 
4511 AB_2139682 
p38 Rabbit 
monoclonal 
40 Cell 
Signaling 
8690 AB_10999090 
phospho-JNK Rabbit 
polyclonal 
54/46 Cell 
Signaling 
9251 AB_331659 
JNK Rabbit 
polyclonal 
54/46 Cell 
Signaling 
9252 AB_2250373 
HMGCR Rabbit 
monoclonal 
97 Abcam ab174830 AB_2749818 
Glucocorticoid 
receptor 
Rabbit 
monoclonal 
94/91 Cell 
Signaling 
12041 AB_2631286 
α tubulin Rabbit 
monoclonal 
52 Cell 
Signaling 
2144 AB_2210548 
β actin Mouse 
monoclonal 
42 Abcam ab8226 AB_306371 
α-His-pyolysin 
antibody 
Rabbit 
polyclonal 
55 Generously 
gifted by 
Prof. B.H. 
Jost, 
University 
of Arizona 
N/A N/A 
Secondary antibodies 
Anti-rabbit IgG  Goat 
polyclonal 
N/A Cell 
Signaling 
7074 AB_2099233 
Anti-mouse IgG Horse 
polyclonal 
N/A Cell 
Signaling 
7076 AB_330924 
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Figure 2.8 Representative whole blot images for the antibodies used in this thesis 
Representative Western blot images, captured with a ChemiDoc XRS System, for each 
of the antibodies used in the present thesis. Protein was collected from bovine 
endometrial stromal cells for the LXRα and ABCA1 blots, from bovine endometrial 
epithelial cells for the LXRβ blot, and from HeLa cervical cells for the remaining 
targets. 
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2.8 OXYSTEROL MEASUREMENT 
2.8.1 Uterine and ovarian follicular fluid collection 
Oxysterols were quantified in the ovary and uterus, from bovine female genital tracts 
collected from healthy, post-pubertal, mixed breed cattle slaughtered as part of the 
daily work at the St Merryn Abattoir, Merthyr Tydfil. Immediately following 
collection, the uteri were individually bagged and placed in a cool box filled with ice 
ready for transport. At the laboratory, the uteri were rinsed with sterile PBS and the 
surface of the endometrium was exposed by a longitudinal cut in each uterine horn. 
Fluid was aspirated from the surface of the endometrium using sterile 20-gauge needle 
and 2 ml endotoxin-free syringe (BD Medical, Oxford, U.K.). 
Ovaries were separated from the reproductive tract within 15 min of slaughter and 
stored in a thermos containing medium comprising Medium 199 (#31150030; Thermo 
Fisher Scientific), 1 % ABAM and 0.1% BSA, that was heated to 37.5⁰C. On returning 
to the laboratory, the ovaries were rinsed with sterile PBS before a sterile 20-gauge 
needle and 2 ml endotoxin-free syringe was used to aspirate follicular fluid from 
dominant (> 8 mm external diameter) and emerged (4 to 8 mm external diameter) 
ovarian follicles. The presence of a corpus luteum indicated that the selected animals 
were cyclic, and only healthy follicles with clear fluid were selected for aspiration. 
2.8.2 Epithelial and stromal cell supernatant sample collection 
Oxysterols were quantified in the supernatants of bovine endometrial stromal and 
epithelial cells following a lipopolysaccharide (LPS) or pyolysin challenge; two major 
virulence factors of uterine pathogens (Sheldon et al., 2002, Amos et al., 2014, Bonnett 
et al., 1991, Sheldon et al., 2010).  
Ultrapure LPS from E. coli 0111:B4 (#tlrl-3pelps; Invivogen, Toulouse, France) was 
reconstituted to 5 mg/ml in ultrapure, endotoxin-free water (provided by Invivogen 
alongside the LPS) and vortexed for 10 min. For storage, the LPS was further diluted 
to 1 mg/ml in the ultrapure, endotoxin-free water, and stored at -20⁰C in 2 ml salinized 
glass vials (#27029; Merck). Prior to use, LPS was defrosted at room temperature, 
sonicated for 5 min in a sonicating water bath, and vortexed for 1 min prior to diluting 
to required challenge concentration (1 µg/ml) in control serum-free medium (RPMI-
1640). The diluted LPS solution was the vortexed for an additional 1 min before use.  
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For experiments, epithelial and stromal cells were seeded at 1.5x105 cells per well in 
complete medium in 6-well culture plates for 24 h and 48 h, respectively, then 
incubated for 24 h in serum-free medium. Cells were then challenged for 24 h with 
control serum-free medium, or medium containing a sub-lytic concentration of 5 HU 
pyolysin or 1 µg/ml LPS. Collected supernatants were stored at -80⁰C ready for 
extraction. 
2.8.3 Sample preparation 
To examine the oxysterol content of bovine endometrial uterine and ovarian fluid and 
endometrial cell supernatants, samples were prepared for liquid chromatography-mass 
spectrometry as described by Abdel-Khalik et al. (2017). For biological fluid samples, 
100 µl was added dropwise to 1 ml ethanol containing 2 ng of [25,26,26,26,27,27,27-
2H6]24R/S-hydroxycholesterol, 2 ng of [25,26,26,26,27,27,27-
2H7]22R-
hydroxycholset-4-en-3-one, and 400 ng of [25,26,26,26,27,27,27-2H7]cholesterol 
(Avanti  Polar  Lipids) whilst under sonication in an ultrasonic bath for 5 min. The 
solution was then adjusted to 70% ethanol and sonicated for a further 5 min. For cell 
supernatants, 1 ml was added to 2.3 ml ethanol using the same standards under 
sonication. Solutions were then centrifuged at 17,000 × g for 30 min at 4⁰C and any 
debris were separated ready for oxysterol extraction. Then, 200-mg Certified Sep-Pak 
C18 columns (Waters, Elstree, Herts, U.K.) were used to separate oxysterols and 
steroid acids from cholesterol. Columns were conditioned, before samples were ran 
through at a rate of 1 to 2 drops per second. A further 5.5 ml 70% ethanol was added 
to the column to give the oxysterol containing fraction: solid phase extraction (SPE)1 
fraction 1. Samples were divided into equal volumes, labelled A and B, and dried 
overnight in a vacuum. 
Once dried, SPE1-Fraction 1 samples were dissolved in 100 µl isopropanol and 1 ml 
of 50 mM phosphate buffer (pH7). To samples labelled “A”, 3 µl of cholesterol 
oxidase from Streptomyces (2 mg/ml in H2O, 44 units/mg protein; Merck) was added, 
“B” samples were left untreated. Both A and B were incubated in a water bath for 1 h 
at 37.5⁰C before the addition of 2 ml absolute methanol and 150 µl glacial acetic acid. 
Finally, 150 mg of [2H0]Girard P reagent (#1126-58-5; Tokyo Chemical Industry, 
Oxford, UK) was added to all samples and vortexed. The derivatization reaction was 
then allowed to occur overnight, in the dark, at room temperature. To remove excess 
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derivatization reagent, we used 60-mg Oasis HLB (Waters) columns. Samples were 
ran through the columns three times and were diluted to 35% and 17.5% methanol for 
the second and third time respectively. The flow through was discarded and sterols 
were eluted from the columns with 3 x 1 ml 100% methanol (to give SPE2 fraction 1 
to 3) and 1 ml absolute ethanol (to give SPE2 fraction 4). All SPE2 fractions were 
stored at -20⁰C ready for analysis. 
2.8.4 Liquid chromatography-mass spectrometry 
Samples were analyzed on an Orbitrap Elite (Thermo Fisher Scientific) equipped with 
an electrospray probe, and a Dionex Ultimate 3000 LC system (Thermo Fisher 
Scientific) (Griffiths et al., 2013, Crick et al., 2015). Two injections were carried out 
per sample with three or more scan events per injection. One event was a high-
resolution (120,000, full width at half maximum height, at m/z 400) MS scan event in 
the Orbitrap analyzer and the rest were multi-stage fragmentation (MSn) scan events 
in the linear ion trap. Quantification was performed with Xcalibur 3.0 (Thermo Fisher 
Scientific) by stable isotope dilution using 24 R/S-[25,26,26,26,27,27,27-
2H6]hydroxycholesterol as the internal standard. Where authentic standards were 
unavailable, oxysterols were identified by retention time, mass and by second 
generation product ion (MS3). Peak areas were used to calculate concentrations (Crick 
et al., 2015). 
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2.9 SHORT INTERFERING RNA DESIGN AND KNOCKDOWN  
Previously validated siRNA (designed in the siDESIGN Centre package from 
Dharmacon GE healthcare) was used to target the genes NRIH2, NRIH3 and HMGCR 
(Table 2.12) (Griffin et al., 2017, Griffin et al., 2018) . A SMARTPool of siRNA 
targeting NR3C1 was purchased from Horizon Discovery (#003424-00-0005; Horizon 
Discovery, Cambridge, UK). 
Table 2.12 Short interfering RNA sequences 
Gene Species Direction Sequence (5’-3’) 
NR1H2 Human Sense G.A.A.G.A.A.G.A.A.G.A.U.U.C.G.G.A.A.A.U.U 
Antisense U.U.U.C.C.G.A.A.U.C.U.U.C.U.U.C.U.U.C 
Bovine Sense A.G.G.U.G.A.A.G.G.U.G.U.C.C.A.G.U.U.A.U.U 
Antisense U.A.A.C.U.G.G.A.C.A.C.C.U.U.C.A.C.C.U 
NR1H3 Human Sense C.C.U.C.A.A.G.G.A.U.U.U.C.A.G.U.U.A.U.U.U 
Antisense A.U.A.A.C.U.G.A.A.A.U.C.C.U.U.G.A.G.G 
Bovine Sense G.C.U.A.A.A.U.G.A.U.G.C.U.G.A.G.U.U.U.U.U 
Antisense A.A.A.C.U.C.A.G.C.A.U.C.A.U.U.U.A.G.C 
HMGCR Human Sense G.G.A.U.A.A.A.C.C.G.A.G.A.A.A.G.A.A.A.U.U 
Antisense U.U.U.C.U.U.U.C.U.C.G.G.U.U.U.A.U.C.C 
ON-TARGETplus non-targeting control pool scramble siRNA (#001810-10-05; 
Horizon Discovery) or target siRNA was dissolved in siRNA buffer (#B-002000-UB-
100; Horizon Discovery) to a final concentration of 20 µM. The scramble or target 
siRNA was then diluted in the required volume of OptiMEM medium (#11058021; 
Thermo Fisher Scientific) with 15 µl Lipofectamine RNA-iMax (#13778150; Thermo 
Fisher Scientific) added per ml OptiMEM in sterile 2 ml reaction tubes. The siRNA 
was vortexed for 30 s and then left to incubate for 15 min at room temperature to allow 
siRNA complex formation. The siRNA complex solution was then added to tissue 
culture plates before the cell type of interest was added in antibiotic-free culture 
medium. Specific volumes and concentrations are described in detail where relevant 
in each research chapter. Cells were incubated with siRNA for 48 h before treatments 
were added as previously described (Griffin et al., 2018, Griffin et al., 2017, Kadiyala 
et al., 2016). The effect of RNA interference on pyolysin challenge is displayed in Fig 
2.9. 
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Figure 2.9 RNA interference of bovine endometrial and HeLa cells 
Leakage of LDH and viability of (A) bovine endometrial epithelial, (B) stromal cells 
and (C) HeLa cervical cells treated for 48 h with control medium, or medium 
containing lipofectamine, or transfected for 48 h with scramble siRNA. Cells were 
then cultured for 24 h in serum-free medium and challenged for 2 h with control 
medium or pyolysin (epithelium 200 HU, stroma 25 HU, HeLa 100 HU). Data are 
presented as mean (SEM); statistical significance was determined using two-way 
ANOVA and Dunnett’s post hoc test; *P < 0.05. 
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2.10 QUANTITATIVE POLYMERASE CHAIN REACTION 
Quantitative polymerase chain reaction (PCR) was used to assess the effectiveness of 
siRNA targeting NRIH2 and NRIH3 in HeLa cervical cells. 
2.10.1 Total RNA Extraction  
Total RNA was isolated from HeLa cells in preparation for quantitative PCR using the 
RNeasy Mini Kit (#74104; Qiagen, Crawley, UK), according to the manufacturer’s 
instructions. Cells were lysed by the addition of with 350 µl RLT lysis buffer and 
thorough scraping. Lysates were transferred to 1.5 ml reaction tubes, and 350 µl 70% 
ethanol was added (mixed by gentle pipetting). Lysates were loaded into RNeasy mini 
spin columns and were centrifuged at 8,500 x g for 15 secs and the flow through was 
discarded. Then 700 µl RW1 buffer was added to the spin column and centrifuged 
again at 8,500 x g for 15 s and the flow through was discarded. The process repeated 
with 500 µl RPE buffer. An additional 500 µl of RPE buffer was added and the column 
was centrifuged at 8,500 x g for 2 min. Flow through was discarded and spin columns 
were transferred to new 2 ml collection tubes and centrifuged at 13,000 x g for 1 min 
to dry the membranes. Spin columns were then transferred to new 1.5 ml collection 
tubes and 30 µl RNase-free water was pipetted directly on to the spin column 
membrane. Spin columns were centrifuged at 8,500 x g for 1 min. Eluted RNA was 
ran through columns again to achieve a maximum yield.  
Quantification of eluted RNA was carried out using the NanoDrop spectrometer (ND-
100 Spectrometer, Labtech International, Uckfield UK). All samples were assumed to 
be free from contamination as the ratios obtained at 260/280 nm and 260/230 nm were 
between 1.8 and 2.2 (as shown in Table 2.13). Samples were then stored at -80⁰C until 
use.  
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Table 2.13 NanoDrop values for RNA isolated from HeLa cells in this project 
Replicate Sample RNA (ng/µl) 260/280 nm 260/230 nm 
 
 
1 
Control 365.8 2.09 2.16 
siScramble  355.8 2.12 1.87 
siNRIH2 348.1 2.11 1.88 
siNR1H3 370.1 2.1 2.06 
siNR1H2+3 355.6 2.09 2.02 
 
 
2 
Control 517.7 2.08 2 
siScramble  523.4 2.07 2.1 
siNRIH2 523.8 2.07 2.11 
siNR1H3 494.6 2.06 2.07 
siNR1H2+3 535.1 2.07 1.87 
 
 
3 
Control 398.9 2.15 1.86 
siScramble  429.1 2.14 2.03 
siNRIH2 432.6 2.14 2.1 
siNR1H3 405.8 2.15 2.08 
siNR1H2+3 384.9 2.15 1.8 
2.10.2 Complementary DNA synthesis 
In preparation for quantitative polymerase chain reaction (PCR), complementary DNA 
(cDNA) was synthesised from 1000 ng extracted RNA using the QuantiTect Reverse 
Transcription kit (#205311; Qiagen), according to the manufacturer’s instructions. 
Total RNA was defrosted on ice and 1000 ng was added to 2 µl genomic DNA wipeout 
buffer in a 200 µl PCR tube. Ice cold RNase-free water was added to reach a total 
volume of 14 µl. Samples were vortexed for 30 s, briefly centrifuged, then incubated 
at 42⁰C for 2 min in a T100™ Thermal Cycler (Bio-Rad). A reverse transcription 
master mix was prepared as shown in Table 2.14 and 6 µl was added to each sample. 
Samples were briefly vortexed and centrifuged and then incubated in a thermal cycler 
at 42⁰C for 15 mins for cDNA synthesis, then at 95⁰C for 3 min to inactivate the reverse 
transcription enzyme. Samples were then kept on ice ready for quantitative PCR.  
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Table 2.14 Complementary DNA synthesis master mix 
Reagent  Volume (µl) 
Quantiscript® Reverse Transcriptase 1 
Quantiscript RT Buffer 4 
RT Primer mix  1 
2.10.3 Quantitative PCR 
For quantitative PCR we used previously validated primers (designed using the NCBI 
primer design tool) against the human genes NR1H2 and NR1H3, with ribosome-like 
protein 19 (RPL19) used as a reference (sequences are shown in Table 2.15) (Griffin 
et al., 2018). 
Table 2.15 Primer sequences 
Gene Direction Sequence (5’ – 3’) 
RPL19 Forward GCGAGCTCTTTCCTTTCGCT 
Reverse TGCTGACGGGAGTTGGCATT 
NR1H2 Forward CAGACTGGGGCGTCCTTTC 
Reverse GACTGCGACTGTGACTGTGA 
NR1H3 Forward GGAGGTACAACCCTGGGAGT 
Reverse AGCAATGAGCAAGGCAAACT 
Primers were reconstituted to 10 µM in RNase-free water. The total reaction volume 
used for quantitative PCR was 25 µl and was prepared as shown in Table 2.16 with 
1.5 µl RNase-free water used as a no template control (NTC). The reaction was 
performed in triplicate on white low-profile plates (#MLL9651; Bio-Rad) using a plate 
set up as shown in Table 2.17. Standard curves were generated from mRNA extracted 
from untreated HeLa cell lysates using a 10-fold serial dilution from neat to 1 x 10-4 in 
nuclease-free water. 
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Table 2.16 Reaction set up for quantitative PCR 
Component  Volume (µl) 
2x QuantiFast SYBR Green PCR Master 
Mix (#204054, Qiagen) 
12.5 
Forward Primer 0.25 
Reverse Primer 0.25 
RNase-free water 10.5 
cDNA  1.5 
Total volume  25 
Table 2.17 Quantitative PCR plate layout 
 1 2 3 4 5 6 7 8 9 10 11 12 
A RPL19 standard curve NR1H2 standard curve siNR1H3: NR1H3 NTC 
RPL19 
NTC 
NR1H3 
NTC 
NR1H2 
B siNR1H3: NR1H2    
C siNR1H2: RPL19    
D siNR1H2: NR1H3    
E NR1H3 standard curve Scramble: RPL19 siNR1H2: NR1H2    
F Scramble: NR1H3 siNR1H2+3: RPL19    
G Scramble: NR1H2 siNR1H2+3: NR1H3    
H siNR1H3: RPL19 siNR1H2+3: NR1H2    
Once wells were loaded, the plate was centrifuged at 500 x g for 1 min. Quantitative 
PCR was then carried out on the CFX Connect Real-time thermal cycler (Bio-Rad) 
using the SYBR green protocol and the cycling conditions described in Table 2.18.  
Table 2.18  Quantitative PCR cycling conditions 
Step Time Temperature (⁰C) Cycles 
Initial activation 5 min 95 1 
Denaturation 10 s 95 
40 
Annealing 30 s 60 
Hold Infinite 4 1 
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Sample target and reference gene abundance was determined using the quantification 
cycle (Cq) values from the appropriate standard curve and changes in mRNA 
abundance were then determined from the ratio of target gene Cq to reference gene 
Cq, using Bio-Rad CFX manager software version 2.1. We used RPL19 as the 
reference gene and Cq values remained consistent regardless of treatments as shown 
in Table 2.19. Data presented in Results for target gene expression is normalized to the 
expression of RPL19.  
Table 2.19 Reference gene (RPL19) expression was consistent across treatments 
Treatment Cq value 
Scramble 17.35 - 18.32 
siNR1H2 17.53 - 18.27 
siNR1H3 17.36 - 18.34 
siNR1H2+NR1H3 17.47 - 18.19 
2.11 STATISTICAL ANALYSIS 
All graphs were prepared using GraphPad Prism 9.0.1 (GraphPad Software, San 
Diego, California, USA). The statistical unit was the animal used to isolate cells or to 
collect fluid from, or each independent experiment with the relevant cell line. 
Statistical analysis was performed using GraphPad Prism 9.0.1 with significance 
attributed when P < 0.05, and data reported as arithmetic mean ± the standard error of 
the mean (SEM). Data was analyzed for normality using the Shapiro-Wilks test, with 
data assumed to be normally distributed when P > 0.05. Comparisons between 
treatments or challenges were made using one-way or two-way analysis of variance 
(ANOVA) followed by a Dunnett, Bonferroni or Tukey post hoc test for multiple 
comparisons, or unpaired two-tailed Student’s t-test, as appropriate for the 
experimental data and as specified in Results and figure legends. In experiments using 
a range of treatment concentrations, P-values are reported for the ANOVA, presenting 
the effect of treatment on pore-forming toxin challenge. Significant differences 
between independent treatments or toxin challenges are presented as follows; 
*P < 0.05, **P < 0.01 and ***P < 0.001. Numerical values are reported where the 
differences between treatments and vehicle control were 0.05 ≤ P ≤ 0.2. In experiments 
investigating the effect of 27-hydroxycholesterol treatment duration on cytoprotection, 
correlation was evaluated using Pearson’s correlation coefficient.  
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3 OXYSTEROLS PROTECT BOVINE ENDOMETRIAL 
CELLS AGAINST PORE-FORMING TOXINS FROM 
PATHOGENIC BACTERIA 
3.1 INTRODUCTION 
Parturition in mammals is often followed by infection of the uterus with multiple 
pathogenic bacteria, and disruption of the protective epithelium of the endometrium to 
expose the underlying stroma. This is a particular problem in Bos taurus dairy cattle, 
where pathogenic bacteria cause postpartum uterine disease and infertility in up to 
40% of animals (Sheldon et al., 2019, Ribeiro et al., 2016). Many of these pathogenic 
bacteria secrete toxins that form pores in cell membranes leading to cell damage. The 
occurrence and severity of disease depends on how effectively the immune system 
kills and removes pathogens, and how well tissues limit damage and tolerate the 
presence of pathogens (Medzhitov et al., 2012, Read et al., 2008, Sheldon et al., 2019, 
Sheldon et al., 2020). The immune system is regulated, at least in part, by steroid 
hormones and oxysterols (Wira et al., 2015, Spann and Glass, 2013, Ogawa et al., 
2005, Cain and Cidlowski, 2017). However, it is not known whether steroid hormones 
or oxysterols can also affect the ability to tolerate pathogens by protecting cells against 
the damage caused by pore-forming toxins.  
Uterine pathogens such as Trueperella pyogenes, Escherichia coli, and 
Staphylococcus aureus secrete pore-forming toxins that can damage the bovine 
endometrium (Sheldon et al., 2002, Amos et al., 2014, Griffin et al., 1974, Bonnett et 
al., 1991). Trueperella pyogenes secretes pyolysin, which is a member of the 
cholesterol-dependent cytolysin family of pore-forming toxins (Amos et al., 2014, 
Peraro and van der Goot, 2016, Billington et al., 1997). These cytolysins specifically 
bind cholesterol, and not other sterol or oxysterol molecules, and/or require 
cholesterol-rich areas in the plasma membrane for pore formation (Bielska et al., 2014, 
Peraro and van der Goot, 2016, Flanagan et al., 2009, Tweten, 2005, Griffin et al., 
2018, Billington et al., 1997). There are three pools of cholesterol in plasma 
membranes: an essential pool, a sphingomyelin-bound pool, and a pool of labile 
cholesterol (Das et al., 2013, Das et al., 2014). It is thought that cholesterol-dependent 
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cytolysins bind to the accessible labile pool of cholesterol in plasma membranes, 
typically when the content of cholesterol exceeds 35 mol% (molar percentage) of 
plasma membrane lipids (Das et al., 2013). Pyolysin is secreted as a 55 kDa monomer 
and 30 to 50 molecules of pyolysin oligomerize to form a β-barrel transmembrane pore 
in the plasma membrane with an 18 nm internal diameter (Billington et al., 1997, Preta 
et al., 2016, Amos et al., 2014). These pores lead to leakage of potassium ions from 
cells within minutes, leakage of cytosolic proteins, such as lactate dehydrogenase 
(LDH) within an hour, changes in the cytoskeleton, and ultimately cytolysis (Tweten, 
2005, Gonzalez et al., 2011, Turner et al., 2020, Peraro and van der Goot, 2016). 
Staphylococcus aureus secretes α-hemolysin, which binds to the plasma membrane 
where 7 molecules oligomerize to form β-barrel transmembrane pores with a 1.6 nm 
internal diameter, which also leads to leakage of cytosolic molecules and causes 
cytolysis (Song et al., 1996, Berube and Bubeck Wardenburg, 2013). Although innate 
immunity and cellular repair mechanisms are well characterized (Gurcel et al., 2006, 
Amos et al., 2014, Gonzalez et al., 2011, Bromfield et al., 2015, Wira et al., 2005, 
Andrews and Corrotte, 2018), less is known about intrinsic protection of cells against 
damage caused by pore-forming toxins.  
Steroid hormones and oxysterols are derivatives of cholesterol that act through nuclear 
receptors to control important physiological functions associated with reproduction 
and metabolism. However, steroid hormones and oxysterols also modulate immunity 
and the risk of disease (Wira et al., 2015, Ogawa et al., 2005, Cain and Cidlowski, 
2017, Dang et al., 2017). For example, in the follicular phase of the oestrus cycle, 
oestradiol concentrations are elevated, and the endometrium is more resistant to 
infection, whist the high concentrations of progesterone experienced during the luteal 
phase can predispose to infection (Lewis, 2003, Lewis, 2004, Wira et al., 2005).  
The trauma of parturition can invoke a stress response, thereby increasing plasma 
cortisol concentrations (Hudson et al., 1976). Primiparous cows experience stressful 
events such as regular pen movements, calving and milking for the first time and 
demonstrate increased plasma cortisol concentrations compared to multiparous cows 
(Galvão et al., 2010). Furthermore, primiparous cows also have higher incidence of 
metritis compared to multiparous cows, and this could be partially attributed to the 
greater cortisol plasma concentrations in primiparous cattle (Galvão et al., 2010). 
Glucocorticoids such as cortisol reduce inflammation through multiple pathways, 
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including inhibiting the intracellular signaling pathways associated with innate 
immunity, but they may also effect the tolerance of cells to bacterial toxins (Cain and 
Cidlowski, 2017). 
Side-chain oxysterols, such as 25-hydroxycholesterol and 27-hydroxycholesterol, also 
suppressing innate immunity, reducing inflammation (Dang et al., 2017, Joseph et al., 
2003, Cunningham, 2000). Side-chain oxysterols are formed in cells that synthesize 
steroid hormones or bile acids, or during cholesterol catabolism, and they have a 
physiological role in cholesterol homeostasis. Side-chain oxysterols act, via 
transcription factors such as the liver X receptors (LXR) LXRα (encoded by NR1H3) 
and LXRβ (NR1H2), which are both expressed in the ovary and uterus (Janowski et 
al., 1996, Wang and Tontonoz, 2018, Mouzat et al., 2013), and by activating acetyl-
coenzyme A acetyltransferase (ACAT) to catalyze cholesterol esterification (Du et al., 
2004). Furthermore, the interferon stimulated production of 25-hydroxycholesterol 
activates ACAT, mobilizing plasma membrane cholesterol to provide immunity 
against several bacterial species such as Listeria monocytogenes and Shigella flexneri 
infection. Therefore, we wondered whether steroids or side-chain oxysterols, in 
addition to modulating immunity, might alter cell-intrinsic protection against the 
damage caused by pore-forming toxins in the endometrium.  
In the present chapter, we tested the hypothesis that progesterone, oestradiol, 
glucocorticoids, or side-chain oxysterols, alter bovine endometrial cell protection 
against pore-forming toxins. To test this hypothesis, we treated bovine endometrial 
epithelial and stromal cells with steroids or oxysterols, then challenged the cells with 
pore-forming toxins to screen for protective compounds. We used pyolysin because T. 
pyogenes is a major pathogen of the endometrium and pyolysin causes endometrial 
cell damage (Bonnett et al., 1991, Amos et al., 2014). Cytoprotection was initially 
assessed by measuring the pyolysin induced leakage of the cytosolic protein LDH and 
by evaluating cell viability. Promising compounds were then explored further by 
measuring changes to cytoskeleton, potassium ion leakage and cytoprotection against 
S. aureus α-hemolysin. We also explored the role of LXRs in cytoprotection and 
examined the presence of oxysterols in the endometrium. 
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3.2 MATERIALS AND METHODS 
3.2.1 Cytoprotection experiments 
For experiments exploring cytoprotection, epithelial and stromal cells (isolated as 
described in Chapter 2)  were seeded in 1 ml/well complete medium at a density of 5 
× 104/ml using 24-well tissue culture plates (unless otherwise specified), with stromal 
cells incubated for 24 h and epithelial cells for 48 h to establish 70% confluency. To 
select an appropriate concentration of pyolysin (generated and purified as described in 
Chapter 2)  to challenge cells, stromal and epithelial cells were cultured for 24 h in 1 
ml/well serum-free medium and then challenged for 2 h with control serum-free 
medium (comprising 200 µl Dulbecco’s phosphate-buffered saline (DPBS) for 15 min, 
then supplemented with 400 µl serum-free medium up to 2 h) or medium containing a 
range of concentrations of pyolysin, as specified in Results. Serum-free medium was 
used because the 1.12 ± 0.05 mM cholesterol present in the FBS used in the present 
study (quantified from 2 independent aliquots of FBS and analysed by Anthony 
Horlock with the cholesterol oxidase-enzymatic endpoint method using the Randox 
Daytona Plus, Randox Laboratories Ltd., Crumlin, UK) might confound the results by 
binding to pyolysin. A 2 h challenge was used because we established previously that 
2 h was sufficient to cause cytolysis (Griffin et al., 2018, Amos et al., 2014); and, we 
aimed to examine cytoprotection against pore-forming toxins, whereas a longer 
challenge might also reflect cell repair and replication. At the end of the challenge 
period, supernatants were collected to measure the leakage of LDH, and cell viability 
was measured using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) assay as described in Chapter 2. 
To examine whether steroids, side-chain oxysterols or synthetic LXR agonists 
protected cells against damage by pyolysin, stromal and epithelial cells were treated 
in 1 ml/well serum-free medium with vehicle or the range of treatment concentrations 
specified in Results of progesterone, oestradiol, hydrocortisone, dexamethasone 
25-hydroxycholesterol, 27-hydroxycholesterol, according to the manufacturers’ 
instructions. Progesterone, oestradiol, and hydrocortisone concentrations were 
selected spanning and exceeding physiological plasma concentrations in cattle, which 
are ~30 nM, ~10 pM, and ~20 nM respectively  (Sheldon et al., 2002, Galvão et al., 
2010, Savio et al., 1993). Oxysterol concentrations were selected, in the absence of 
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data in cattle, based on concentrations in human plasma of 2 ± 3 ng/ml 
25-hydroxycholesterol and 154 ± 43 ng/ml 27-hydroxycholesterol, with the latter 
selected for initial experiments because it is the most abundant (Dzeletovic et al., 
1995). The synthetic LXR agonists T0901317 (N-(2,2,2-tri-fluoro-ethyl)-N-[4-(2,2,2-
trifluoro-1-hydroxy-1-trifluoro-methyl-ethyl)-phenyl]-benzenesulfonamide) and 
GW3965 (3-(3-(2-chloro-3-trifluorome-thylbenzyl-2,2-
diphenylethylamino)propoxy)phenylacetic acid) were used as described previously 
(Schultz et al., 2000, Oliver et al., 2001). Treatments were applied for 24 h based on 
previous studies of cytoprotection (Statt et al., 2015, Griffin et al., 2018), except for 
experiments exploring the duration of 27-hydroxycholesterol required to protect cells 
against pyolysin, where cells were for a range of times up to 24 h, as specified in 
Results. After the treatment period, the supernatants were discarded, and then the cells 
were challenged for 2 h, except where specified in Results, with control serum-free 
medium or medium containing the selected concentrations of pyolysin that caused cell 
damage (stroma, 25 HU; epithelium, 200 HU), without further treatment. 
To examine the role of LXRα and LXRβ in oxysterol cytoprotection against pyolysin, 
we used short interfering ribonucleic acid (siRNA) to target NR1H3 and NR1H2, 
respectively, as validated previously in bovine endometrial cells by a > 90% reduction 
in expression of NR1H3 and NR1H2 messenger RNA (mRNA) (Griffin et al., 2018). 
Cells were transfected with scrambled siRNA (ON-TARGETplus Non-targeting 
Control Pool; Horizon discovery) or siRNA designed using Dharmacon siDESIGN 
Centre to target NR1H3 or NR1H2 (described in Chapter 2). A mixture of 20 pmol 
siRNA, 1.5 µl Lipofectamine RNAiMAX Reagent and 100 µl Opti-MEM 1 medium 
was added to each well of a 24-well plate and incubated for 20 min at room 
temperature. Bovine endometrial stromal and epithelial cells were then seeded with 5 
× 104 cells in 900 µl RPMI-1640 medium with 10% FBS for 48 h. Cells were then 
treated with vehicle, 25 ng/ml 27-hydroxycholesterol or 25 nM T0901317 for 24 h in 
serum-free medium prior to a 2 h challenge with control medium or medium 
containing pyolysin (stroma, 25 HU; epithelium, 200 HU). At the end of the challenge 
period, supernatants were collected to measure the leakage of LDH, and cell viability 
was measured using an MTT assay. 
To examine the role of ACAT in oxysterol cytoprotection we used the selective ACAT 
inhibitor Sandoz 58-035 (SZ58-035) (Ross et al., 1984) Bovine endometrial stromal 
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and epithelial cells were washed twice with phosphate-buffered saline (PBS) then 
treated with vehicle or 10 µM SZ58-035 in serum-free medium for 16 h as previously 
described (Abrams et al., 2020). The cells were then washed twice with PBS then 
incubated for 24 h in serum-free culture medium containing 25 ng/ml 
27-hydroxycholesterol or 25 nM T0901317 in combination with vehicle or 10 µM 
SZ58-035. Cells were challenged for 2 h with control medium or medium containing 
pyolysin (stroma, 25 HU; epithelium, 200 HU). At the end of the challenge period, 
supernatants were collected to measure the leakage of LDH, and cell viability was 
measured using an MTT assay. 
To determine if cytoprotection extended beyond cholesterol-dependent cytolysins, 
after a 24 h treatment in serum-free medium containing vehicle or 25 ng/ml 
27-hydroxycholesterol, the cells were challenged for 24 h with 8 µg/5 × 104 cells 
α-hemolysin (added in 200 µl Dulbecco’s phosphate-buffered saline (DPBS) for 15 
min, then supplemented with 400 µl serum-free medium up to 24 h)  from 
Staphylococcus aureus. The concentration of α-hemolysin and duration of challenge 
was based on previous work (Mestre et al., 2010); and, on preliminary experiments in 
HeLa cervical and A549 cells (data shown in Chapter 4; Fig 4.12, 4.13) where shorter 
challenge periods did not cause sufficient cytolysis to explore cytoprotection. At the 
end of the challenge period, supernatants were collected to measure the leakage of 
LDH, and cell viability was measured using an MTT assay. 
3.2.2 Potassium 
The leakage of potassium from cells was measured to further evaluate cytoprotection 
against cytolysin-induced membrane pores, as described previously (Turner et al., 
2020), and in Chapter 2. Cells were seeded at a density of 1.5 × 105 cells/well in 3 
ml/well complete medium using 6-well culture plates. Stromal cells were incubated 
for 24 h and epithelial cells for 48 h, before treatment in 3 ml/well serum-free medium 
containing vehicle, 5 ng/ml 25-hydroxycholesterol, 25 ng/ml 27-hydroxycholesterol, 
25 nM T0901317, 125 nM GW3965, or 0.5 mM MβCD as a positive control to deplete 
cellular cholesterol (Griffin et al., 2018, Amos et al., 2014). The supernatants were 
discarded, the cells were washed three times with potassium-free choline buffer (129 
mM choline-Cl, 0.8 mM MgCl2, 1.5 mM CaCl2, 5 mM citric acid, 5.6 mM glucose, 10 
mM NH4Cl, 5 mM H3PO4, pH 7.4; all Merck), and then incubated in potassium-free 
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choline buffer with control medium or pyolysin for 5 min (epithelium, 200 HU; 
stroma, 25 HU), or α-hemolysin for 15 min (no potassium leakage was visible from 
stromal cells after 5 min of α-hemolysin challenge). Supernatants were then collected, 
and potassium was measured using a Jenway PFP7 flame photometer as described in 
Chapter 2. 
3.2.3 Cholesterol 
To quantify cellular cholesterol, epithelial and stromal cells (1.5 × 105 cells/well) were 
cultured for 24 h and 48 h respectively in 3 ml/well complete medium using 6-well 
culture plates. Cells were then treated for 24 h in 3 ml/well serum-free medium 
containing vehicle, 5 ng/ml 25-hydroxycholesterol, 25 ng/ml 27-hydroxycholesterol 
or 0.5 mM MβCD. At the end of the treatment period, cells were washed twice with 
DPBS and collected in 250 µl cholesterol assay 1X Reaction Buffer and stored 
at -20⁰C. Cellular cholesterol was measured using the Amplex Red Cholesterol Assay 
Kit as described in Chapter 2. Protein abundance was measured in samples using a DC 
protein assay, and cholesterol concentrations were normalized to protein 
concentrations (Nicholson and Ferreira, 2009).  
3.2.4 Immunofluorescence 
To examine the cytoskeleton, cells were stained with the actin dye phalloidin, as 
described previously (Turner et al., 2020), and in Chapter 2. Briefly, 5 × 104 epithelial 
or stromal cells were cultured on glass cover slips in 24-well culture plates in complete 
medium for 24 h or 48 h, respectively, before treatment for 24 h in serum-free medium 
containing vehicle, 25 ng/ml 27-hydroxycholesterol or 25 nM T0901317. The 
supernatants were discarded, and the cells challenged with control medium or medium 
containing pyolysin for 2 h, or α-hemolysin for 24 h. At the end of the challenge period 
cells were stained with Alexa Fluor 555-conjugated phalloidin and 4,6-diamidino-2-
phenylindole (DAPI) then imaged as described in Chapter 2. The proportion of cells 
that had cytoskeletal changes (cytoskeletal contraction, disrupted shape, or loss of 
actin fibre definition) were counted using > 45 stromal or > 150 epithelial cells per 
treatment, across 3 independent images per replicate.  
Filipin III from Streptomyces filipinensis was used to stain cholesterol, using stromal 
cells because of their higher cholesterol content than epithelial cells (Amos et al., 
2014). Briefly, 5 × 104 epithelial or stromal cells/well were seeded in complete 
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medium on glass cover slips in 24-well culture plates for 24 h or 48 h, respectively 
before treatment for 24 h in serum-free medium with vehicle, 25 ng/ml 
27-hydroxycholesterol, 5 ng/ml 25-hydroxycholesterol, or 0.5 mM MβCD. Staining 
and imaging was carried out as described in Chapter 2. Three independent images 
were captured per treatment replicate, and total cell fluorescence was calculated from 
3 cells per image using Fiji (Schindelin et al., 2012). 
3.2.5 Western Blotting 
Binding of pyolysin to plasma membranes was quantified as described previously with 
minor modifications (Billington et al., 1997, Amos et al., 2014). Stromal cells were 
seeded at a density of 1.5 x 105 cells/well in 3 ml/well complete medium using 6-well 
culture plates for 24 h, and then treated for 24 h in 3 ml/well serum-free medium 
containing vehicle, 50 nM progesterone, 0.1 nM oestradiol, 10 µM hydrocortisone, 
25 ng/ml 27-hydroxycholesterol or 0.5 mM MβCD, before a 2 h challenge with control 
serum-free medium or 25 HU pyolysin. The medium was then discarded, and the cells 
were washed with 300 μl ice-cold PBS and lysed with 100 μl PhosphoSafe Extraction 
Reagent. Protein was extracted and quantified using a DC assay, and 10 μg/lane protein 
separated using 10% (vol/vol) SDS-polyacrylamide gel electrophoresis as described 
in Chapter 2. The average peak density of bands was quantified and normalized to 
α-tubulin using Fiji (Schindelin et al., 2012). 
To validate the effectiveness of siRNA targeting NR1H2 and NR1H3, cell lysates were 
stored in PhosphoSafe Extraction Reagent for Western blot quantification of LXRα, 
and LXRβ, and adenosine triphosphate binding cassette subfamily A member 1  
(ABCA1), which is an LXR-induced protein (Ito et al., 2015). Protein was separated 
using 10% (LXRα and LXRβ) and 7.5% (ABCA1) SDS-polyacrylamide gel 
electrophoresis as described in Chapter 2. Average peak band density was quantified 
and normalized to α-tubulin or β-actin using Fiji as described in Results (Schindelin et 
al., 2012). 
3.2.6 Oxysterols 
To quantify oxysterols in the ovary and uterus of freshly slaughtered cattle using liquid 
chromatography-mass spectrometry as described in Chapter 2, fluid was collected 
from dominant (> 8 mm external diameter) and emerged (4 to 8 mm external diameter) 
ovarian follicles and uterine fluid aspirated from the surface of the  endometrium. In 
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addition, we explored whether oxysterols were secreted into endometrial epithelial or 
stromal cell supernatants in response to lipopolysaccharide (LPS) or pyolysin as 
described in Chapter 2. The LPS acted as a positive control, as LPS stimulates the 
release of 25-hydroxycholesterol from murine macrophages (Reboldi et al., 2014).  
3.2.7 Statistical analysis 
The statistical unit was the animal used to isolate cells or to collect fluid samples from. 
Statistical analysis was performed using GraphPad Prism 9.0.1. Data are reported as 
arithmetic mean (SEM), and significance attributed when P < 0.05. Comparisons 
between treatments or challenges were made using analysis of variance (ANOVA) 
followed by Dunnett, Bonferroni or Tukey post hoc test for multiple comparison, or 
unpaired two-tailed Student’s t-test as specified in Results. Correlation was evaluated 
using Pearson’s correlation coefficient. 
3.3 RESULTS  
3.3.1 27-hydroxycholesterol protected endometrial cells against pyolysin 
To first determine concentrations of pyolysin to test cytoprotection we challenged 
endometrial epithelial and stromal cells for 2 h with a range of concentrations of 
pyolysin. Pyolysin-induced pore formation was determined by the leakage of LDH 
into cell supernatants, and cytolysis was evaluated by measuring cell viability. In both 
epithelial and stromal cells, pyolysin caused a concentration-dependent leakage of 
LDH and a reduction in cell viability (Fig 3.1). For subsequent cytoprotection 
experiments, we selected 200 HU/5 × 104 cells pyolysin to challenge epithelial cells 
and 25 HU/5 × 104 cells pyolysin to challenge stromal cells as these concentrations 
increase LDH leakage (P < 0.001, ANOVA and Dunnett’s post hoc test, n=4) and 
caused cytolysis, significantly reducing cell viability (P < 0.001, ANOVA and 
Dunnett’s post hoc test, n=4). 
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Figure 3.1 Pyolysin damages bovine endometrial cells 
Leakage of LDH into supernatants, and cell viability determined by MTT assay for 
bovine endometrial (A) epithelial and (B) stromal cells challenged for 2 h with control 
medium or the indicated concentrations of pyolysin. Data are presented as mean 
(SEM) using values from 4 independent animals; statistical significance was 
determined using one-way ANOVA and Dunnett’s post hoc test; *P < 0.05, 
**P < 0.01, ***P < 0.001.  
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To screen for cytoprotective treatments, epithelial and stromal cells were treated for 
24 h with a range of concentrations of progesterone, oestradiol, hydrocortisone, 
dexamethasone, or 27-hydroxycholesterol, and then challenged for 2 h with control 
medium or pyolysin. As before, pyolysin increased the leakage of LDH into cell 
supernatants (P < 0.001, Fig 3.2, 3.3) and caused cytolysis as determined by reduced 
cell viability (P < 0.001, Fig 3.2, 3.3). Compared with vehicle, treatment with 
progesterone, oestradiol or hydrocortisone had little effect on the pyolysin-induced 
leakage of LDH or cytolysis (Fig 3.2, 3.3). There was a trend for reduced cytolysis in 
epithelial cells treated with the synthetic glucocorticoid dexamethasone, though there 
was no reduction in LDH leakage, and it did not protect stromal cells (Fig 3.4). 
However, 27-hydroxycholesterol reduced pyolysin-induced leakage of LDH and 
protected against cytolysis in both cell types (Fig 3.5). Specifically, 25 ng/ml 
27-hydroxycholesterol reduced pyolysin-induced leakage of LDH from epithelial and 
stromal cells by 56% and 82% (P < 0.001, two-way ANOVA and Dunnett’s post hoc 
test) respectively; and reduced pyolysin-induced cytolysis in epithelial and stromal 
cells from > 60% to < 5% and < 15% (P < 0.05) respectively. The use of a control 
challenge demonstrated that 27-hydroxycholesterol did not affect the leakage of LDH 
(P > 0.99) or cell viability (P > 0.63) of endometrial cells.  
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Figure 3.2 Steroids do not protect endometrial epithelial cells against pyolysin 
Leakage of LDH and viability of bovine endometrial epithelial cells treated for 24 h in 
serum-free medium containing vehicle (V) or the indicated concentrations of 
progesterone, oestradiol, or hydrocortisone and then challenged for 2 h with control 
medium or 200 HU pyolysin. Data are presented as mean (SEM) using cells from 3 
independent animals; statistical significance determined by two-way ANOVA and P-
values reported for the effect of each treatment on pyolysin challenge. 
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Figure 3.3 Steroids do not protect endometrial stromal cells against pyolysin 
Leakage of LDH and viability of bovine endometrial stromal cells treated for 24 h in 
serum-free medium containing vehicle (V) or the indicated concentrations of (A) 
progesterone, (B) oestradiol, or (C) hydrocortisone and then challenged for 2 h with 
control medium or 25 HU pyolysin. Data are presented as mean (SEM) using cells 
from ≥ 3 independent animals; statistical significance determined by two-way 
ANOVA and P-values reported for the effect of each treatment on pyolysin challenge. 
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Figure 3.4 Dexamethasone does not protect endometrial cells against pyolysin  
Leakage of LDH and viability of (A) epithelial or (B) stromal cells treated for 24 h in 
serum-free medium containing vehicle (V) or the indicated concentrations of 
dexamethasone and then challenged for 2 h with control medium or pyolysin 
(epithelium 200 HU, stroma 25 HU). Data are presented as mean (SEM) using cells 
from ≥ 3 independent animals; statistical significance determined by two-way 
ANOVA and P-values reported for the effect of treatment on pyolysin challenge. 
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Figure 3.5 27-hydroxycholesterol protects endometrial cells against pyolysin 
Leakage of LDH and viability of (A) epithelial or (B) stromal cells treated for 24 h in 
serum-free medium containing vehicle (V) or the indicated concentrations of 27-
hydroxycholesterol and then challenged for 2 h with control medium or pyolysin 
(epithelium 200 HU, stroma 25 HU). Data are presented as mean (SEM) using cells 
from ≥ 3 independent animals; statistical significance determined by two-way 
ANOVA and P-values reported for the effect of treatment on pyolysin challenge. 
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Treatment with 25 ng/ml 27-hydroxycholesterol consistently reduced pyolysin-
induced cytolysis of epithelial cells from a further 6 animals (Fig 3.6A), and stromal 
cells from a further 9 animals (Fig 3.6B), in experiments carried out to assess whether 
biological variation between animals might influence our observations. Furthermore, 
the level of cytoprotection was correlated with the duration of 27-hydroxycholesterol 
treatment (from 0 to 24 h) in epithelial (Pearson’s correlation coefficient, r2 = 0.94, P 
< 0.001; Fig 3.7A) and stromal (Pearson’s correlation coefficient, r2 = 0.94, P < 0.001; 
Fig 3.7B) cells, with protection evident after > 8 h treatment (P < 0.001, ANOVA and 
Dunnett’s post hoc test). 
To examine whether 27-hydroxycholesterol also protected cells against changes in the 
actin cytoskeleton and cell shape, cells were stained with phalloidin (Turner et al., 
2020). Challenging epithelial and stromal cells for 2 h with pyolysin reduced the 
definition of actin fibers, altered cell shape, and in some cells the cytoskeleton 
collapsed (Fig 3.8). However, 24 h treatment with 27-hydroxycholesterol protected 
against pyolysin-induced cytoskeletal changes in epithelial cells (22 ± 2 vs 99 ± 1% 
cells damaged, t-test, P < 0.01, n = 3, Fig 3.8A) and stromal cells (30 ± 9 vs 77 ± 8% 
cells damaged, t-test, P < 0.01, n = 4, Fig 3.8B).  
Together these results provided evidence that 27-hydroxycholesterol, protected bovine 
endometrial epithelial and stromal cells against pyolysin. As the concentrations of 
progesterone, oestradiol and glucocorticoids screened in our model system did not 
significantly protect endometrial cells against pyolysin, further experiments in the 
present chapter focused on side-chain oxysterols.  
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Figure 3.6 27-hydroxycholesterol consistently protects bovine endometrial cells 
against pyolysin 
Viability of (A) epithelial or (B) stromal cells treated for 24 h in serum-free medium 
containing vehicle or 25 ng/ml 27-hydroxycholesterol (27-HC) then challenged for 2 
h with control medium or pyolysin (epithelium 200 HU, stroma 25 HU). Data are 
presented as mean (SEM) using cells from 6 independent animals for epithelial cells 
and 9 animals for stromal cells; statistical significance determined by two-way 
ANOVA and Bonferroni’s post hoc test; ***P < 0.001. 
 
 
Figure 3.7 27-hydroxycholesterol protection increases with treatment duration  
Viable cells expressed as a percentage of control challenge for (A) epithelial and (B) 
stromal cells treated for the indicated time periods with 25 ng/ml 27-
hydroxycholesterol (27-HC), and then challenged for 2 h with control medium or 
pyolysin (epithelium 200 HU, stroma 25 HU). Dots represent individual values from 
4 independent animals, and Pearson correlation coefficients are reported (r). Line of 
best fit is displayed. 
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Figure 3.8 27-hydroxycholesterol protects bovine endometrial cells against 
pyolysin-induced actin cytoskeletal changes 
Fluorescent microscope images of (A) epithelial and (B) stromal cells treated for 24 h 
with vehicle or 25 ng/ml 27-hydroxycholesterol (27-HC), then challenged for 2 h with 
control medium or pyolysin (epithelium 200 HU, stroma 25 HU), and stained with 
fluorescent phalloidin (white) and DAPI (red); images are representative of 4 
independent experiments. Quantification of cytoskeletal changes are reported in text. 
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3.3.2 Side-chain oxysterols protect cells against pyolysin 
To explore whether cytoprotection against pyolysin was limited to 
27-hydroxycholesterol, we treated endometrial cells for 24 h with another oxysterol, 
25-hydroxycholesterol, prior to the 2 h challenge with pyolysin (Fig 3.9). Treatment 
with 50 ng/ml 25-hydroxycholesterol reduced stromal cell viability by 37% (P < 0.001, 
Fig 3.10B, grey bars), though lower concentrations did not significantly alter cell 
viability (P = 0.91). Significantly, 25-hydroxycholesterol reduced the pyolysin-
induced leakage of LDH from both epithelial and stromal cells and protected against 
cytolysis. Specifically, 5 ng/ml 25-hydroxycholesterol reduced pyolysin-induced 
leakage of LDH from epithelial and stromal cells by 84% and 79% (P < 0.001, two-
way ANOVA and Dunnett’s post hoc test), respectively, and reduced pyolysin-
induced cytolysis from > 60% to > 5% and 25% respectively (P < 0.01). 
To test whether oxysterol cytoprotection against pyolysin persisted beyond the 2 h 
challenge period, we treated endometrial cells with vehicle, 5 ng/ml 
25-hydroxycholesterol, or 25 ng/ml 27-hydroxycholesterol for 24 h, but then 
challenged the cells for 24 h with pyolysin without further treatments. Both 
25-hydroxycholesterol and 27-hydroxycholesterol prevented the pyolysin-induced 
leakage of LDH and cytolysis in both epithelial and stromal cells (Fig 3.10). 
To evaluate whether oxysterols protected against the initial formation of pyolysin 
pores, we measured the leakage of potassium into cell supernatants 5 min after a 
pyolysin challenge (Gonzalez et al., 2011, Turner et al., 2020). Epithelial and stromal 
cells were treated for 24 h with vehicle, 5 ng/ml 25-hydroxycholesterol or 25 ng/ml 
27-hydroxycholesterol. We used 0.5 mM MβCD used as a control because it depletes 
cholesterol from plasma membranes (Das et al., 2013, Amos et al., 2014). Vehicle 
treated epithelial and stromal cells leaked potassium within 5 min of pyolysin 
challenge, and MβCD reduced pyolysin-induced leakage of potassium from stromal 
but not epithelial cells (Fig 3.11). However, treatment with 25-hydroxycholesterol or 
27-hydroxycholesterol prevented pyolysin-induced leakage of potassium in both 
epithelial (P < 0.05, Fig 3.11A) and stromal (P < 0.001, Fig 3.11B) cells. Collectively, 
the data in Fig 3.2 to 3.11 provide evidence that 25-hydroxycholesterol and 27-
hydroxycholesterol protect endometrial cells against pyolysin.  
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Figure 3.9 25-hydroxycholesterol protects endometrial cells against pyolysin 
Leakage of LDH and viability of (A) epithelial and (B) stromal cells treated for 24 h 
in serum-free medium containing vehicle (V) or the indicated concentrations of 25-
hydroxycholesterol and then challenged for 2 h with control medium or pyolysin 
(epithelium 200 HU, stroma 25 HU). Data are presented as mean (SEM) using cells 
from ≥ 3 independent animals; statistical significance determined by two-way 
ANOVA and P-values reported for the effect of treatment on pyolysin challenge. 
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Figure 3.10 Side-chain oxysterol protection persists for 24 h 
Leakage of LDH and viability of (A) epithelial and (B) stromal cells treated for 24 h 
in serum-free medium containing vehicle, 5 ng/ml 25-hydroxycholesterol (25-HC), or 
25 ng/ml 27-hydroxycholesterol (27-HC) and then challenged for 2 h with control 
medium or pyolysin (epithelium 200 HU, stroma 25 HU). Data are presented as mean 
(SEM) using cells from ≥ 3 independent animals; statistical significance determined 
by one-way ANOVA and Dunnett’s post hoc test; *P < 0.05, **P < 0.01, ***P < 0.001. 
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Figure 3.11 Oxysterols prevent pyolysin-induced potassium leakage 
Leakage of potassium from (A) epithelial and (B) stromal cells treated for 24 h with 
vehicle, 5 ng/ml 25-hydroxycholesterol (25-HC), 25 ng/ml 27-hydroxycholesterol (27-
HC), or 1 mM MβCD, and then challenged for 5 min with control medium or pyolysin 
(epithelium 200 HU, stroma 25 HU). Dots represent the values from ≥ 4 independent 
animals; statistical significance was determined using one-way ANOVA with 
Dunnett’s post hoc test; *P < 0.05, ***P < 0.001. 
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3.3.3 Cellular cholesterol 
We next considered potential mechanisms for side-chain oxysterol cytoprotection. 
Cholesterol-dependent cytolysins bind cholesterol in plasma membranes and reducing 
cellular cholesterol using MβCD or statins can protect against cytolysis (Statt et al., 
2015, Amos et al., 2014). We found that treatment with 0.5 mM MβCD for 24 h 
reduced bovine endometrial epithelial cell cholesterol by 26% compared with vehicle 
(Fig 3.12A), and stromal cell cholesterol by 43% (Fig 3.12B). However, 25-
hydroxycholesterol and 27-hydroxycholesterol cholesterol did not significantly alter 
the abundance of cholesterol in epithelial (P = 0.81 and p = 0.37, respectively, Fig 
3.12A), or stromal cells (P = 0.93 and P = 0.89, respectively, Fig 3.12B). 
To further examine cellular cholesterol, we stained stromal cells with filipin III, which 
binds to unesterified cholesterol (Maxfield and Wustner, 2012). 
Methyl-β-cyclodextrin reduced filipin III binding, with a 44% reduction in 
fluorescence compared with the vehicle control (Fig 3.12C, D). However, there was 
no significant effect of 25-hydroxycholesterol (P = 0.39) or 27-hydroxycholesterol (P 
= 0.98) on filipin III binding, although there appeared to be increased staining 
surrounding the nucleus. 
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Figure 3.12 Oxysterols do not reduce bovine endometrial cell cholesterol 
Cellular cholesterol in (A) epithelial and (B) stromal cells treated for 24 h with vehicle, 
5 ng/ml 25-hydroxycholesterol (25-HC), 25 ng/ml 27-hydroxycholesterol (27-HC), or 
0.5 mM MβCD. Data are presented as mean (SEM) from ≥ 3 independent animals; 
statistical significance was determined using one-way ANOVA with Dunnett’s post 
hoc test; treatment effects cholesterol, *P < 0.05. Additionally, total cell fluorescence 
was quantified (C) from confocal microscope images (D) of cells stained using filipin 
III to visualize cholesterol (white, scale bares are 20 µm). Data are presented as mean 
(SEM) using cells from 4 independent animals; statistical significance was determined 
using one-way ANOVA and Dunnett’s pot hoc test; *P < 0.05. 
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Serum-free medium was used for experiments exploring cytoprotection. However, 
cells can take up cholesterol from the lipoproteins in serum (Brown and Goldstein, 
1986). To investigate whether this might alter side-chain oxysterol cytoprotection, we 
treated epithelial and stromal cells for 24 h with 27-hydroxycholesterol or 
25-hydroxycholesterol in culture medium containing 10% fetal calf serum, prior to the 
2 h pyolysin challenge. As serum contains LDH, it was not possible to evaluate the 
leakage of LDH. Treatment with 27-hydroxycholesterol or 25-hydroxycholesterol in 
the presence of serum protected both epithelial cells (Fig 3.13A) and stromal cells (Fig 
3.13B) against pyolysin-induced cytolysis.  
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Figure 3.13 Oxysterols protect bovine endometrial cells against pyolysin in the 
presence of serum 
Viability of (A) epithelial and (B) stromal cells treated for 24 h with vehicle, or the 
indicated concentrations of 25-hydroxycholesterol (25-HC) or 27-hydroxycholesterol 
(27-HC) in complete medium containing 10% serum, and then challenged for 2 h with 
control serum-free medium or pyolysin (epithelium 200 HU, stroma 25 HU). Data are 
presented as mean (SEM) from ≥ 3 independent animals; statistical significance was 
determined using two-way ANOVA and P-values reported for the effect of treatment 
on pyolysin challenge.  
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As cholesterol-dependent cytolysins bind accessible cholesterol in plasma membranes 
(Das et al., 2013), we also examined the binding of pyolysin to cells. Stromal cells 
were used because they contain more cholesterol than epithelial cells. Treatment with 
MβCD reduced pyolysin binding by 85%, compared with vehicle, and treatment with 
27-hydroxycholesterol reduced pyolysin binding by 65% (Fig 3.14).  
Accessible cholesterol in plasma membranes can be depleted with little effect on total 
cellular cholesterol, by activating ACAT esterification of cholesterol by side-chain 
oxysterols but not LXR agonists (Du et al., 2004, Abrams et al., 2020). To examine 
whether ACAT contributed to cytoprotection against pyolysin damage, we treated 
endometrial cells with the ACAT inhibitor SZ58-035 for 16 h, followed by treatment 
with vehicle, 27-hydroxycholesterol, or the LXR agonist T0901317 for a further 24 h 
in the continued presence of SZ58-035 for a further 24 h. Treatment with SZ58-035 
impaired 27-hydroxycholesterol, but not T0901317 cytoprotection against pyolysin 
challenge in epithelial (Fig 3.15A) and stromal (Fig 3.15B) cells. Collectively, these 
data provide evidence to suggest the side-chain oxysterol cytoprotection is partly 
dependent on reducing accessible membrane cholesterol.  
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Figure 3.14 27-hydroxycholesterol reduces pyolysin binding 
Representative Western blot of pyolysin binding and α-tubulin for stromal cells treated 
for 24 h with vehicle, 50 nM progesterone, 0.1 nM oestradiol, 10 µM hydrocortisone, 
25 ng/ml 27-hydroxycholesterol (27-HC), or 0.5 mM MβCD and then challenged for 
2 h with control medium or 25 HU pyolysin. Densitometry data were normalized to α-
tubulin and presented as mean (SEM) from 3 experiments; statistical significance was 
determined using ANOVA with Dunnett’s post hoc test; *P < 0.05. 
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Figure 3.15 27-hydroxycholesterol cytoprotection is partly ACAT dependent  
Leakage of LDH and viability of (A) epithelial and (B) stromal cells cultured for 16 h 
with vehicle or 10 µM SZ5-035, then treated for 24 h with vehicle, 25 ng/ml 27-
hydroxycholesterol (27-HC), or 25 nM T0901317, in the continuing presence of 
vehicle or SZ5-035, and then challenged for 2 h with control medium or pyolysin 
(epithelium 200 HU, stroma 25 HU). Data are presented as mean (SEM) from 4 
independent experiments; statistical significance was determined using two-way 
ANOVA and Tukey’s post hoc test; *P < 0.05, **P < 0.01. 
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3.3.4 Liver X receptors have a role in oxysterol cytoprotection 
We next examined the role of LXRs in cytoprotection against pyolysin because 
oxysterols are ligands for LXRα and LXRβ (Wang and Tontonoz, 2018). Our first 
approach was to use T0901317 and GW3965, which are synthetic ligands for both 
LXRα and LXRβ, but structurally unrelated to oxysterols (Schultz et al., 2000, Oliver 
et al., 2001, Wang and Tontonoz, 2018). Endometrial cells were treated for 24 h with 
a range of concentrations of T0901317 or GW3965, followed by a 2 h challenge with 
pyolysin. Treatment with T0901317 or GW3965 reduced the pyolysin-induced LDH 
leakage from epithelial cells by up to 25% (P < 0.01, Fig 3.16A) and 33% (P < 0.05, 
Fig 3.17B) respectively, but did not significantly prevent cytolysis. In stromal cells, 
both T0901317 (P < 0.001, Fig 3.16C) and GW3965 (P < 0.001, Fig 3.16D) reduced 
pyolysin-induced leakage of LDH and cytolysis. Specifically, 50 nM T0901317 and 
250 nM GW3965 reduced pyolysin-induced LDH leakage from stromal cells by 70% 
and 75%, respectively. Treatment with T0901317 or GW3965, did not reduce the 
pyolysin-induced leakage of potassium from epithelial cells (Fig 3.17A), however, 
they tended to reduce potassium leakage from stromal cells (P = 0.07, Fig 3.17B).  
109 
 
 
Figure 3.16 LXR agonists protect bovine endometrial cells against pyolysin 
Leakage of LDH and viability of (A, B) epithelial and (C, D) stromal cells cultured for 
24 h in serum-free medium containing vehicle (V) or the indicated concentrations of 
(A, C) T0901317, or (B, D) GW3965 and then challenged for 2 h with control medium 
or pyolysin (epithelium 200 HU, stroma 25 HU). Data are presented as mean (SEM) 
using cells from ≥ 3 independent animals; statistical significance determined by two-
way ANOVA and P-values reported for the effect of treatment on pyolysin challenge. 
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Figure 3.17 LXR agonists decrease pyolysin-induced potassium leakage in 
stromal cells 
Leakage of potassium from (A) epithelial and (B) stromal cells treated for 24 h with 
vehicle, 25 nM T0901317, 125 nM GW3965, and then challenged for 5 min with 
control medium or pyolysin (epithelium 200 HU, stroma 25 HU). Dots represent the 
values from 4 independent animals; statistical significance was determined using one-
way ANOVA with Dunnett’s post hoc test; ***P < 0.01. 
Our second approach was to reduce the expression of LXRα and LXRβ using siRNA 
to target NR1H3 and NR1H2, respectively, as previously validated at the mRNA and 
protein level (Griffin et al., 2018). Additional validation in this study demonstrated 
that siRNA targeting NR1H3 and NR1H2 reduced LXRα and LXRβ protein 
abundance, and the abundance of the LXR-induced protein ABCA1 (Fig 3.18) (Ito et 
al., 2015). Epithelial and stromal cells were transfected with siRNA targeting NR1H3 
and NR1H2 independently and in combination, before 24 h treatment with 
27-hydroxycholesterol or T0901317, and then a 2 h challenge with pyolysin. Targeting 
both NR1H3 and NR1H2, limited the protective effect of 27-hydroxycholesterol on 
pyolysin-induced LDH leakage and cytolysis in epithelial cells (scramble vs. double 
knockdown, 68% vs. 56% reduction in LDH leakage, 2% vs 21% cytolysis, Fig 3.19A) 
and stromal cells (94% vs. 70% reduction in LDH leakage, 23% vs. 31% cytolysis, Fig 
3.19B). Targeting both NR1H3 and NR1H2 also diminished T0901317 cytoprotection 
in both epithelial and stromal cells (Fig 3.20).  
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Figure 3.18 siRNA targeting NR1H3 and NR1H2 reduced the abundance of LXR 
and ABCA1 protein  
Representative Western blots of LXRα, LXRβ, and ABCA1 in (A,B) epithelial and 
(C,D) stromal cells (Western blots for LXRβ in stromal cells had staining that 
precluded analysis) transfected with scrambled siRNA or siRNA targeting NR1H3 or 
NR1H2. β and-actin and α-tubulin were used as loading controls. Image representative 
from 4 independent experiments. Densitometry data were normalized to the loading 
control and presented as mean (SEM); statistical significance was determined using 
one-way ANOVA and P-values are reported for Dunnett’s post hoc test; *P < 0.05, 
**P < 0.01. 
112 
 
 
Figure 3.19 27-hydroxycholesterol cytoprotection is partly LXR dependent  
Leakage of LDH and viability of (A) epithelial and (B) stromal cells transfected for 48 
h with scramble siRNA or siRNA targeting NR1H2 and NR1H3, treated for 24 h with 
vehicle or 25 ng/ml 27-hydroxycholesterol (27-HC), and then challenged for 2 h with 
control medium or pyolysin (epithelium 200 HU, stroma 25 HU). Data are presented 
as mean (SEM) from 4 independent animals; statistical significance was determined 
using two-way ANOVA and Tukey’s post hoc test; *P < 0.05, **P < 0.01. 
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Figure 3.20 T0901317 cytoprotection is LXR dependent  
Leakage of LDH and viability of (A) epithelial and (B) stromal cells transfected for 48 
h with scramble siRNA or siRNA targeting NR1H2 and NR1H3, treated for 24 h with 
vehicle or 25 nM T0901317, and then challenged for 2 h with control medium or 
pyolysin (epithelium 200 HU, stroma 25 HU). Data are presented as mean (SEM) from 
4 independent animals; statistical significance was determined using two-way 
ANOVA and Tukey’s post hoc test; ***P < 0.001. 
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To provide verification that 27-hydroxycholesterol and T0901317 induced target gene 
expression at the concentrations used in this study, we examined the treatment effect 
on ABCA1 abundance (Fig 3.21). T0901317 increased ABCA1 protein abundance in 
both epithelial and stromal cells. Additionally, 27-hydroxycholesterol increased 
ABCA1 abundance in epithelial cells and there was a trend for an increase in stroma 
cells. Taken together, these data provide evidence that cytoprotection against pyolysin 
is at least partially dependent on both LXRα and LXRβ.  
 
Figure 3.21 27-hydroxycholesterol and T0901317 increase ABCA1 protein  
Representative Western blots of ABCA1 in (A) epithelial and (B) stromal cells treated 
for 24 h with vehicle, 25 ng/ml 27-hydroxycholesterol (27-HC), or 25 nM T0901317. 
α-tubulin was used as a loading control. Image representative from 3 independent 
experiments. Densitometry data for ABCA1 were normalized to α-tubulin and 
presented as mean (SEM); statistical significance was determined using one-way 
ANOVA and P-values are reported for Dunnett’s post hoc test; *P < 0.05, 
***P < 0.001. 
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3.3.5 Side-chain oxysterols protect cells against α-hemolysin 
To determine whether oxysterol cytoprotection extended beyond pyolysin, we treated 
cells for 24 h with vehicle, 25 ng/ml 27-hydroxycholesterol, or 25 nM T0901317, and 
then challenged the cells with S. aureus α-hemolysin for 24 h in the absence of further 
treatments (Fig 3.22). The α-hemolysin challenge induced the leakage of LDH, 
reduced the viability of stromal cells (Fig 3.22B) and there was a trend for reduced 
epithelial cell viability (P = 0.1, Fig 3.22A). 27-hydroxycholesterol treatment reduced 
LDH leakage and cytolysis in both cell types, although T0901317 had no significant 
affect. A 15 min α-hemolysin challenge did not cause potassium leakage from 
epithelial cells (P = 0.99, Fig 3.23A), however, 27-hydroxycholesterol, but not 
T0901317, reduced the leakage of potassium from stromal cells (Fig 3.23B).  
Treatment with 27-hydroxycholesterol also protected against α-hemolysin-induced 
changes in the cytoskeletal of epithelial cells (44 ± 3 vs 90 ± 3% cells damaged, t-test, 
P < 0.01, n = 3, Fig 3.24A) and stromal cells (9 ± 1 vs 62 ± 6% cells damaged, t-test, 
P < 0.01, n = 3, Fig 3.24B). Together these data provide evidence for 
27-hydroxycholesterol cytoprotection of endometrial epithelial and stromal cells 
against an α-hemolysin.  
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Figure 3.22 27-hydroxycholesterol protects cells against α-hemolysin damage  
Leakage of LDH and viability of (A) epithelial and (B) stromal cells cultured for 24 h 
in serum-free medium containing vehicle, 25 ng/ml 27-hydroxycholesterol (27-HC), 
or 25 nM T0901317 and then challenged for 24 h with control medium or 8 µg α-
hemolysin. Data are presented as mean (SEM) using cells from 4 independent animals; 
statistical significance determined by one-way ANOVA and Dunnett’s post hoc test; 
*P < 0.05, **P < 0.01, ***P < 0.001. 
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Figure 3.23 27-hydroxycholesterol reduces α-hemolysin-induced potassium 
leakage in stromal cells  
Leakage of potassium from (A) epithelial and (B) stromal cells treated for 24 h with 
vehicle, 25 ng/ml 27-hydroxycholesterol (27-HC), 25 nM T0901317, and then 
challenged for 15 min with control medium or 8 µg α-hemolysin. Dots represent the 
values from 4 independent animals; statistical significance was determined using one-
way ANOVA with Dunnett’s post hoc test; **P < 0.01. 
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Figure 3.24 27-hydroxycholesterol protects bovine endometrial cells against α-
hemolysin-induced actin cytoskeletal changes  
Fluorescent microscope images of (A) epithelial and (B) stromal cells treated for 24 h 
with vehicle or 25 ng/ml 27-hydroxycholesterol (27-HC), then challenged for 2 h with 
control medium or 8 µg α-hemolysin and stained with fluorescent phalloidin (white) 
and DAPI (red); images are representative from 3 independent experiments. 
Quantification of cytoskeletal changes are reported in text. 
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3.3.6 Oxysterols are present in the bovine endometrium 
 We used mass spectrometry to understand the biological relevance of oxysterols in 
the bovine reproductive tract. We detected a range of oxysterols in uterine and ovarian 
follicular fluid, with the abundance greater in the latter (Fig 3.25, Table 3.1). Notably, 
25-hydroxycholesterol and 27-hydroxycholesterol were detected in the uterine fluid as 
well as 7α-25-hydroxycholesterol, a 25-hydroxycholesterol metabolite. 
 
Figure 3.25 Oxysterols are present in bovine uterine and ovarian follicular fluid  
Chromatographic separation (m/z 534.4054 ± 5 ppm) of indicated oxysterols from (A) 
uterine fluid and (B) emerged and (C) dominant ovarian follicular fluid sample 
derivatized with [2H0] Girard P reagent. 
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Table 3.1 Oxysterol concentrations in biological samples  
Concentrations of oxysterols in samples of uterine or follicular fluid from emerged (4-
8 mm diameter) or dominant (> 8 mm diameter) ovarian follicles (data are reported as 
mean ± SEM, n= 3 per sample). * Dehydration products of cholestane-3β,5α,6β-triol. 
Oxysterol Uterine fluid 
(ng/ml) 
Emerged follicle 
fluid   
(ng/ml) 
Dominant follicle 
fluid 
(ng/ml) 
22R-hydroxycholesterol 0.2 ± 0.2 2.3 ± 0.8 2.4 ± 1.5 
24S-hydroxycholesterol 0.2 ± 0.2 0.2 ± 0.1 0.5 ± 0.1 
25-hydroxycholesterol 3.9 ± 0.6 13.4 ± 10.5 26.8 ± 11.4 
25-hydroxycholest-4-en-3-one 0.0 ± 0.0 0.1 ± 0.1 2.1 ± 1.8 
27-hydroxycholesterol 19.9 ± 4.9 104.3 ± 69.7 244.6 ± 99.5 
27-hydroxycholest-4-en-3-one 0.0 ± 0.0 0.5 ± 0.2 6.8 ± 5.2 
7β-hydroxycholesterol 0.8 ± 0.8 0.4 ± 0.2 0.4 ± 0.2 
7α-hydroxycholesterol 8.3 ± 4.9 0.9 ± 0.6 1.1 ± 0.0 
7α-hydroxycholest-4-en-3-one 17.0 ± 8.4 0.2 ± 0.1 1.3 ± 1.1 
6β-hydroxycholesterol* 7.1 ± 0.9 2.3 ± 0.6 2.2 ± 0.2 
6β-hydroxycholest-4-en-3-one* 0.8 ± 0.5 0.2 ± 0.1 0.9 ± 0.6 
7-oxocholesterol 13.2 ± 1.5 2.8 ± 1.0 6.8 ± 5.1 
24,25-epoxycholesterol 0.6 ± 0.6 7.5 ± 4.9 9.3 ± 7.3 
24,25-epoxycholest-4-en-3-one 0.0 ± 0.0 0.3 ± 0.2 6.6 ± 5.3 
24,27-dihydroxycholesterol 0.5 ± 0.5 5.8 ± 3.0 4.8 ± 3.0 
24,27-dihydroxycholest-4-en-3-one 0.0 ± 0.0 0.3 ± 0.2 2.6 ± 2.3 
7α,25-dihydroxycholesterol 1.3 ± 0.7 0.7 ± 0.4 2.0 ± 1.5 
7α,25-dihydroxycholest-4-en-3-one 1.5 ± 0.4 1.5 ± 0.5 16.7 ± 12.6 
7α,27-dihydroxycholesterol 0.0 ± 0.0 0.2 ± 0.2 0.0 ± 0.0 
7α,27-dihydroxycholest-4-en-3-one 2.3 ± 0.7 1.3 ± 0.2 13.8 ± 6.4 
3β,7β-dihydroxycholest-5-en-26-oic acid 0.0 ± 0.0 2.3 ± 0.2 2.0 ± 1.0 
7β-hydroxy-3-oxocholest-4-en-26-oic acid  0.0 ± 0.0 0.3 ± 0.17 0.5 ± 0.2 
3β,7α-dihydroxycholest-5-en-26-oic acid 4.9 ± 2.5 13.2 ± 6.9 6.5 ± 4.2 
7α-hydroxy-3-oxocholest-4-en-26-oic acid 81.3 ± 20.0 76.8 ± 21.0 258.9 ± 136.8 
3β,22R-dihydroxycholest-5-en-26-oic acid 0.0 ± 0.0 23.5 ± 14.7 23.9 ± 13.5 
22R-hydroxy-3-oxocholest-4-en-26-oic acid 0.0 ± 0.0 3.0 ± 1.6 11.1 ± 4.7 
20R,22R,25-trihydroxycholesterol 0.9 ± 0.9 10.7 ± 5.5 2.4 ± 1.8 
20R,22R,25-trihydroxycholest-4-en-3-one 1.1 ± 0.8 2.4 ± 0.7 39.5 ± 21.3 
7α,24,25-trihydroxycholest-4-en-3-one 4.8 ± 2.5 4.3 ± 1.3 20.5 ± 13.2 
3β-hydroxycholest-5-enoic acid 12.7 ± 6.8 283.3 ± 249.4 295.8 ± 118.4 
3-oxocholest-4-enoic acid 4.4 ± 3.1 20.8 ± 12.9 11.1 ± 4.7 
3β,7α,24-trihydroxycholest-5-en-26-oic acid 0.0 ± 0.0 0.57 ± 0.57 0.0 ± 0.0 
7α,24-dihydroxy-3-oxocholest-4-en-26-oic acid 3.6 ± 1.8 5.1 ± 0.2 16.4 ± 6.8 
3β,7α,25-trihydroxycholest-5-en-26-oic acid 0.0 ± 0.0 0.8 ± 0.6 1.5 ± 0.9 
7α,25-dihydroxy-3-oxocholest-4-en-26-oic acid 2.5 ± 1.4 3.1 ± 1.1 12.3 ± 6.3 
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As Gram-negative bacteria and T. pyogenes are common endometrial pathogens, we 
next considered whether endometrial cells might secrete oxysterols in response to their 
major virulence factors, LPS and pyolysin (Sheldon et al., 2010, Sheldon et al., 2002, 
Griffin et al., 1974, Bonnett et al., 1991, Amos et al., 2014). We also used LPS as a 
control because it stimulates the release of 25-hydroxycholesterol from murine 
macrophages (Reboldi et al., 2014).   Epithelial and stromal cells were challenged with 
1 µg/ml LPS or a 5 HU sub-lytic concentration of pyolysin for 24 h, and the 
supernatants collected for mass spectrometry. Few oxysterols were collected in serum-
free culture medium (Table 3.2); however, epithelial cell supernatants contained 
several oxysterols, notably including 25-hydroxycholesterol (Fig 3.26, 3.27A). The 
concentration of 25-hydroxycholesterol increased by 97% following LPS challenge 
and by 220% following pyolysin challenge. However, 27-hydroxycholesterol was not 
detected in stromal or epithelial cell supernatants, and 25-hydroxycholesterol was 
barely detectable in the supernatant of stromal cells (Fig 3.26, 3.27B). Together these 
data provide evidence for oxysterols in the reproductive tract, and the release of 
25-hydroxycholesterol from epithelial cells challenged with LPS or pyolysin. 
Table 3.2 Oxysterol concentrations in culture medium 
Concentrations of oxysterols detected in serum-free culture medium. 
 
Oxysterol  ng/ml 
6β-hydroxycholesterol 0.39 
6β-hydroxycholest-4-en-3-one 0.24 
7-oxocholesterol 1.15 
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Figure 3.26 Endometrial cells release oxysterols 
Concentrations of oxysterols in supernatants from epithelial and stromal cells 
challenged with control medium, or medium containing 1 µg/ml LPS, or 5 HU 
pyolysin. Data are presented as mean (SEM) from 3 independent animals; statistical 
significance was determined using two-way ANOVA and Dunnett’s post hoc test; 
*P < 0.05, **P < 0.01, ***P < 0.001. 
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Figure 3.27 Pyolysin-induced oxysterol release in stromal and epithelial cells  
Chromatographic separation (m/z 534.4054 ± 5 ppm) of indicated oxysterols from the 
supernatant of (A) stroma and (B) epithelial cells challenged for 24 h with 5 HU 
pyolysin, derivatized with [2H0] Girard P reagent.  
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3.4 DISCUSSION 
In this study we discovered that both 25-hydroxycholesterol and 27-
hydroxycholesterol enhanced bovine endometrial cells intrinsic protection against 
pore-forming toxins from uterine pathogens. Whilst progesterone, oestradiol, 
hydrocortisone, and dexamethasone provided no significant protection against 
pyolysin at the concentrations and treatment duration examined in this chapter, treating 
epithelial or stromal cells with 25-hydroxycholesterol or 27-hydroxycholesterol, 
reduced the formation of pyolysin-induced plasma membrane pores and protected cells 
against damage. Although the side-chain oxysterols did not significantly alter cellular 
cholesterol abundance, there was reduced binding of pyolysin to cells, and 
cytoprotection was at least partly dependent on ACAT and LXRs. The side-chain 
oxysterol cytoprotection of endometrial cells also extended beyond a 
cholesterol-dependent cytolysin to S. aureus α-hemolysin. Interestingly, the 
concentrations of side-chain oxysterols we used in vitro were similar to the 
concentration of 25-hydroxycholesterol or 27-hydroxycholesterol we measured in the 
reproductive tract. Furthermore, pyolysin stimulated the release of more 
25-hydroxycholesterol from epithelial cells. We suggest that side-chain oxysterols 
might be released by epithelial cells to help protect stromal cells against pore-forming 
toxins from pathogenic bacteria. 
Challenging bovine endometrial epithelial and stromal cells with pyolysin induced the 
formation of membrane pores, as determined by leakage of potassium and LDH from 
cells. Pyolysin-induced cell damage was determined by changes in the actin 
cytoskeleton and cell shape, and reduced cell viability. These effects are typical of 
cholesterol-dependent cytolysins, which are the most common pore-forming toxins 
secreted by pathogenic bacteria (Peraro and van der Goot, 2016, Gurcel et al., 2006, 
Gonzalez et al., 2011). As previously reported, epithelial cells were more tolerant of 
pyolysin than stromal cells (Amos et al., 2014). This innate tolerance to pathogens is 
typical of epithelia (Medzhitov et al., 2012, Amos et al., 2014). However, loss of the 
epithelium associated with trauma during parturition, postpartum physiological 
regeneration of the epithelium, and damage by pore-forming toxins from invading 
pathogens, may explain the increased risk of developing postpartum uterine disease 
once underlying sensitive stromal cells are exposed to T. pyogenes and S. aureus.  
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It was surprising that progesterone, oestradiol or glucocorticoids, did not significantly 
alter pyolysin-induced cells leakage of LDH or endometrial cytolysis because the 
dogma is that progesterone, oestradiol and glucocorticoids modulate the risk of 
disease, particularly in the genital tract (Wira et al., 2015, Ogawa et al., 2005, Spann 
and Glass, 2013). However, these findings are similar to previous findings that ovarian 
steroids did not alter endometrial cell immune responses to LPS (Saut et al., 2014). 
Our most striking finding was that either 27-hydroxycholesterol or 
25-hydroxycholesterol protected endometrial epithelial and stromal cells against 
cytolysis in the face of pyolysin challenges that normally caused > 50% cytolysis. 
Treatment with 25 ng/ml 27-hydroxycholesterol or 5 ng/ml 25-hydroxycholesterol 
reduced the leakage of potassium and LDH and prevented pyolysin-induced changes 
in the actin cytoskeleton and cell shape. This cytoprotection was effective even when 
cells were treated in medium containing 10% serum, and protection against pyolysin 
persisted for at least 24 h. Our findings support a recent observation that mouse bone 
marrow-derived macrophages stimulated with interferon may protect against 
cholesterol-dependent cytolysins perfringolysin O, streptolysin O and anthrolysin O 
through an oxysterol-dependent mechanism (Zhou et al., 2020). Furthermore, injection 
of 25-hydroxycholesterol into the skin of mice 6 h before a 48 h challenge with 
anthrolysin O reduced tissue damage in vivo (Zhou et al., 2020). However, there is a 
contradictory study, where treating Chinese Hamster Ovary cells with 1 μg/ml 
25-hydroxycholesterol for 1 h followed by 4 h with proaerolysin and 
25-hydroxycholesterol increased cell damage (Gurcel et al., 2006).  
In the present study we also examined protection against S. aureus α-hemolysin, which 
is not so dependent on the abundance of cholesterol in target cell membranes. 
Furthermore, the lower calcium permeability of small diameter pores impairs 
reparative mechanisms, emphasizing the importance of identifying methods to protect 
cells against these toxins (Brito et al., 2019). We found that treating endometrial cells 
with 27-hydroxycholesterol also reduced α-hemolysin-induced leakage of potassium 
and LDH and prevented cytolysis. The cells required a longer challenge with 
α-hemolysin than pyolysin to study cytolysis, which might reflect the ten-fold smaller 
diameter of the pores formed by α-hemolysin than pyolysin (Peraro and van der Goot, 
2016, Song et al., 1996, Preta et al., 2016). However, taken together, our results 
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provide evidence for oxysterol cytoprotection of endometrial cells against 
pore-forming toxins. 
The abundance of oxysterols in the bovine reproductive tract had not been considered 
previously. However, we detected the presence of 27-hydroxycholesterol and 
25-hydroxycholesterol in uterine and ovarian follicular fluid. A greater abundance of 
oxysterols was detected in ovarian follicular fluid compared to the uterine fluid. 
Ovarian cells synthesize steroid hormones to regulate reproductive function 
(Drummond, 2006). Steroidogenesis in the ovary is augmented by tropic hormones 
that also increase sterol synthesis, possibly explaining the greater abundance of 
oxysterols in follicular fluid (Strauss et al., 1991). Interestingly, the concentrations of 
oxysterols observed in the uterine fluid were similar to the concentrations we used to 
treat endometrial cells.  
Although it was known that LPS stimulation of mouse macrophages upregulates 
cholesterol-25-hydroxylase resulting in 25-hydroxycholesterol secretion (Diczfalusy 
et al., 2009, Dang et al., 2017, Reboldi et al., 2014), we unexpectedly found that 
epithelial cells released 25-hydroxycholesterol, and that pyolysin stimulated further 
release of 25-hydroxycholesterol. These findings imply that epithelial cells might 
release oxysterols to protect stromal cells against the damage caused by invading 
pathogens. Oxysterol cytoprotection may complement the defenses against pore-
forming toxins that depend on immune and repair mechanisms (Gurcel et al., 2006, 
Amos et al., 2014, Gonzalez et al., 2011, Bromfield et al., 2015, Wira et al., 2005, 
Andrews and Corrotte, 2018). We suggest that oxysterols from the ovary or oxysterols 
released during infection of the uterus may help the endometrium tolerate the presence 
of pathogenic bacteria that secrete pore-forming toxins.  
Side-chain oxysterol cytoprotection is likely achieved through multiple protective 
mechanisms. Oxysterols regulate cholesterol homeostasis, increase cholesterol 
esterification, modify cell membranes, and activate LXRs (Cyster et al., 2014, 
Schroepfer, 2000, Wang and Tontonoz, 2018, Du et al., 2004, Abrams et al., 2020). 
Cholesterol-dependent cytolysins require accessible cholesterol, which is independent 
of the essential pool and sphingomyelin-bound pools of cholesterol in plasma 
membranes (Das et al., 2013, Abrams et al., 2020) Synthesis, uptake, efflux and 
breakdown of cholesterol alters only the accessible pool of cholesterol in plasma 
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membranes, typically when membrane cholesterol exceeds 35 mol% of total lipids 
(Tweten, 2005, Das et al., 2013). Consequently, small changes in membrane 
cholesterol around this threshold markedly alter the binding of cholesterol-dependent 
cytolysins to plasma membranes (Peraro and van der Goot, 2016, Das et al., 2014, 
Tweten, 2005, Amos et al., 2014). In the present study, 27-hydroxycholesterol reduced 
pyolysin binding to cells, even though oxysterols did not significantly reduce cellular 
cholesterol or staining with filipin III, and cytoprotection was not affected by treating 
cells with oxysterols in culture medium with serum containing cholesterol. These 
findings agree with recent observations that interferon-induced 25-hydroxycholesterol 
protected mouse macrophages against cytolysins and reduced binding of anthrolysin 
O, without reducing cellular cholesterol abundance or filipin III staining (Zhou et al., 
2020). Furthermore, 25-hydroxycholesterol and 27-hydroxycholesterol depleted the 
labile pool of cholesterol in plasma membranes accessible to anthrolysin O, without 
reducing total cellular cholesterol (Abrams et al., 2020). Oxysterols reduced the labile 
cholesterol in membranes that was accessible to cholesterol-dependent cytolysins by 
limiting cholesterol biosynthesis and/or increasing ACAT esterification of cholesterol 
(Abrams et al., 2020, Zhou et al., 2020). In the present study, an ACAT inhibitor also 
decreased oxysterol cytoprotection against pyolysin. However, we additionally found 
that using siRNA to target both NR1H3 and NRIH2, but not each independently, 
reduced the level of oxysterol cytoprotection against pyolysin. Furthermore, the 
synthetic LXR ligands T0901317 and GW3965 also protected stromal cells against 
pyolysin, reducing pyolysin-induced leakage of LDH from stromal cells by 70–75%, 
almost as effectively as the 82–84% reduction by the oxysterols. Collectively, these 
observations lead to the suggestion that oxysterol cytoprotection is partly regulated 
through ACAT and common targets of LXRα and LXRβ. 
Other mechanisms of cytoprotection to consider may not involve the binding of toxins 
to membranes. For example, oxysterols can stimulate increased cytosolic calcium, 
which could activate protective mechanisms such as endocytosis, exocytosis, caspase 
activity, and the unfolded protein response (Mackrill, 2011, Andrews and Corrotte, 
2018, Cassidy and O'Riordan, 2013, Gonzalez et al., 2011). Therefore, the role of ion 
flux in oxysterol cytoprotection will be investigated in Chapter 4. Additionally, 25- 
and 27-hydroxycholesterol are known to bind to oestrogen receptors and modulate 
their activity in an oestrogen independent manner, so repeating experiments in an 
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oestrogen receptor deficient cell line might highlight any involvement (Sato et al., 
2004). Another possibility is that cholesterol-dependent cytolysins may bind to the 
oxysterols as they only differ from cholesterol by one hydroxyl group. However, there 
was no evidence for this in the present study because oxysterols in treatment media 
were not in direct contact with the pyolysin in challenge media, levels of 
cytoprotection were correlated with the duration of oxysterol treatment, and oxysterols 
protected against α-hemolysin, which is less dependent on cholesterol than pyolysin 
(Peraro and van der Goot, 2016, Berube and Bubeck Wardenburg, 2013). Similarly, 
binding of perfringolysin O to liposomes was not detected even with concentrations of 
60 mol% 25-hydroxycholesterol (Bielska et al., 2014). Finally, oxysterols might alter 
the expression or distribution of glycans in plasma membrane, because many 
cholesterol-dependent cytolysis bind membrane glycans as well as cholesterol 
(Shewell et al., 2020); although, this remains to be explored for pyolysin. 
There are a few key limitations to the findings of the present chapter. Firstly, as we 
examined protection against isolated pore-forming toxins, we cannot verify that 
oxysterol treatment would provide bovine endometrial cells with significant protection 
against T. pyogenes infection, as the bacterium secretes other virulence factors such as 
neuraminidases, fimbriae, and collagen-binding proteins (Jost and Billington, 2005). 
Future work might address this by challenging cells with live bacterium or examining 
the effect of in vivo oxysterol treatment in cattle infected with T. pyogenes.  
Secondly, we discount progesterone, oestradiol and glucocorticoids as cytoprotective 
agents in the present chapter, as they did not significantly affect pyolysin-induced 
LDH leakage and cytolysis in bovine endometrial cells. However, we do not provide 
sufficient evidence to confirm that they do not alter intrinsic cell protection against 
pore-forming toxins. Though glucocorticoids are explored further in Chapter 5, further 
work should examine a range of progesterone and oestradiol treatment durations, 
repeat experiments in a range of cell types with different toxins, use different methods 
to assess pore-forming toxin damage, and investigate cognate receptor activity to 
confirm steroid treatment is having the desired effect. 
Additionally, we only examined the protection afforded by 25- and 27-
hydroxycholesterol and the cytoprotective properties of other oxysterols remain to be 
identified. Ring modified oxysterols, such as 7β-hydroxycholesterol, in particular 
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warrant investigation as they demonstrate distinctly different functions to the side-
chain oxysterols used in this chapter (Lordan et al., 2009).  
Finally, the limited number of animals used to collect samples for oxysterol 
measurement by mass spectrometry restricts the impact of this data. While we provide 
a novel insight into the presence of oxysterols in the bovine endometrium, without 
additional replicates we cannot provide a reliable estimate for typical concentrations 
in bovine ovarian follicular and uterine fluid. Furthermore, additional work might 
examine oxysterol concentrations in both healthy and diseased cattle to establish 
whether bacterial infection affects oxysterol abundance. 
In conclusion, we found that side-chain oxysterols protected bovine endometrial cells 
against pore-forming toxins. It was striking that 25-hydroxycholesterol and 
27-hydroxycholesterol provided near complete protection against pyolysin and 
α-hemolysin. The oxysterol cytoprotection against pyolysin included ACAT and LXR 
dependent mechanisms. Oxysterols were present in uterine and ovarian fluids, and 
epithelial cells released 25-hydroxycholesterol in response to pyolysin. These results 
provide evidence that oxysterols enhance endometrial cell-intrinsic protection against 
pore-forming toxins. Our findings imply that side-chain oxysterols help protect bovine 
endometrial cells against the damage caused by pore-forming toxins, defending the 
endometrium against pathogenic bacteria.   
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4 SIDE-CHAIN OXYSTEROLS PROTECT HUMAN 
EPITHELIAL CELLS AGAINST DAMAGE FROM PORE-
FORMING TOXINS  
4.1 INTRODUCTION 
Side-chain oxysterols regulate cholesterol homeostasis through transcriptional and 
non-genomic mechanisms (Bielska et al., 2012, Bielska et al., 2014) and manipulate 
the accessibility of plasma membrane cholesterol to inhibit bacterial dissemination 
(Abrams et al., 2020). Additionally, 25-hydroxycholesterol inhibits the inflammatory 
response in macrophages (Reboldi et al., 2014, Cyster et al., 2014, Dang et al., 2017). 
Chapter 3 established that 25-hydroxycholesterol and 27-hydroxycholesterol 
protected bovine endometrial cells against pyolysin, and the present chapter aims to 
expand on this finding by exploring side-chain oxysterol cytoprotection in a variety of 
human epithelial cells and further investigating the mechanisms involved. 
Mucosal epithelial cells provide a primary defence to bacterial infection, protecting 
underlying sensitive cells and tissues cells. Although pathogenic bacteria can use 
cholesterol-dependent cytolysins to damage this epithelial barrier, pore formation is 
sensitive to changes in plasma membrane cholesterol (Lange et al., 1989, van Meer et 
al., 2008, Goluszko and Nowicki, 2005, Mazzon and Mercer, 2014). The majority of 
cholesterol is sequestered by proteins and lipids such as sphingomyelin (Das et al., 
2014, Endapally et al., 2019). However, cholesterol becomes accessible to cholesterol-
dependent cytolysins when cholesterol exceeds 35 mol% of total plasma membrane 
lipids, and pore formation can be prevented by depleting this cytolysin-accessible pool 
(Das et al., 2013). For example, inhibiting 3-hydroxy 3-methylglutaryl coenzyme A 
reductase (HMGCR) with statins, inhibiting farnesyl-diphosphate farnesyltransferase 
1 with zaragozic acid and depleting cellular cholesterol with cyclodextrins confer 
resistance to cholesterol-dependent cytolysin damage (Statt et al., 2015, Griffin et al., 
2018, Amos et al., 2014).  
Side-chain oxysterols such as 25-hydroxycholesterol and 27-hydroxycholesterol 
regulate cholesterol homeostasis through several mechanisms. Both 25-
hydroxycholesterol and 27-hydroxycholesterol regulate cholesterol abundance via 
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liver X receptor binding, with the former pore potent (Lehmann et al., 1997, Wang and 
Tontonoz, 2018). These side-chain oxysterols also bind to Insig-2, promoting Insig-
Scap binding, and thereby inhibiting the processing of sterol regulatory element-
binding proteins and suppressing cholesterol synthesis (Radhakrishnan et al., 2007). 
Additionally, 25-hydroxycholesterol and 27-hydroxycholesterol promote cholesterol 
esterification through the endoplasmic reticulum-resident protein acetyl-coenzyme A 
acetyltransferase (ACAT) (Bielska et al., 2014). We therefore considered whether 
side-chain oxysterols might increase the intrinsic protection of human epithelial cells 
against the damage caused by pore-forming toxins. 
In this chapter, we investigated whether side-chain oxysterols could protect human 
epithelial cells against bacterial toxins that cause pathology through plasma membrane 
pore-formation. To test this hypothesis, we treated a variety of epithelial cells with 
side-chain oxysterols and then challenged cells with pore-forming toxins. Pyolysin 
was used as a model cholesterol-dependent cytolysin, as it forms pores in many types 
of mammalian cells and unlike other cholesterol-dependent cytolysins, it does not 
require thiol-activation in vitro (Billington et al., 1997). However, we also examined 
cytoprotection against α-hemolysin from S. aureus, a toxin that does not rely 
specifically on cholesterol for cytolysis. Cell protection against pore-forming toxin 
challenge was evaluated by measuring the leakage of potassium ions or lactate 
dehydrogenase (LDH), evaluating cell viability, and through microscopy. We also 
investigated whether oxysterol cytoprotection was mechanistically associated with 
mitogen-activated protein kinase (MAPK) signalling, ion flux, LXR expression, or 
ACAT activation.  
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4.2 MATERIALS AND METHODS 
4.2.1 Cytoprotection experiments 
To determine the amount of pyolysin required to study cytoprotection, HeLa, A549, 
Hep-G2, and NC1-H441 cells (4 × 104 cells/well) were cultured in serum-free medium 
for 24 h and then challenged for 2 h with control serum-free medium (comprising 200 
µl Dulbecco’s phosphate-buffered saline (DPBS) for 15 min, then supplemented with 
400 µl serum-free medium up to 2 h) or medium containing a range of concentrations 
of pyolysin as specified in Results. HeLa and A549 cells were selected as they are 
often used to explore cellular responses to cholesterol-dependent cytolysins (Gonzalez 
et al., 2011, Turner et al., 2020, Statt et al., 2015, Ratner et al., 2006), while Hep-G2 
and NC1-H441 cells were selected as they were also susceptible to toxin damage. A 2 
h challenge was selected, as previous research and our experiments in Chapter 2 
demonstrated that 2 h was sufficient to cause ~75% cytolysis (Amos et al., 2014, 
Griffin et al., 2018); and a longer challenge might reflect repair mechanisms and 
replication instead of indicating tolerance. At the end of the challenge, we measured 
the leakage of LDH leakage into cell supernatants and assessed cell viability using a 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay as 
described in Chapter 2. For subsequent cytoprotection experiments we selected 
pyolysin challenges that increased LDH leakage and caused cytolysis in HeLa (100 
HU/well, Fig 4.1), A549 (25 HU/well, Fig 4.8A), Hep-G2 (100 HU/well, Fig 4.8B) 
and NC1-H441 (200 HU/well, Fig 4.8C) cells, see Results section.  
To examine whether side-chain oxysterols protected cells against pyolysin, HeLa, 
A549, Hep-G2, and NC1-H441 cells were incubated in 1 ml/well serum-free medium 
(as fetal bovine serum (FBS) can cause extracellular signal-regulated kinase 1 and 2 
(ERK1/2) phosphorylation (Renshaw et al., 1997), and alter cholesterol homeostasis 
(Brown and Goldstein, 1986), which could obscure treatment effects) containing 
vehicle, 25-hydroxycholesterol, or 27-hydroxycholesterol.  The role of LXR agonists 
in cytoprotection was explored by treating HeLa and A549 cells with T0901317 (N-
(2,2,2-tri-fluoro-ethyl)-N-[4-(2,2,2-trifluoro-1-hydroxy-1-trifluoro-methyl-ethyl)-
phenyl]-benzenesulfonamide) and GW3965 (3-(3-(2-chloro-3-trifluorome-
thylbenzyl-2,2-diphenylethylamino)propoxy)phenylacetic acid). Oxysterol 
concentrations, as specified in Results, were informed by the concentrations in human 
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plasma of 154 ± 43 ng/ml 27-hydroxycholesterol and 2 ± 3 ng/ml 25-
hydroxycholesterol human physiology (Dzeletovic et al., 1995), alongside the 25 
ng/ml 27-hydroxycholesterol and 5 ng/ml 25-hydroxycholesterol required to protect 
bovine endometrial cells with cytoprotection against pyolysin in Chapter 3.  
Treatments were applied for 24 h based on previous work investigating cytoprotection 
(Statt et al., 2015, Griffin et al., 2018, Amos et al., 2014); except for experiments 
exploring the duration of 27-hydroxycholesterol treatment required to protect cells 
against pyolysin, where HeLa cells were treated with 10 ng/ml 27-hydroxycholesterol 
for a range of times up to 24 h as specified in Results. After the treatment period, 
supernatants were discarded, and cells were challenged for 2 h with control serum-free 
medium or medium containing pyolysin in the absence of treatments. To determine 
whether protection extended beyond pyolysin, HeLa and A549 cells were treated for 
24 h with vehicle or 10 ng/ml 27-hydroxycholesterol, and then challenged with 8 µg 
α-hemolysin for 24 h (added in 200 µl Dulbecco’s phosphate-buffered saline (DPBS) 
for 15 min, then supplemented with 400 µl serum-free medium up to 24 h). The 
concentration and duration of α-hemolysin required to challenge cells was determined 
by culturing cells for 24 h in serum-free medium and then challenging cells for a range 
of time periods from 0 to 24 h using the concentrations specified in Results. 
Experiments were informed by the concentration of α-hemolysin used to induce 
autophagy in HeLa cells (Mestre et al., 2010, Mestre and Colombo, 2012). At the end 
of the challenge period, supernatants were collected to measure LDH leakage and cell 
viability was evaluated using an MTT assay. Transmitted light micrographs were 
captured at the end of the challenge period in designated experiments using an 
Axiocam ERc 5s microscope camera (Zeiss). The proportion of normal, blebbing, and 
fragmented cells were counted using 2 independent images per treatment replicate. 
To determine whether cytolysis could be prevented by  pyolysin binding directly to 
residual treatment in wells, we tested the effect of oxysterol and pyolysin co-
incubation. HeLa cells were cultured for 24 h in serum-free medium. Control and 
pyolysin challenge (100 HU/well) were prepared in serum-free medium containing 
vehicle, 10 ng/ml 25-hydroxycholesterol, 10 ng/ml 27-hydroxycholesterol, or 0.5 mM 
cholesterol as a positive control, vortexed for 30 s, then added to cells for 2 h. 
Supernatants were then collected to measure the leakage of LDH, and cell viability 
was measured using an MTT assay  
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To examine the role of ACAT in cytoprotection against pyolysin we used a selective 
ACAT inhibitor Sandoz 58-035 (SZ58-035) (Ross et al., 1984). HeLa cells were 
washed twice with phosphate-buffered saline (PBS) then treated with vehicle or 10 
µM SZ58-035 in serum-free medium for 16 h as previously described (Abrams et al., 
2020). Cells were then washed twice with PBS, then incubated for 24 h in serum-free 
culture medium containing 10 ng/ml 25-hydroxycholesterol, or 10 ng/ml 
27-hydroxycholesterol in combination with vehicle or 10 µM SZ58-035. Cells were 
challenged for 2 h with control medium or medium containing 100 HU pyolysin. At 
the end of the challenge period, supernatants were collected to measure the leakage of 
LDH, and cell viability was measured using an MTT assay. 
To disrupt sphingomyelin-cholesterol complexes and explore their influence on 
protection against pyolysin damage, we used the enzyme sphingomyelinase from S. 
aureus (Das et al., 2014). HeLa cells were treated with serum-free medium containing 
vehicle, or 10 ng/ml 27-hydroxycholesterol for 24 h. Supernatants were discarded, and 
cells were washed twice with PBS. Cells were then treated for 30 mins in serum-free 
medium with or without 100 mU/ml sphingomyelinase as previously described 
(Abrams et al., 2020). After the treatment period, cells were washed twice with PBS, 
and then challenged for 2 h with control medium, or medium containing 25 HU 
pyolysin (selected because sphingomyelinase treatment increased the susceptibility of 
cells to pyolysin damage). At the end of the challenge period, supernatants were 
collected to measure the leakage of LDH, and cell viability was measured using an 
MTT assay.  
To explore the mechanisms involved in side-chain oxysterol cytoprotection, we 
focused on 27-hydroxycholesterol due to its abundance in human plasma (Dzeletovic 
et al., 1995). To examine the role of calcium influx on oxysterol protection against 
pyolysin, HeLa cells were cultured for 24 h in serum-free medium containing vehicle 
or 10 ng/ml 27-hydroxycholesterol. Supernatants were discarded, and cells were 
washed twice with calcium-free DPBS (#14190250; Thermo Fisher Scientific). Cells 
were challenged for 2 h with a control or pyolysin challenge (100 HU) prepared in 
control medium (1.8 mM CaCl2) or calcium-free medium (#21068; Thermo Fisher 
Scientific) to impair calcium ion influx. After the challenge period, supernatants were 
collected to measure the leakage of LDH, and cell viability was measured using an 
MTT assay. 
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To examine the role of potassium efflux on oxysterol protection against pyolysin, 
HeLa cells were cultured for 24 h in serum-free medium containing vehicle or 10 ng/ml 
27-hydroxycholesterol. Pyolysin challenge (100 HU) was prepared in control serum-
free medium (5.3 mM KCl), low-potassium medium (5 mM KCl, 140 mM NaCl, 10 
mM Hepes, 1.3 mM CaCl2, 0.5 mM MgCl2, 0.36 mM K2HPO4, 0.44 mM KH2PO4, 5.5 
mM D-glucose, 4.2 mM NaHCO3) or high-potassium medium (140 mM KCl, 5 mM 
NaCl, 10 mM Hepes, 1.3 mM CaCl2, 0.5 mM MgCl2, 0.36 mM K2HPO4, 0.44 mM 
KH2PO4, 5.5 mM D-glucose, 4.2 mM NaHCO3) to prevent potassium efflux (Gurcel 
et al., 2006). Cells were washed twice with control, low-potassium, or high-potassium 
medium prior to a 2 h challenge. Supernatants were collected to measure the leakage 
of LDH, and cell viability was measured using an MTT assay. 
To examine the role of LXRα and LXRβ in oxysterol cytoprotection, we used short-
interfering ribonucleic acid (siRNA) to target NR1H3 and NR1H2, respectively. Hela 
cells were transfected with scramble siRNA, or siRNA designed using Dharmacon 
siDESIGN Centre to target NR1H3 and NR1H2 (described in Chapter 2). A mixture 
of 20 pmol of siRNA, 100 ul Opti-MEM 1 medium and 1.5 µl Lipofectamine 
RNAiMAX Reagent were added to each well of a 24-well plate and incubated for 20 
min, then 4 x 104 cells HeLa cells were seeded in  900 ul DMEM medium 
supplemented with 10% FBS for 48 h. Quantitative polymerase chain reaction was 
performed on cells to validate the effectiveness of the siRNA as described in Chapter 
2. Supernatants were discarded and cells were treated with vehicle, 10 ng/ml 27-
hydroxycholesterol, or 50 nM T0901317 for 24 h in serum-free culture medium prior 
to a 2 h challenge with control medium or medium containing 100 HU pyolysin. At 
the end of the challenge period, supernatants were collected to measure LDH leakage 
and cell viability was measured using an MTT assay. 
4.2.2 Potassium 
The leakage of potassium from cells was measured to assess whether treatments 
prevented toxins forming pores in the cell membrane. HeLa or A549 cells were seeded 
at a density of 1.5 x 105 cells/well in 3 ml/well complete medium using 6-well culture 
plates and incubated for 24 h, before a 24 h treatment with 3 ml/well serum-free 
medium containing vehicle, 25-hydroxycholesterol, 27-hydroxycholesterol 
(concentrations specified in Results), 50 nM T0901317, or 1 mM methyl-β-
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cyclodextrin (MβCD, #C4555; Merck) as a control known to protect HeLa cells 
against pyolysin by depleting cellular cholesterol (Preta et al., 2015). Supernatants 
were discarded, and the cells were washed three times with potassium-free buffer (129 
mM choline-Cl, 0.8 mM MgCl2, 1.5 mM CaCl2, 5 mM citric acid, 5.6 mM glucose, 10 
mM NH4Cl, 5 mM H3PO4 , pH 7.4; all Merck), and then incubated in potassium-free 
buffer with the indicated concentration of pyolysin for 5 min at 37⁰C. Alternatively, 
cells were incubated in potassium-free buffer with control medium or 8 µg/5 × 104 
cells α-hemolysin for 15 min (no potassium leakage was visible from HeLa cells after 
5 min of α-hemolysin challenge). Supernatants were collected and potassium was 
measured using a Jenway PFP7 flame photometer as described in Chapter 2. 
4.2.3 Cholesterol 
To quantify the cellular cholesterol concentrations of HeLa cells (1.5 x 105 cells /well) 
were seeded in 3 ml/well complete medium using 6-well culture plates for 24 h. Cells 
were treated with vehicle, 10 ng/ml 25-hydroxycholesterol, 10 ng/ml 27-
hydroxycholesterol, or 1 mM MβCD in 3 ml/well serum-free medium for a further 24 
h. After the treatment period, cells were washed twice with DPBS then collected in 
250 µl/ well cholesterol assay 1X Reaction Buffer and stored at -20⁰C. Cellular 
cholesterol was measured using the Amplex Red Cholesterol Assay Kit as described 
in Chapter 2. Protein abundance was measured in samples using a DC protein assay 
(Bio-Rad), and cholesterol concentrations were normalized to protein concentrations. 
4.2.4 Immunofluorescence 
Staining cells with phalloidin as described previously, visualized cell damage (Turner 
et al., 2020). Briefly, 4 x 104 HeLa and A549 cells per well were cultured on glass 
cover slips in 24-well culture plates in complete-medium for 24 h, before a 24 h 
treatment in serum-free medium containing vehicle, 25-hydroxycholesterol, 27-
hydroxycholesterol (concentrations specified in Results), 50 nM T0901317, 125 nM 
GW3965, or 1 mM MβCD as a control to deplete cellular cholesterol. The supernatants 
were discarded, and the cells challenged with control medium or medium containing 
pyolysin for 2 h, or α-hemolysin for 24 h. At the end of the challenge period cells were 
stained with Alexa Fluor 555-conjugated phalloidin and 4,6-diamidino-2-phenylindole 
(DAPI) and then imaged as described in Chapter 2. The proportion of cells that had 
cytoskeletal changes (cytoskeletal contraction, disrupted shape, or loss of actin fibre 
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definition) were counted using >135 cells per treatment across 3 independent images 
per replicate.  
4.2.5 Western Blotting 
First, we explored the effects of oxysterol treatment on pyolysin induced MAPK 
signalling. HeLa cells were seeded at a density of 1.5 x 105 cells/well in 3 ml/well 
complete medium using 6-well culture plates for 24 h, and then treated for 24 h in 3 
ml/well serum-free medium containing vehicle, 10 ng/ml 27-hydroxycholesterol, or 
50 nM T0901317, then challenge with control serum-free medium or medium 
containing 100 HU pyolysin for 10 min. Secondly, we investigated the effect of 
oxysterol treatment on the abundance of membrane bound pyolysin. HeLa cells were 
seeded at 1.5 x 105 cells/well on 6-well plates in complete medium for 24 h, and then 
treated for 24 h in serum-free medium containing vehicle, 10 ng/ml 27-
hydroxycholesterol, 50 nM T0901317, before a 2 h challenge with control serum-free 
medium or medium containing 100 HU pyolysin. Supernatants were discarded, cells 
were washed with 300 μl ice cold PBS, and lysed with 100 μl PhosphoSafe Extraction 
Reagent. Protein isolation and Western blotting were performed as described in 
Chapter 2. The average peak density of bands was quantified and normalized to α-
tubulin using Fiji (Schindelin et al., 2012). Phosphorylated proteins were normalized 
to their cognate total protein.  
4.2.6 Statistical analysis 
The statistical unit was each independent passage of the relevant cell line. Statistical 
analysis was performed using GraphPad Prism 9.0.1. Data are reported as arithmetic 
mean (SEM), and significance attributed when P < 0.05. Comparisons between 
treatments or challenges were made using analysis of variance (ANOVA) followed by 
Dunnett, Bonferroni or Tukey post hoc test for multiple comparisons, or unpaired two-
tailed Student’s t-test as specified in Results.  
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4.3 RESULTS 
4.3.1 Side-chain oxysterol cytoprotection against pyolysin in HeLa cells 
HeLa cells were challenged with a range of concentrations of pyolysin to determine 
the amount required to damage cells (Fig 4.1). We evaluated pyolysin-induced pore-
formation in HeLa cells, identifying the concentration-dependent leakage of potassium 
ions into cell supernatants after 5 min (Fig 4.1A), leakage of LDH after 2 h (Fig 4.1B) 
and cytolysis, evaluated by the MTT cell viability assay (Fig 4.1C).  
Additionally, we examined the effect of pyolysin on cell morphology. Pyolysin 
challenge caused cell fragmentation and induced the formation of large plasma 
membrane blebs (representative examples displayed in Fig 4.2). The proportion of 
fragmented cells following pyolysin challenge increased in a concentration dependent 
manner (Fig 4.3, 4.4). Interestingly the plasma membrane blebs were not always 
apparent in cells challenged with > 100 HU pyolysin, with cells losing all structural 
integrity. This suggests that pyolysin damages causes cells to progress from a normal 
to a blebbing and finally a fragmented phenotype. For subsequent cytoprotection 
experiments, we selected a 100 HU pyolysin challenge that increased potassium and 
LDH leakage (P < 0.001, ANOVA and Dunnett’s post hoc test, n=4) and caused 
cytolysis, reducing cell viability by >80%.   
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Figure 4.1 Pyolysin causes HeLa cell cytolysis  
(A) Leakage of potassium from HeLa cells challenged for 5 min with control medium 
or pyolysin and (B) leakage of LDH into supernatants, and cell viability determined 
by MTT assay for HeLa cells challenged for 2 h with control medium or the indicated 
amount of pyolysin. Data are presented as mean (SEM) with dots representing the 
values from 4 independent experiments; statistical significance was determined using 
one-way ANOVA and Dunnett’s post hoc test; *P < 0.05, **P < 0.01, ***P < 0.001.  
 
 
Figure 4.2Pyolysin induces membrane blebbing and fragments HeLa cells 
Phase contrast microscopy HeLa cells challenged for 2 h with control medium or 100 
HU pyolysin. Images are representative of 3 independent experiments. 
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Figure 4.3 Pyolysin damages HeLa cells  
Phase contrast microscopy of HeLa cells cultured for 24 h in serum-free medium, then 
challenged for 2 h with control medium or the indicated amount of pyolysin. Images 
are representative of 3 independent experiments.  
 
Figure 4.4 Pyolysin induces HeLa cell plasma membrane blebbing 
Percentage of normal, blebbing, or fragmented HeLa cells treated for 24 h in serum-
free medium, then challenged with the indicated amount of pyolysin for 2 h. Data are 
presented as mean (SEM) from 4 independent experiments.   
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To establish whether oxysterols would protect HeLa cells against pyolysin damage, 
cells were treated for 24 h with a range of concentrations of 25-hydroxycholesterol 
and 27-hydroxycholesterol. The cells were then challenged for 2 h with control 
medium or pyolysin in the absence of treatment. Pyolysin challenge resulted in the 
leakage of LDH into cell supernatants and cytolysis (P < 0.001, Fig 4.5A, B). However, 
treatment with 25-hydroxycholesterol (> 10 ng/ml) or 27-hydroxycholesterol (> 10 
ng/ml) provided maximal protection against the pyolysin-induced leakage of LDH and 
cytolysis. The use of a control challenge showed that 27-hydroxycholesterol and 25-
hydroxycholesterol did not significantly alter the leakage of LDH (P > 0.97) or the 
MTT assay (P > 0.91). For further experiments exploring side-chain oxysterol 
cytoprotection we selected 10 ng/ml 25-hydroxycholesterol and 10 ng/ml 27-
hydroxycholesterol as these concentrations represented the lowest dose required to 
provide maximal protection.  
To evaluate whether side-chain oxysterols protected against initial pyolysin pore 
formation, we measured the leakage of potassium into cell supernatants within 5 min 
of pyolysin challenge (Gonzalez et al., 2011, Turner et al., 2020). Prior to the pyolysin 
challenge HeLa cells were treated with 10 ng/ml 25-hydroxycholesterol, 10 ng/ml 27-
hydroxycholesterol or 1 mM MβCD as a control to deplete cellular cholesterol (Preta 
et al., 2015). Pyolysin challenge caused potassium leakage in vehicle treated cells, but 
not in MβCD treated cells (Fig 4.5C). Significantly, 25-hydroxycholesterol and 27-
hydroxycholesterol treatment also reduced pyolysin-induced potassium leakage.  In 
independent experiments investigating the effect of treatment duration, cytoprotection 
was evident after 4 h (P < 0.001, ANOVA and Dunnett’s post hoc test, n = 5, Fig 4.5D) 
and maximal with >12 h of treatment.  
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Figure 4.5 Side-chain oxysterols protect HeLa cells against pyolysin damage 
(A,B) Leakage of LDH and viability of HeLa cells cultured for 24 h in serum-free 
medium containing vehicle (V) or the indicated concentrations of 25-
hydroxycholesterol or 27-hydroxycholesterol and then challenged for 2 h with control 
medium or 100 HU pyolysin. Data are presented as mean (SEM) with dots representing 
values from cells from 4 independent experiments; statistical significance determined 
by two-way ANOVA and P-values are reported for the effect of treatment on pyolysin 
challenge. (C) Leakage of potassium from HeLa cells treated for 24 h with vehicle, 10 
ng/ml 25-hydroxycholesterol (25-HC), 10 ng/ml 27-hydroxycholesterol (27-HC), or 1 
mM MβCD, and then challenged for 5 min with control medium or 100 HU pyolysin. 
Dots represent individual values from 4 independent experiments; statistical 
significance was determined using one-way ANOVA with Dunnett’s post hoc test; 
***P < 0.001. (D) Viability of HeLa cells treated for the indicated time periods with 
10 ng/ml 27-hydroxycholesterol, and then challenged for 2 h with control medium or 
100 HU pyolysin. Pyolysin data are presented as percentage viability of control 
challenge, with dots representing individual values across 1 to 6 independent 
experiments. 
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Staining cells with phalloidin visualized cell damage. Pyolysin challenge reduced actin 
fibre definition, causing the cytoskeleton to collapse around the nucleus, however, this 
was reduced by depleting cellular cholesterol using MβCD (16 ± 4 vs 83 ± 5% cells 
damaged, P < 0.001, ANOVA and Dunnett’s post hoc test, n = 3, Fig 4.6). Both 25-
hydroxycholesterol and 27-hydroxycholesterol treatment also reduced pyolysin-
induced cytoskeletal changes in HeLa cells (20 ± 4 and 18 ± 5 vs 83 ± 5% cells 
damaged, P < 0.001, ANOVA and Dunnett’s post hoc test, n = 3).  
Large plasma membrane blebs were formed on HeLa cells challenged with pyolysin, 
and cells demonstrated a complete loss of shape and structure appearing fragmented. 
Treatment with 25-hydroxycholesterol, 27-hydroxycholesterol and MβCD reduced the 
formation of plasma membrane blebs (P < 0.01, ANOVA and Dunnett’s post hoc test, 
Fig 4.7, Table 4.1), increasing the number of normal cells following pyolysin challenge 
(P < 0.001, ANOVA and Dunnett’s post hoc test, Fig 4.7, Table 4.1), and preventing 
cell fragmentation (P < 0.05, ANOVA and Dunnett’s post hoc test, Fig 4.7, Table 4.1). 
Together these data provide evidence for side-chain oxysterol cytoprotection of HeLa 
cells against pyolysin.  
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Figure 4.6 Side-chain oxysterols protect HeLa cells against pyolysin-induced 
actin cytoskeletal changes 
Fluorescent microscope images of HeLa cells treated for 24 h with vehicle, 10 ng/ml 
25-hydroxycholesterol (25-HC), 10 ng/ml 27-hydroxycholesterol (27-HC), or 1 mM 
MβCD, then challenged for 2 h with control medium or 100 HU pyolysin and stained 
with fluorescent phalloidin (white) and DAPI (red); images are representative from 4 
independent experiments. Quantification of cytoskeletal changes are reported in text. 
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Figure 4.7 Oxysterols protect HeLa cells against pyolysin-induced blebbing  
Phase contrast microscopy of HeLa cells treated for 24 h with vehicle, 10 ng/ml 25-
hydroxycholesterol (25-HC), 10 ng/ml 27-hydroxycholesterol (27-HC), or 1 mM 
MβCD, then challenged for 2 h with control medium or 100 HU pyolysin; images are 
representative from 4 independent experiments, scale bars = 50 µm. 
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Table 4.1 Quantification of HeLa cell morphology after oxysterol treatment and 
pyolysin challenge 
Percentage of normal, blebbing, or fragmented HeLa cells treated for 24 h with vehicle, 
10 ng/ml 25-hydroxycholesterol, 10 ng/ml 27-hydroxycholesterol, or 1 mM MβCD, 
then challenged for 2 h with 100 HU pyolysin. Cells were imaged by phase contrast 
microscopy and categorized as normal, blebbed or fragmented, with >100 cells 
evaluated across two independent images per treatment replicate. Raw data were 
analyzed by ANOVA and Tukey’s post hoc test with superscript indicating the 
differences between vehicle and treatments (*P<0.05, **P < 0.01, ***P < 0.001), and 
data are reported as mean ± SEM for the pyolysin challenge as a percentage of the 
control challenge. 
Treatment  Replicates Percentage of cells 
Normal Blebbing Fragmented 
Vehicle 7 15 ± 5  43 ± 7  42 ± 10  
25-hydroxycholesterol 3 95 ± 2 *** 1 ± 1 ** 4 ± 2 * 
27-hydroxycholesterol 5 91 ± 3 *** 3 ± 1 *** 6 ± 2 * 
MβCD 3 86 ± 4 *** 6 ± 1 ** 8 ± 3 * 
 
4.3.2 Side-chain oxysterol cytoprotection against pyolysin is generalized 
To establish if oxysterol cytoprotection against pyolysin was generalized beyond HeLa 
cervical cells, we tested A549 lung alveolar epithelial cells because they are often used 
to study cholesterol-dependent cytolysins (Mestre and Colombo, 2012, Statt et al., 
2015). Hep-G2 liver cells and NC1-H441 lung cells were used to provide additional 
validation as these cells were also susceptible to pyolysin damage (Fig 4.8). We first 
determined the amount of pyolysin required to damage cells, selecting challenges that 
caused LDH leakage and cytolysis in A549 (25 HU/well; P < 0.001, ANOVA and 
Dunnett’s post hoc test, n=4, Fig 4.8A), Hep-G2 (100 HU/well; P < 0.001, ANOVA 
and Dunnett’s post hoc test, n=4, Fig 4.8B) and NC1-H441 (200 HU/well; P < 0.001, 
ANOVA and Dunnett’s post hoc test, n = 4, Fig 4.8C) cells.  
147 
 
 
Figure 4.8 Cytolytic activity of pyolysin in A549, Hep-G2 and NC1-H441 cells  
Leakage of LDH into supernatants, and cell viability determined by MTT assay for 
(A) A549, (B) Hep-G2, and (C) NC1-H441 cells challenged for 2 h with control 
medium or pyolysin. Data are presented as mean (SEM) with dots representing the 
values from 4 independent experiments; statistical significance was determined using 
one-way ANOVA and Dunnett’s post hoc test; **P < 0.01, ***P < 0.001. 
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Having established suitable pyolysin challenge concentrations, we treated A549 cells 
with 25-hydroxycholesterol or 27-hydroxycholesterol for 24 h and then challenged 
them with control medium or pyolysin for 2 h. Pyolysin challenge caused LDH leakage 
and cytolysis compared with control challenge (P < 0.001 Fig. 4.9A,B). Treatment 
with 25-hydroxycholesterol and 27-hydroxycholesterol reduced pyolysin-induced 
LDH leakage and cytolysis. Specifically, pyolysin induced LDH leakage was reduced 
by 90.5% and 80% by 50 ng/ml 25-hydroxycholesterol and 25 ng/ml 27-
hydroxycholsterol respectively, therefore these concentrations were used for 
additional cytoprotective experiments in A549 cells. Vehicle treated A549 cells leaked 
potassium ions after a 5 min pyolysin challenge (P < 0.001, Fig. 4.9C), however, this 
leakage was reduced by 25-hydroxycholesterol, 27-hydroxycholesterol or MβCD 
treatment. A 2 h pyolysin challenge resulted in morphological and cytoskeletal 
changes in A549 cells (Fig 4.10). Treatment with both 25- and 27-hydroxycholesterol 
prevented pyolysin-induced actin changes as effectively as depleting cellular 
cholesterol with MβCD (15 ± 5, 17 ± 3, and 14 ± 2 vs 73 ± 3% cells damaged, P < 
0.001, ANOVA and Dunnett’s post hoc test, n = 3), with cells largely maintaining the 
morphology observed in control challenged cells. In addition, 27-hydroxycholesterol 
protected Hep-G2 and NC1-H441 cells against pyolysin challenge, reducing LDH 
leakage by 58% and 59% respectively, as well as reducing cytolysis (Fig 4.11). 
Together this data provide evidence that side-chain oxysterols protect multiple cell 
lines against pyolysin challenge.  
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Figure 4.9 Side-chain oxysterols protect A549 cells against pyolysin damage 
(A,B) Leakage of LDH and viability of A549 cells cultured for 24 h in serum-free 
medium containing vehicle (V) or the indicated concentrations of 25-
hydroxycholesterol or 27-hydroxycholesterol and then challenged for 2 h with control 
medium or 25 HU pyolysin. Data are presented as mean (SEM) with dots representing 
values from cells from 4 independent experiments; statistical significance determined 
by two-way ANOVA and P-values are reported for the effect of treatment on pyolysin 
challenge. (C) Leakage of potassium from A549 cells treated for 24 h with vehicle, 50 
ng/ml 25-hydroxycholesterol (25-HC), 25 ng/ml 27-hydroxycholesterol (27-HC), or 1 
mM MβCD, and then challenged for 5 min with control medium or 25 HU pyolysin. 
Dots represent individual values from 4 independent experiments; statistical 
significance was determined using one-way ANOVA with Dunnett’s post hoc test; 
***P < 0.001. 
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Figure 4.10 Oxysterols protect A549 cells against pyolysin-induced actin 
cytoskeletal changes 
Fluorescent microscope images of A549 cells treated for 24 h with vehicle, 50 ng/ml 
25-hydroxycholesterol (25-HC), 25 ng/ml 27-hydroxycholesterol (27-HC), or 1mM 
MβCD then challenged for 2 h with control medium or 25 HU pyolysin and stained 
with fluorescent phalloidin (white) and DAPI (red); images are representative from 4 
independent experiments. Quantification of cytoskeletal changes are reported in text. 
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Figure 4.11 27-hydroxycholesterol cytoprotection in Hep-G2 and NC1-H44 cells. 
Leakage of LDH and viability of (A) Hep-G2 and (B) NCI-H441 cells treated for 24 
h with vehicle or 10 ng/ml 27-hydroxycholesterol (27-HC), and then challenged for 2 
h with control medium or pyolysin (Hep-G2, 100 HU; NC1-H441, 200 HU). Data are 
presented as mean (SEM) from 4 independent experiments; statistical significance was 
determined using two-way ANOVA and Bonferroni’s post hoc test; **P < 0.01, 
***P < 0.001. 
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4.3.3 Side-chain oxysterols protect cells against α-hemolysin 
To explore if side-chain oxysterol cytoprotection extended beyond cholesterol-
dependent cytolysins, we also examined protection against a member of the hemolysin 
family of cytolysins, S. aureus α-hemolysin (Seilie and Bubeck Wardenburg, 2017, 
Song et al., 1996). Pyolysin forms pores with an 18 nm internal diameter compared to 
the 1.4 nm diameter transmembrane pores formed by S. aureus α-hemolysin (Preta et 
al., 2016, Song et al., 1996). Therefore, differing cytolytic activities are expected. To 
determine a suitable α-hemolysin challenge a range of durations and concentrations 
were explored in HeLa (Fig 4.12) and A549 (Fig 4.13) cells. For cytoprotection 
experiments we selected a 24 h 8 µg α-hemolysin as it caused LDH leakage and 
cytolysis in both HeLa and A549 cells.  
 
Figure 4.12 Cytolytic activity of S. aureus α-hemolysin in HeLa cells 
HeLa cells were cultured for 24 h in serum-free medium and then (A) challenged for 
the indicated times with control serum-free medium or 8 µg α-hemolysin, or (B) for 
the 24 h with control medium or the indicated concentration of α-hemolysin. The 
leakage of LDH was measured in cell supernatants and cell viability was determined 
by MTT. Data are presented as mean (SEM) from 4 independent experiments; 
statistical significance was determined using one-way ANOVA and Dunnett’s post 
hoc test; *P < 0.05, **P < 0.01, ***P < 0.001.  
153 
 
 
Figure 4.13 Cytolytic activity of S. aureus α-hemolysin in A549 cells  
A549 cells were cultured for 24 h in serum-free medium and then (A) challenged for 
the indicated times with control serum-free medium or 8 µg α-hemolysin, or (B) for 
24 h with control medium or the indicated concentration of α-hemolysin. The leakage 
of LDH was measured in cell supernatants and cell viability was determined by MTT 
assay. Data are presented as mean (SEM) from 4 independent experiments; statistical 
significance was determined using one-way ANOVA and Dunnett’s post hoc test; 
*P < 0.05, **P < 0.01, ***P < 0.001.  
. 
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To examine side-chain oxysterol protection against α-hemolysin, we treated HeLa and 
A549 cells with 25-hydroxycholesterol or 27-hydroxycholesterol for 24 h and then 
challenged cells for 24 h with S. aureus α-hemolysin. The α-hemolysin challenge 
caused potassium ion leakage, LDH leakage, and cytolysis in HeLa (Fig 4.14) and 
A549 cells (Fig 4.14). Treatment with 27-hydroxycholesterol prevented cytolysis and 
reduced LDH leakage by 83% and 86% in HeLa (Fig 4.14A) and A549 (Fig 4.15A) 
cells respectively. Additionally, treatment with 25-hydroxycholesterol or 27-
hydroxycholesterol reduced the pyolysin-induced leakage of potassium ions compared 
with vehicle treatment in both cell lines (Fig 4.14B. Fig 4.15B). Treatment with 27-
hydroxycholesterol also reduced α-hemolysin induced cytoskeletal changes in HeLa 
(35 ± 1 vs 85 ± 3% cells damaged, t-test, n = 3, P < 0.001, Fig 4.14C) and A549 (18 ± 
4 vs 84 ± 6% cells damaged, t-test, n = 3, P < 0.01, Fig 4.15C) cells. Together this data 
provide evidence that side-chain oxysterols protect cells against S. aureus α-
hemolysin. 
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Figure 4.14 27-hydroxycholesterol protects HeLa cells against α-hemolysin 
(A) Leakage of LDH and viability of HeLa cells treated for 24 h with vehicle or 10 
ng/ml 27-hydroxycholesterol (27-HC), and then challenged for 24 h with 8 µg α-
hemolysin. Data are presented as mean (SEM) from 4 independent experiments; 
statistical significance was determined using two-way ANOVA and Bonferroni’s post 
hoc test; **P < 0.01, ***P < 0.001. (B) Leakage of potassium from HeLa cells treated 
for 24 h with vehicle, 10 ng/ml 25-hydroxycholesterol, or 10 ng/ml 27-
hydroxycholesterol and then challenged for 15 min with control medium or 8 µg α-
hemolysin. Dots represent individual values from 4 independent experiments; 
statistical significance was determined using one-way ANOVA with Dunnett’s post 
hoc test; *P < 0.05. (C) Fluorescent microscope images of HeLa cells treated for 24 h 
with vehicle or 10 ng/ml 27-hydroxycholesterol, then challenged for 24 h with control 
medium or 8 µg α-hemolysin and stained with fluorescent phalloidin (white) and DAPI 
(red); images are representative from 3 independent experiments. Quantification of 
cytoskeletal changes are reported in text. 
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Figure 4.15: 27-hydroxycholesterol protects A549 cells against α-hemolysin. 
(A) Leakage of LDH and viability of A549 cells treated for 24 h with vehicle or 25 
ng/ml 27-hydroxycholesterol (27-HC), and then challenged for 24 h with 8 µg α-
hemolysin. Data are presented as mean (SEM) from 4 independent experiments; 
statistical significance was determined using two-way ANOVA and Bonferroni’s post 
hoc test; ***P < 0.001. (B) Leakage of potassium from A549 cells treated for 24 h with 
vehicle, 50 ng/ml 25-hydroxycholesterol, or 25 ng/ml 27-hydroxycholesterol 
challenged for 15 min with control medium or 8 µg α-hemolysin. Dots represent 
individual values from 4 independent experiments; statistical significance was 
determined using one-way ANOVA with Dunnett’s post hoc test; *P < 0.05. (C) 
Fluorescent microscope images of A549 cells treated for 24 h with vehicle or 25 ng/ml 
27-hydroxycholesterol, then challenged for 24 h with control medium or 8 µg α-
hemolysin and stained with fluorescent phalloidin (white) and DAPI (red); images are 
representative from 3 independent experiments. Quantification of cytoskeletal changes 
are reported in text. 
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4.3.4 Cellular cholesterol 
Plasma membrane cholesterol is a requirement for pyolysin binding and pore-
formation (Billington et al., 1997). Depleting total cellular cholesterol using 
cyclodextrins reduces pyolysin-induced cell damage (Amos et al., 2014). A 24 h 
treatment with 1 mM MβCD reduced cholesterol in HeLa cells by 49% compared with 
vehicle treated cells (Fig 4.16A). However, neither 25-hydroxycholesterol (P = 0.99) 
or 27-hydroxycholesterol (P = 0.97) significantly altered total cellular cholesterol.  
Serum free medium was used for experiments exploring the effect of oxysterol 
treatment on cytoprotection, however, to determine whether serum affected 
cytoprotection, HeLa cells were treated for 24 h with 25-hydroxycholesterol in 
medium containing 10% fetal calf serum, before a 2 h pyolysin challenge in serum-
free medium. The presence of 10% serum did not prevent 25-hydroxycholesterol 
protection against pyolysin induced LDH leakage or cytolysis (Fig 4.16B), however, 
in the presence of serum 100 ng/ml 25-hydroxycholesterol was required to provide 
maximal protection as opposed to 10 ng/ml in serum-free medium (Fig 4.16C).  
To address a concern that side-chain oxysterols might prevent cytolysis by binding to 
residual treatment in wells, we prepared pyolysin challenges in medium containing 25-
hydroxycholesterol, 27-hydroxycholesterol, or cholesterol, before challenging HeLa 
cells for 2 h. Unlike cholesterol, coincubation with side-chain oxysterols did not affect 
the cytolytic activity of pyolysin, providing some evidence to suggest that the 
oxysterols do not protect cells by binding to pyolysin (Fig 4.16D). 
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Figure 4.16 Side-chain oxysterols do not reduce HeLa total cell cholesterol 
(A) Cellular cholesterol in HeLa cells treated for 24 h with vehicle, 10 ng/ml 25-
hydroxycholesterol (25-HC), 10 ng/ml 27-hydroxycholesterol (27-HC), or 1 mM 
MβCD. Data are presented as mean (SEM) from 4 independent experiments; statistical 
significance was determined using one-way ANOVA with Dunnett’s post hoc test; 
**P < 0.01. (B) Leakage of LDH and viability of HeLa cells treated for 24 h with 
vehicle, or the indicated concentrations of 25-hydroxycholesterol in complete medium 
containing 10% serum, and then challenged for 2 h with control medium or 100 HU 
pyolysin. Data are presented as mean (SEM) from 4 independent experiments; 
statistical significance was determined using two-way ANOVA and P-values reported 
for the effect of treatment on pyolysin challenge. (C) Percentage of viable HeLa cells 
treated for 24 h with vehicle or the indicated concentration of 25-hydroxycholesterol 
in serum-free or complete medium containing 10% serum, then challenged with 100 
HU pyolysin. Data are presented as mean (SEM) from ≥ 3 independent experiments; 
statistical significance was determined by two-way ANOVA and Bonferroni’s post 
hoc test; *P < 0.05, **P < 0.01. (D) Leakage of LDH and viability of HeLa cells 
challenged for 2 h with control medium or 100 HU pyolysin, mixed with vehicle, 10 
ng/ml 25-hydroxycholesterol, 10 ng/ml 27-hydroxycholesterol, or 0.5 mM cholesterol. 
Data are presented as mean (SEM) from 3 independent experiment; statistical 
significance was determined by two-way ANOVA and Dunnett’s post hoc test; *P < 
0.05.  
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As oxysterols did not affect total cellular cholesterol over the time required to provide 
cytoprotection, we aimed to investigate changes to cholesterol in the plasma 
membrane. There are three distinct pools of plasma membrane cholesterol: a 
sphingomyelin-sequestered pool, a residual pool, and a pool accessible to cholesterol-
dependent cytolysin binding (Das et al., 2014). Treating HeLa cells with 27-
hydroxycholesterol or T0901317 reduced pyolysin binding by 71% and 55% 
respectively (Fig 4.17). The membrane -bound enzyme ACAT converts cholesterol in 
the ER to cholesterol esters which can trigger rapid membrane remodelling reducing 
cholesterol accessibility (Chang et al., 2009, Abrams et al., 2020). Treatment with the 
ACAT inhibitor SZ58-035 partially restored pyolysin-induced LDH leakage and 
cytolysis in cells treated with 25-hydroxycholesterol or 27-hydroxycholesterol (Fig 
4.18).  
 
Figure 4.17 27-hydroxycholesterol reduces pyolysin binding 
Representative Western blot of pyolysin binding and α-tubulin for HeLa cells treated 
for 24 h with vehicle, 50 nM T0901317, or 10 ng/ml 27-hydroxycholesterol (27HC), 
and then challenged for 2 h with control medium or 100 HU pyolysin. Densitometry 
data were normalized to α-tubulin and presented as mean (SEM) from 4 experiments; 
statistical significance was determined using ANOVA with Dunnett’s post hoc test; 
**P < 0.01, ***P < 0.001. 
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Figure 4.18 27-hydroxycholesterol cytoprotection is partially ACAT-dependent  
(A) Leakage of LDH and (B) viability of HeLa cells cultured for 16 h with vehicle or 
10 µM SZ58-035, then treated for 24 h with vehicle, 10 ng/ml 25-hydroxycholesterol 
(25-HC), or 10 ng/ml 27-hydroxycholesterol (27-HC), in the continuing presence of 
vehicle or SZ58-035, and then challenged for 2 h with control medium or 100 HU 
pyolysin. Data are presented as mean (SEM) from 4 independent experiments; 
statistical significance was determined using two-way ANOVA with Tukey’s post hoc 
test; *P < 0.05, ***P < 0.001.  
If side-chain oxysterol cytoprotection is dependent on ACAT-dependent cholesterol 
esterification, then we reasoned that restoring the accessible pool of cholesterol should 
re-establish the susceptibility of cells to pyolysin. Sphingomyelinase disrupts 
sphingomyelin-sequestered cholesterol, generating additional pools of accessible 
cholesterol in the plasma membrane (Das et al., 2014, Abrams et al., 2020). 
Sphingomyelinase treatment increased LDH leakage and cytolysis from cells 
challenged with pyolysin (P < 0.001, Fig 4.19B). 27-hydroxycholesterol treatment still 
reduced LDH leakage and cytolysis, however, in the presence of sphingomyelinase 
27-hydroxycholesterol protection against cytolysis was reduced from 100% to 66%. 
Together this data provide some evidence that oxysterols protect cells against pyolysin 
by reducing toxin binding through the modulation of cholesterol accessibility.. 
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Figure 4.19 Sphingomyelinase treatment doesn’t prevent 27-hydroxycholesterol 
cytoprotection 
(A) Leakage of LDH and (B) viability of HeLa cells were cultured for 24 h in serum-
free medium containing vehicle, 10 ng/ml 27-hydroxycholesterol, treated for 30 min 
in serum-free medium containing vehicle or 100 mU/ml sphingomyelinase, and then 
challenged for 2 h with control serum-free medium or 25 HU pyolysin. Data are 
presented as mean (SEM) from 4 independent experiments; statistical significance was 
determined using two-way ANOVA and Tukey’s post hoc test; **P < 0.01, 
***P < 0.001. 
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4.3.5 Ion flux does not contribute to oxysterol cytoprotection 
Pore-forming toxins activate the MAPK cell stress response and damage repair 
mechanisms in response to potassium efflux and calcium influx (Kloft et al., 2009, 
Cassidy and O'Riordan, 2013, Gonzalez et al., 2011). The MAPKs ERK1/2, p38 and 
JNK are activated by pyolysin challenge (Preta et al., 2015). 27-hydroxycholesterol 
and T0901317 treatment did not cause MAPK phosphorylation (Fig 4.20). 
Furthermore, treatment with 27-hydroxycholesterol or T0901317 inhibited pyolysin 
induced phosphorylation of ERK1/2, p38 or JNK. 
We next considered whether oxysterol cytoprotection was dependent on calcium or 
potassium. Depleting calcium from the challenge medium increased pyolysin-induced 
cell damage; shown by increased LDH leakage and cytolysis (Fig 4.21A). However, 
27-hydroxycholesterol provided protection against pyolysin damage regardless of 
calcium concentration in the challenge medium. Furthermore, although pyolysin 
challenge in low-potassium medium (5 mM) resulted in increased LDH leakage and 
cytolysis compared with high potassium (140 mM to prevent efflux), 27-
hydroxycholesterol still provided protection (Fig 4.21B). Together this data provide 
evidence to suggest that 27-hydroxycholesterol protection against pyolysin is not 
dependent on the influx of calcium ions, the efflux of potassium ions, or MAPK 
phosphorylation. 
163 
 
 
Figure 4.20 27-hydroxycholesterol and T0901317 reduces pyolysin-induced 
MAPK phosphorylation 
Representative Western blot of phosphorylated and total ERK1/2, p38 and JNK, and 
α-tubulin for HeLa cells treated for 24 h with vehicle, 10 ng/ml 27-hydroxycholesterol 
(27-HC), or 50 nM T0901317, and challenged for 10 min with control medium or 100 
HU pyolysin. Densitometry data were normalized to α-tubulin and presented as mean 
(SEM) from 3 independent experiments; statistical significance was determined using 
ANOVA and Tukey’s post hoc test; *P < 0.05, **P < 0.01. 
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Figure 4.21 Calcium ion influx and potassium ion efflux does not affect 27-
hydroxycholesterol cytoprotection 
Leakage of LDH and viability of Hela cells treated for 24 h in control serum-free 
medium containing vehicle or 10 ng/ml 27-hydroxycholesterol (27-HC), and then 
challenged for 2 h with 100 HU pyolysin in (A) low/high potassium medium or (B) in 
medium +/- calcium. Data are presented as mean (SEM) of 4 independent experiments; 
statistical significance was determined using two-way ANOVA and Bonferroni’s post 
hoc test; **P < 0.01, ***P < 0.001. 
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4.3.6 Liver X receptor agonists protect HeLa cells against pyolysin 
As side-chain oxysterols are ligands for the liver X receptors, we explored their role 
in cytoprotection. Our first approach was to use siRNA to reduce the expression of 
both LXRα and LXRβ. Transfecting HeLa cells with siRNA targeting NR1H3 and 
NR1H2 reduced the expression of LXRα and LXRβ by > 80% (Fig 4.22), but had no 
significant effect on 27-hydroxycholesterol protection (Fig 4.23).  
 
Figure 4.22 siRNA reduces the expression of NR1H2 and NR1H3 
HeLa cells were transfected with scramble siRNA or siRNA targeting (A) NR1H2 and 
(B) NR1H3 for 48 h. The mRNA expression of each cognate gene and the reference 
gene RPL19 were measured by qPCR. Data are presented as mean with dots 
representing the values from 3 independent passages. Data were analysed by one-way 
ANOVA and Dunnett’s post hoc test; **P < 0.01, ***P < 0.001. 
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Figure 4.23 27-hydroxycholesterol cytoprotection was not LXR dependent 
Leakage of LDH and viability of HeLa cells transfected for 48 h with scramble siRNA 
or siRNA targeting NR1H2 and NR1H3, treated for 24 h with vehicle or 10 ng/ml 27-
hydroxycholesterol, and then challenged for 2 h with control medium or 100 HU 
pyolysin. Data are presented as mean (SEM) from 4 independent experiments; 
statistical significance was determined using two-way ANOVA and Tukey’s post hoc 
test. 
Our second approach was to use synthetic agonists for LXRα and LXRβ. Treating cells 
with T0901317 or GW3965, reduced the leakage of LDH and cytolysis caused by 
pyolysin challenge (Fig 4.24A, 4.24B). Interestingly, only GW3965 reduced the 
pyolysin-induced leakage of potassium ions (Fig 4.24C). In separate experiments 
investigating the effect of T0901317 treatment duration cytoprotection was evident 
after 6 h (Fig 4.24D). Additionally, pyolysin-induced actin-cytoskeletal changes were 
reduced by treatment with T0901317 (37 ± 9 vs 83 ± 5% cells damaged, P < 0.01, 
ANOVA and Dunnett’s post hoc test, n = 3, Fig 4.25) and GW3965 (23 ± 11 vs 83 ± 
5% cells damaged, P < 0.001, ANOVA and Dunnett’s post hoc test, n = 3, Fig 4.25). 
Simultaneously targeting both NR1H3 and NR1H2 reduced the protective effects of 
T0901317, increasing LDH leakage and cytolysis compared with cells treated with 
non-targeting siRNA, providing some evidence that the agonist was providing 
protection through the liver X receptors (Fig 4.26).  
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Figure 4.24 Liver X receptor agonists protect HeLa cells against pyolysin 
(A,B) Leakage of LDH and viability of HeLa cells cultured for 24 h in serum-free 
medium containing vehicle (V) or the indicated concentrations of T0901317 or 
GW39665 and then challenged for 2 h with control medium or 100 HU pyolysin. Data 
are presented as mean (SEM) from 4 independent experiments; statistical significance 
determined by two-way ANOVA and P-values reported for the effect of treatment 
pyolysin challenge. (C) Leakage of potassium from HeLa cells treated for 24 h with 
vehicle, 50 nM T0901317, 125 nM GW3965, or 1 mM MβCD, and then challenged 
for 5 min with control medium or 100 HU pyolysin. Dots represent individual values 
from 4 independent experiments; statistical significance was determined using one-
way ANOVA with Dunnett’s post hoc test; **P < 0.01, ***P < 0.001. (D) Viability of 
HeLa cells treated for the indicated time periods with 50 nM T0901317, and then 
challenged for 2 h with control medium or 100 HU pyolysin. Pyolysin data are 
presented as percentage viability of control challenge, with dots representing 
individual values from independent experiments. 
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Figure 4.25 Liver X receptor agonists protect HeLa cells against pyolysin-induced 
actin cytoskeletal changes 
Fluorescent microscope images of HeLa cells treated for 24 h with vehicle, 50 nM 
T0901317, or 125 nM GW3965, then challenged for 2 h with control medium or 100 
HU pyolysin and stained with fluorescent phalloidin (white) and DAPI (red); images 
are representative from 4 independent experiments. Quantification of cytoskeletal 
changes are reported in text. 
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Figure 4.26 T0901317 cytoprotection against pyolysin is LXR dependent 
Leakage of LDH and viability of HeLa cells transfected for 48 h with scramble siRNA 
or siRNA targeting NR1H2 and NR1H3, treated for 24 h with vehicle or 50 nM 
T0901317, and then challenged for 2 h with control medium or 100 HU pyolysin. Data 
are presented as mean (SEM) from 4 independent experiments; statistical significance 
was determined using two-way ANOVA and Tukey’s post hoc test; **P < 0.01, 
***P < 0.001. 
Liver X receptor cytoprotection extended to A549 lung cells, reducing pyolysin-
induced LDH leakage and cytolysis (Fig 4.27). Treatment with T0901317 reduced 
pyolysin-induced actin cytoskeletal changes (21 ± 6 vs 73 ± 3% cells damaged, P < 
0.01, t-test, n = 3, Fig 4.28). Collectively, this data provides evidence that 27-
hydroxycholesterol treatment does not exploit the liver X receptor in HeLa cervical 
cells to confer cytoprotection. However, treatment with the synthetic liver X receptor 
agonists can protect cells against pyolysin damage.  
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Figure 4.27 Liver X receptor agonists protect A549 cells against pyolysin 
(A,B) Leakage of LDH and viability of HeLa cells cultured for 24 h in serum-free 
medium containing vehicle (V) or the indicated concentrations of T0901317 or 
GW39665 and then challenged for 2 h with control medium or 25 HU pyolysin. Data 
are presented as mean (SEM) with dots representing values from cells from 3 - 4 
independent experiments; statistical significance determined by two-way ANOVA and 
P-values are reported for the effect of treatment on pyolysin challenge. 
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Figure 4.28 T0901317 protects A549 cells against pyolysin-induced actin 
cytoskeletal changes 
Fluorescent microscope images of A549 cells treated for 24 h with vehicle or 50 nM 
T0901317, then challenged for 2 h with control medium or 25 HU pyolysin, and 
stained with fluorescent phalloidin (white) and DAPI (red); images are representative 
from 3 independent experiments. Quantification of cytoskeletal changes are reported 
in text. 
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4.4 DISCUSSION 
This chapter provides evidence that side-chain oxysterols protect human epithelial 
cells against the damage caused by pore-forming toxins. Treatment with 25-
hydroxycholesterol or 27-hydroxycholesterol protected four types of epithelial cells 
against pyolysin damage. The oxysterols reduced cytolysin-induced leakage of 
potassium ions and lactate dehydrogenase, limited cytoskeletal changes, and reduced 
cytolysis. This oxysterol cytoprotection did not appear to depend on potassium or 
calcium, MAPK phosphorylation, or the liver X receptors, but instead depended on 
ACAT reducing the cytolysin-accessible cholesterol in plasma membranes. The 
oxysterols also protected epithelial cells against damage caused by S. aureus α-
hemolysin. Collectively, these finding imply that oxysterols can increase the intrinsic 
protection of epithelial cells against pore-forming toxins and may help protect tissues 
against pathogenic bacteria.  
The key finding of this chapter was the ability of both 25-hydroxycholesterol and 27-
hydroxycholesterol to reduce HeLa cell cytolysis caused by a pyolysin challenge that 
typically reduced cell viability by > 70%. Side-chain oxysterol treatment appeared to 
reduce pyolysin pore-formation, as shown by decreased potassium leakage within 5 
min of challenge and decreased LDH leakage within 2 h. Furthermore, pyolysin-
induced ERK1/2, p38 and JNK phosphorylation was reduced in 27-hydroxycholesterol 
treated cells. Cytoprotection extended to the A549, Hep-G2, and NC1-H441 epithelial 
cell lines and against S. aureus α-hemolysin. A longer challenge period was required 
to study α-hemolysin cytolysis compared with pyolysin, possibly due to the ten-fold 
smaller pore-diameter (Preta et al., 2016, Song et al., 1996). Repairing the damage 
caused by small toxin pores is challenging as the lower calcium permeability of small 
pores impairs calcium-dependent protective responses (Brito et al., 2019, Walev et al., 
1993), however, 27-hydroxycholesterol completely protected both HeLa and A549 
against α-hemolysin induced cytolysis. Stimulating macrophages with interferon has 
recently been shown to protect macrophages against perfringolysin O, streptolysin O 
and anthrolysin O damage, through the production of 25-hydroxycholesterol (Zhou et 
al., 2020). The findings of this chapter (along with the findings of Chapter 3) expand 
on these findings, highlighting the cytoprotective properties of 27-hydroxycholesterol 
in addition to 25-hydroxycholesterol and demonstrate that protection extends to human 
epithelial cells and against additional toxins.  
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Side-chain oxysterols regulate cholesterol homeostasis, though in the present chapter 
25-hydroxycholesterol or 27-hydroxycholesterol treatment had no significant effect on 
the total cellular cholesterol of HeLa cells. Additionally, there was no significant effect 
on total cellular cholesterol in Chapter 3 where bovine endometrial cells were treated 
with 25-hydroxycholesterol (5 ng/ml) or 27-hydroxycholesterol (25 ng/ml) for 24 h, 
and in a previous study where Chinese hamster ovary cells were treated with 25-
hydroxycholesterol (2 µg/ml) for 20 h (Abrams et al., 2020). Only a small portion of 
plasma membrane cholesterol, is accessible to cholesterol-dependent cytolysins (Das 
et al., 2013), and in this chapter, 27-hydroxycholesterol treatment reduced pyolysin 
binding. Recent studies have discovered the ability of oxysterols to provide innate 
immunity to bacterial infection and antiviral immunity by remodelling plasma 
membrane cholesterol through the actions of the ACAT enzymes (Abrams et al., 2020, 
Zhou et al., 2020, Wang et al., 2020), and in the present chapter, inhibiting ACAT with 
SZ58-035 reduced 27-hydroxycholesterol cytoprotection against pyolysin. However, 
some 27-hydroxycholesterol cytoprotection against pyolysin was evident in cells 
treated with SZ58-035 and 27-hydroxycholesterol still provided protection in cells 
treated with sphingomyelinase. Furthermore, oxysterol driven ACAT-dependent 
cholesterol esterification is a fast-acting method of remodelling the plasma membrane 
lipid composition, whereas in the present chapter >12 h treatment with 27-
hydroxycholesterol cytoprotection was required for maximal protection. Therefore, it 
seems likely that ACAT cholesterol esterification is not the sole protective mechanism 
involved. Side-chain oxysterols also control cholesterol homeostasis by suppressing 
sterol responsive element binding protein 2 (SREBP2) (Brown et al., 2018). This 
slower acting transcriptional mechanism might prevent the replenishment of plasma 
membrane accessible cholesterol over time and explain the benefit of prolonged 
treatment. Additionally, oxysterols can reduce cholesterol biosynthesis by increasing 
HMGCR degradation. Future work might target these pathways to explore their impact 
on oxysterol cytoprotection. 
There are a multitude of cellular responses deployed by host cells to repair pore-
forming toxin damage independent of membrane cholesterol (Gonzalez et al., 2011, 
Brito et al., 2019). Calcium ion influx activates plasma membrane repair pathways and 
cytoskeletal remodelling (Wippel et al., 2011, Tam et al., 2013, Babiychuk et al., 
2009). Depleting calcium from the pyolysin challenge medium to impair calcium 
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influx in the present chapter increased pyolysin-induced cytolysis but did not affect 
27-hydroxycholesterol protection. Previous studies have noted calcium ion oscillations 
triggered within seconds of 25-hydroxycholesterol treatment in human aortic smooth 
muscle cells and monocytes (Ares et al., 1997, Lemaire-Ewing et al., 2009). Further 
research is required to establish whether side-chain oxysterols trigger calcium ion 
oscillations in the cells used in this chapter, and whether this could contribute to 
protection by activating reparative pathways in advance of pyolysin challenge. 
Potassium efflux also mediates cellular responses to pore-forming toxins, such as 
MAPK activation (Huffman et al., 2004, Munoz-Planillo et al., 2013, Cabezas et al., 
2017). However, impairing efflux by increasing the concentration of potassium in the 
challenge medium did not affect 27-hydroxycholesterol cytoprotection. Additionally, 
pyolysin challenge caused less ERK1/2, p38, and JNK phosphorylation in cells treated 
with 27-hydroxycholesterol. This reduction in MAPK activation, alongside the 
reduced LDH and potassium leakage and pyolysin binding in the present study 
suggests that side-chain oxysterol treatment is preventing pyolysin from forming 
plasma membrane pores. Therefore, it seems unlikely that typical host cell reparative 
pathways would be activated and contribute to protection.  
Side-chain oxysterols are ligands for the liver X receptors (Lehmann et al., 1997). 
However, in the current chapter, reducing the expression of NR1H2 and NR1H3, either 
separately or in combination, had no effect on oxysterol cytoprotection. Interestingly, 
Chapter 3 demonstrated that liver X receptors play a partial role in the 27-
hydroxycholesterol cytoprotection of the bovine endometrium against pore-forming 
toxin damage, highlighting the diverse functions of oxysterol signalling between cell 
types. Although 27-hydroxycholesterol cytoprotection was independent of liver X 
receptors in the present chapter, activating the liver X receptors with T0901317 or 
GW3965 provided HeLa cells with some protection against pyolysin damage, reducing 
cytolysis, LDH leakage, MAPK activation, and pyolysin-induced cytoskeletal 
changes, as well as decreasing pyolysin binding. GW3965 also protected macrophages 
against cholesterol-dependent cytolysin damage (Zhou et al., 2020). The liver X 
receptors have also been demonstrated to play a critical role in Mycobacterium 
Tuberculosis infection. Production of IL-36 regulates cholesterol synthesis through the 
induction of CH25H and CYP27A1 and the subsequent activation of the liver X 
receptors by 25-hydroxycholesterol and 27-hydroxycholesterol respectively (Ahsan et 
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al., 2016, Ahsan et al., 2018). Additionally, IL-36 production regulates the liver X 
receptor-dependent production of antimicrobial peptides such as cathelicidin, β-
defensin 1, and β-defensin 2 that inhibit pathogen growth (Ahsan et al., 2018). As the 
production of these antimicrobial peptides can be stimulated by both oxysterols and 
synthetic liver X receptor agonists, future research might investigate whether they are 
produced in the present model system and whether they might contribute to 
cytoprotection. 
As mentioned in Chapter 3, some side-chain oxysterols, such as 27-
hydroxycholesterol, also demonstrate oestrogenic activity (Umetani et al., 2007, 
Matsubayashi et al., 2021). There is evidence to suggest that HeLa cells do not express 
the oestrogen receptor (DuSell et al., 2008), and cytoprotection was clearly established 
in this cell type, making it unlikely that the oestrogen receptor is involved in the 
protective mechanism. However, the absence of all oestrogen receptor isoforms in 
HeLa cells is inconclusive, and expression is evident in the other cell types used in this 
thesis. Therefore, future work might use inhibitors or siRNA to target the oestrogen 
receptor and verify its role in oxysterol cytoprotection.  
In conclusion, we found that side-chain oxysterols protect human epithelial cells 
against pore-forming toxins. Treatment with 25-hydroxycholesterol or 27-
hydroxycholesterol increased the intrinsic cell protection of HeLa and A549 cells 
against the damage caused by pyolysin and α-hemolysin. This protection was partially 
dependent on ACAT. Our findings demonstrate that oxysterols can increase the 
intrinsic protection of epithelial cells against pore-forming toxins and may help protect 
tissues against pathogenic bacteria.  
176 
 
5 GLUCOCORTICOIDS PROTECT HUMAN CELLS 
AGAINST PORE-FORMING TOXIN DAMAGE 
5.1 INTRODUCTION 
Increasing the tolerance of tissue cells to bacterial pore-forming toxins can help reduce 
the damage caused by bacterial infection (Medzhitov et al., 2012). Chapters 3 and 4 
highlight the ability of side-chain oxysterols to increase the intrinsic protection of 
eukaryotic cells against pore-forming toxins. However, there is limited research into 
protective mechanisms, and it is likely that more remain to be discovered. 
Glucocorticoid treatment reduces the mortality of bacterial infections in humans, such 
as pneumonia caused by Streptococcus pneumoniae  (Stern et al., 2017). Whilst this is 
commonly attributed to their anti-inflammatory properties, glucocorticoids may also 
increase the intrinsic protection of cells against pore-forming toxins. Dexamethasone 
and hydrocortisone did not significantly increase the intrinsic protection of bovine 
endometrial cells against pyolysin in Chapter 3, though the pleiotropic effects of 
glucocorticoids are often cell type and context specific (Weikum et al., 2017). 
Therefore, the next obvious step was to examine the protective effect of 
glucocorticoids in another species and cell type. 
The endogenous glucocorticoid cortisol is secreted in response to stress, inhibiting 
inflammation and supporting tissue repair (Kadmiel and Cidlowski, 2013, Cain and 
Cidlowski, 2017). Synthetic glucocorticoids such as dexamethasone and fluticasone 
propionate are used therapeutically in patients as anti-inflammatory drugs (Newton, 
2014). Glucocorticoids induce responses by binding to the widely expressed 
glucocorticoid receptor (encoded by NR3C1), which leads to transcription factor 
repression, gene regulation, and non-genomic effects (Yamamoto, 1985, Bamberger 
et al., 1996). These effects include a diverse array of cellular functions such as the 
production of inflammatory mediators, suppressing innate immunity, inhibiting 
MAPK stress responses, and altering cell differentiation and metabolism (So et al., 
2007, Wang et al., 2004, Weikum et al., 2017).  
This chapter challenged the hypothesis that glucocorticoids increase the intrinsic 
protection of human tissue cells against pore-forming toxins. To test this hypothesis, 
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we treated several types of cells with glucocorticoids before challenging them with 
cholesterol-dependent cytolysins or α-hemolysin. We evaluated cytoprotection by 
measuring the leakage of lactate dehydrogenase (LDH) and potassium ions and toxin-
induced changes in cell morphology and cytolysis. We also determined the role of the 
glucocorticoid receptor in cytoprotection and investigated potential mechanisms for 
glucocorticoid cytoprotection against pore-forming toxins. 
5.2 MATERIALS AND METHODS 
5.2.1 Cytoprotection experiments 
To examine whether glucocorticoids protected cells against pyolysin, HeLa, A549, 
Hep-G2, NC1-H441 (4 × 104 cells/well), and NDHF cells (1.4 × 104 cells/well) were 
incubated in 1ml/well serum-free media containing vehicle, dexamethasone, 
hydrocortisone, or fluticasone propionate. Concentrations are as specified in Results 
and were initially based on the manufacturers’ instructions and previous publications 
(Johnson, 1998, Garside et al., 2004, Croxtall et al., 2002). A 24 h treatment duration 
was selected based on previous work investigating tolerance and cytoprotection and 
on the work carried out in Chapters 3 and 4 (Statt et al., 2015, Griffin et al., 2018, 
Amos et al., 2014); except for experiments exploring the duration of glucocorticoid 
treatment required to protect cells against pyolysin, where HeLa cells were treated with 
10 µM dexamethasone or 10 µM hydrocortisone for a range of times up to 24 h as 
specified in Results. After the treatment period, supernatants were discarded, and cells 
were challenged for 2 h, or as specified in Results, with control serum-free medium 
(comprising 200 µl Dulbecco’s phosphate-buffered saline (DPBS) for 15 min, then 
supplemented with 400 µl serum-free medium up to 2 h) or medium containing 
pyolysin (HeLa: 100 HU, A549: 25 HU, Hep-G2: 100 HU, NCI-H441: 200 HU, 
NDHF: 25 HU). To determine whether protection extended beyond pyolysin, after a 
24 h treatment with 10 µM dexamethasone, HeLa and A549 cells were challenged for 
2 h with a range of concentrations of streptolysin O, as specified in Results, or for 24 
h with a range of concentrations of α-hemolysin , as specified in Results. At the end of 
the challenge period LDH leakage and cell viability was evaluated as described in 
Chapter 2. Transmitted light micrographs were captured at the end of the challenge 
period in designated experiments using an Axiocam ERc 5s microscope camera 
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(Zeiss). The proportion of normal, blebbing, and fragmented cells were counted using 
2 independent images per treatment replicate.  
To investigate the mechanisms involved in glucocorticoid cytoprotection we used 
RU486, an antiglucocorticoid, cycloheximide, a translation inhibitor, and actinomycin 
D, a transcription inhibitor. HeLa or A549 cells were incubated in serum-free medium 
with vehicle, 10 µM dexamethasone, or 10 µM hydrocortisone, in combination with 
vehicle, 10 µM RU486, or 1 µg/ml cycloheximide as specified in Results. 
Alternatively, cells were treated with vehicle or 0.25 µg/ml actinomycin D for 2 h, 
then treated for 24 h with the combinations of vehicle, 10 µM dexamethasone, and 
actinomycin D, as specified in Results. Supernatants were discarded and the cells were 
challenged for 2 h with control medium or medium containing pyolysin (HeLa: 100 
HU, A549: 25 HU). After the challenge period LDH leakage was evaluated from 
supernatants and cell viability was assessed by MTT. 
To examine the role of the glucocorticoid receptor and 3-hydroxy 3-methylglutaryl 
coenzyme A reductase (HMGCR; a target of the glucocorticoid receptor (Cavenee and 
Melnykovych, 1977)) in cytoprotection, short-interfering ribonucleic acid (siRNA) 
was used to knockdown the expression of NR3C1 or HMGCR. HeLa cells were 
transfected with scramble siRNA, ON-TARGETplus SMARTPool Human NR3C1 
siRNA (#L-003424-00-0005; Horizon discovery) or siRNA designed using 
Dharmacon siDESIGN Centre to target HMGCR (as described in Chapter 2). In 24-
well culture plates, 50 pmol of siRNA was added to 100 µl/well Opti-MEM 1 medium 
with 1.5 µl Lipofectamine RNAiMAX Reagent and incubated for 20 min at room 
temperature. HeLa cells were then seeded at a density of 4 x 104 cells/well in 900 µl 
DMEM medium supplemented with 10% serum for 48 h. Cells were then treated with 
vehicle, 10 µM dexamethasone or 10 µM hydrocortisone for 24 h in serum-free culture 
medium prior to a 2 h challenge with control medium or medium containing 100 HU 
pyolysin. At the end of the challenge period, supernatants were collected to measure 
LDH leakage and cell viability was measured using an MTT assay. 
To determine whether cholesterol supplementation would affect glucocorticoid 
cytoprotection, HeLa cells were treated with vehicle, 10 µM dexamethasone, or 10 µM 
hydrocortisone in serum-free medium, or serum-free medium containing 30 µg/ml 
cholesterol for 24 h (Statt et al., 2015). After the treatment period, cells were 
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challenged for 2 h with control serum-free medium, or medium containing 100 HU 
pyolysin. Supernatants were then collected to measure the leakage of LDH, and cell 
viability was measured using an MTT assay.  
To examine the role of acetyl-coenzyme A acetyltransferase (ACAT) in glucocorticoid 
cytoprotection against pyolysin we used the selective ACAT inhibitor S58-035 (Ross 
et al., 1984, Abrams et al., 2020). HeLa cells were washed twice with PBS then treated 
with vehicle or 10 µM SZ5-035 in serum-free culture medium. After a 16 h incubation, 
cells were washed twice with PBS, then incubated for 24 h in serum-free culture 
medium containing 10 ng/ml 27-hydroxycholesterol or 10 µM dexamethasone, in 
combination with vehicle or 10 µM SZ5-035. Medium was then discarded, and cells 
were challenged for 2 h with control medium or medium containing 100 HU pyolysin. 
At the end of the challenge period, supernatants were collected to measure the leakage 
of LDH, and cell viability was measured using an MTT assay. 
To explore the effect of serum on cytoprotection, HeLa cells were treated with 10 µM 
dexamethasone in medium containing 0 to 10% serum, or 10% charcoal-stripped 
serum for 24 h. To examine the time required for serum to reverse glucocorticoid 
cytoprotection against pyolysin, cells were treated with vehicle or 10 µM 
dexamethasone in serum-free medium and then supplemented with 10% serum for a 
range of time periods from 0 to 24 h, as specified in Results. To investigate whether 
the effect of serum on cytoprotection was reversible, cells were treated with 10 µM 
dexamethasone in complete medium or serum-free medium. At a range of time points, 
from 0 to 24 h, supernatants were discarded, cells were washed twice with PBS, and 
fresh serum-free medium was added for the remainder of the treatment duration. After 
the treatment period, cells were challenged for 2 h with control serum-free medium, or 
medium containing 100 HU pyolysin. At the end of the challenge period, cell viability 
was measured using an MTT assay. 
To examine the role of calcium influx on glucocorticoid protection against pyolysin, 
HeLa cells were cultured for 24 h in medium containing vehicle or 10 µM 
dexamethasone. Supernatants were discarded, and cells were washed twice with 
calcium-free DPBS. Pyolysin challenge (100 HU) was prepared in 200 µl of calcium-
free or calcium-containing DPBS. Cell were challenged for 15 min before wells were 
supplemented with 400 µl of serum-free DMEM or serum-free DMEM without 
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calcium (as specified in Results) for the remaining 1 h 45 min of the challenge period. 
Supernatants were collected to measure the leakage of LDH, and cell viability was 
measured using an MTT assay. 
To examine the role of potassium efflux on glucocorticoid protection against pyolysin, 
HeLa cells were cultured for 24 h in medium containing vehicle or 10 µM 
dexamethasone. Pyolysin challenge (100 HU) was prepared in control medium (5.3 
mM KCL), low-potassium medium (5 mM KCl, 140 mM NaCl, 10 mM Hepes, 1.3 
mM CaCl2, 0.5 mM MgCl2, 0.36 mM K2HPO4, 0.44 mM KH2PO4, 5.5 mM D-glucose, 
4.2 mM NaHCO3) or high-potassium medium (5 mM NaCl, 140 mM KCl, 10 mM 
Hepes, 1.3 mM CaCl2, 0.5 mM MgCl2, 0.36 mM K2HPO4, 0.44 mM KH2PO4, 5.5 mM 
D-glucose, 4.2 mM NaHCO3) to prevent potassium efflux (Gurcel et al., 2006). Cells 
were washed twice with control, low-potassium, or high-potassium medium prior to a 
2 h challenge. Supernatants were collected to measure the leakage of LDH, and cell 
viability was measured using an MTT assay. 
5.2.2 Potassium 
The leakage of potassium from cells was measured to assess whether the treatments 
prevented toxins forming pores in the cell membrane. HeLa and A549 cells were 
seeded at a density of 1.5 x 105 cells/well in 3 ml/well complete medium using 6-well 
culture plates and incubated for 24 h, before a 24 h treatment with vehicle, 10 µM 
dexamethasone, 10 µM hydrocortisone, or 1 mM methyl-β-cyclodextrin (MβCD) in 3 
ml/well serum-free medium. Supernatants were discarded, and the cells were washed 
3 times with potassium-free choline buffer (129 mM choline-Cl, 0.8 mM MgCl2, 1.5 
mM CaCl2, 5 mM citric acid, 5.6 mM glucose, 10 mM NH4Cl, 5 mM H3PO4, pH 7.4; 
all Merck), and then incubated in potassium-free buffer with control medium or the 
indicated concentration of pyolysin or streptolysin O for 5 min at 37⁰C. Alternatively, 
cells were incubated in potassium-free buffer with control medium or 8 µg/5 × 104 
cells α-hemolysin for 15 min (no potassium leakage was visible from HeLa cells after 
5 min of α-hemolysin challenge). Supernatants were then collected, and potassium was 
measured using a Jenway PFP7 flame photometer as described in Chapter 2. 
5.2.3 Cholesterol 
To quantify the cellular cholesterol concentrations of HeLa and A549 cells, 1.5 x 105 
cells /well were seeded on 6-well culture plates in 3 ml/well complete medium for 24 
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h. Cells were treated with or without the concentrations of dexamethasone specified in 
Results, 10 µM hydrocortisone or 1 mM MβCD in 3 ml/well serum-free medium for a 
further 24 h. After the treatment period, cells were washed twice with DPBS then 
collected in 250 µl/ well cholesterol assay 1X Reaction Buffer and stored at -20⁰C. 
Cellular cholesterol was measured using the Amplex Red Cholesterol Assay Kit as 
described in Chapter 2. Protein abundance was measured in samples using a DC 
protein assay, and cholesterol concentrations were normalized to total protein 
concentrations. 
5.2.4 Immunofluorescence 
To visualize cell damage, 4 x 104 HeLa or A549 cells/well were seeded on glass cover 
slips in complete medium using 24-well culture plates for 24 h, before treatment for 
24 h in serum-free media with vehicle, 10 µM dexamethasone, or 10 µM 
hydrocortisone. The supernatants were discarded, and the cells challenged with control 
medium or medium containing pyolysin for 2 h, or α-hemolysin for 24 h. At the end 
of the challenge period cells were stained with Alexa Fluor 555-conjugated phalloidin 
and 4,6-diamidino-2-phenylindole (DAPI), then imaged as described in Chapter 2. 
The proportion of cells that had cytoskeletal changes (cytoskeletal contraction, 
disrupted shape, or loss of actin fibre definition) after pyolysin challenge were counted 
using >135 cells per treatment across 3 independent images per replicate. 
To further investigate cell shape following pyolysin challenge, HeLa cells (4 x 104 
cells/well) were cultured on glass cover slips in complete medium using 24-well 
culture plates for 24 h, then treated for 24 h in serum-free media containing vehicle or 
10 µM dexamethasone. Supernatants were discarded, and cells were challenged for 2 
h with control medium or medium containing pyolysin (100 HU). At the end of the 
challenge period, cells were stained with CellMask Deep Red and DAPI, then imaged 
as described in Chapter 2. 
5.2.5 Western blotting 
First, we explored the effects of glucocorticoid treatment on pyolysin-induced MAPK 
signalling. HeLa cells were seeded at a density of 1.5 x 105 cells/well in 3 ml/well 
complete medium using 6-well plates for 24 h, and then treated for 24 h in 3 ml/well 
serum-free medium containing vehicle, 10 µM dexamethasone, 10 µM 
hydrocortisone, or 1 mM MβCD, then challenged with control serum-free medium or 
182 
 
medium containing 100 HU pyolysin for 10 min. Secondly, we investigated the effect 
of glucocorticoid treatment on the abundance of membrane bound pyolysin. HeLa cells 
were seeded at 1.5 x 105 cells/well in 3 ml/well complete medium using 6-well plates 
for 24 h, and then treated for 24 h in 3 ml/well serum-free medium containing vehicle, 
10 µM dexamethasone, 10 µM hydrocortisone, 50 nM T0901317, 10 ng/ml 27 
hydroxycholesterol or 1 mM MβCD, before a 2 h challenge with control serum-free 
medium or medium containing 100 HU pyolysin. Finally, the abundance of 
glucocorticoid receptor and HMGCR protein was used to verify the effectiveness of 
siRNA targeting NR3C1 and HMGCR. 
At the end of all experiments, supernatants were discarded, cells were washed with 
300 μl ice-cold PBS, and lysed with 100 μl PhosphoSafe Extraction Reagent. Protein 
isolation and Western blotting was performed as described in Chapter 2. The average 
peak density of bands was quantified and normalized to α-tubulin using Fiji 
(Schindelin et al., 2012). Phosphorylated proteins were normalized to their cognate 
total protein.  
5.2.6 Statistical analysis 
The statistical unit was each independent passage of the relevant cell line. Statistical 
analysis was performed using GraphPad Prism 9.0.1. Data are reported as arithmetic 
mean (SEM), and significance attributed when P < 0.05. Comparisons between 
treatments or challenges were made using analysis of variance (ANOVA) followed by 
Dunnett, Bonferroni or Tukey post hoc test for multiple comparisons, or unpaired two-
tailed Student’s t-test as specified in Results.  
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5.3 RESULTS 
5.3.1 Glucocorticoid cytoprotection against pyolysin in HeLa cells 
To investigate whether glucocorticoids were cytoprotective, HeLa cells were treated 
with a range of concentrations of dexamethasone or hydrocortisone and then 
challenged for 2 h with 100 HU pyolysin (challenge concentration and duration 
informed by experiments in Chapter 4). Cells were treated in serum-free medium, 
because the 1.12 mM cholesterol in the serum used throughout this thesis might 
confound the results by binding to cholesterol-dependent cytolysins, and serum 
activates signalling pathways (Iyer et al., 1999). In contrast to the experiments using 
bovine endometrial cells in Chapter 3, dexamethasone and hydrocortisone treatment 
protected HeLa cells as shown by the reduced the pyolysin-induced leakage of LDH 
and cytolysis (Fig 5.1A,B). Specifically, 10 µM dexamethasone and 10 µM 
hydrocortisone provided maximal protection, reducing pyolysin-induced LDH leakage 
by 84% and 70%, respectively; and reducing pyolysin-induced cytolysis of > 84% to 
9% and 26%, respectively. Therefore, these concentrations were selected for further 
cytoprotection experiments. Treating HeLa cells with 10 µM dexamethasone or 10 µM 
hydrocortisone reduced pyolysin-induced leakage of potassium (Fig 5.1C, D), as 
effectively as depleting cellular cholesterol with MβCD to prevent pore formation 
(Amos et al., 2014). In independent experiments, dexamethasone protected HeLa cells 
against a range of pyolysin challenge concentrations (Fig 5.2). Additionally, 
glucocorticoid cytoprotection against pyolysin was evident after 6 h treatment with 
glucocorticoids and was maximal after 18–24 h (Fig 5.3A, B). Finally, dexamethasone 
cytoprotection persisted against a 24 h pyolysin challenge (Fig 5.3C). 
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Figure 5.1 Glucocorticoids protect HeLa cells against pyolysin damage 
Leakage of LDH and viability of HeLa cells following treatment for 24 h with vehicle 
or the indicated concentrations of (A) dexamethasone or (B) hydrocortisone, and then 
challenge for 2 h with control medium or 100 HU pyolysin. Data are presented as mean 
(SEM) from 4 independent experiments; statistical significance was determined using 
two-way ANOVA, and P-values reported for the effect of treatment on pyolysin 
challenge. (C,D) Leakage of potassium from HeLa cells treated for 24 h with vehicle, 
10 µM dexamethasone, 10 µM hydrocortisone, or 1 mM MβCD, and then challenged 
for 5 min with control medium or 100 HU pyolysin. Dots represent individual values 
from 4 independent experiments; statistical significance was determined using one-
way ANOVA with Dunnett’s post hoc test; ***P < 0.001. 
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Figure 5.2 Dexamethasone protects HeLa cells against a range of pyolysin 
challenge concentrations 
(A) Leakage of LDH and (B) viability of HeLa cells treated for 24 h with vehicle or 
10 µM dexamethasone, and then challenged for 2 h with control medium or the 
indicated concentrations of pyolysin. Data are presented as mean (SEM) from 4 
independent experiments; statistical significance was determined using two-way 
ANOVA and Bonferroni’s post hoc test; **P < 0.01, ***P < 0.001. 
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Figure 5.3 Glucocorticoid cytoprotection requires > 6 h treatment and persists 
against longer pyolysin challenge durations  
Viability of HeLa cells treated for the indicated time periods with (A) 10 µM 
dexamethasone or (B) 10 µM hydrocortisone, and then challenged for 2 h with control 
medium or 100 HU pyolysin. Pyolysin data are presented as percentage viability of 
control challenge, with dots representing individual values from independent 
experiments. (C) Viability of cells treated for 24 h with vehicle or 10 µM 
dexamethasone, and then challenged for the indicated time with control medium or 
100 HU pyolysin. Pyolysin data are presented as mean (SEM) percentage viability of 
control challenge from 4 independent experiments. Statistical significance was 
determined using two-way ANOVA and Bonferroni’s post hoc test; ***P < 0.001.  
Treatment with dexamethasone and hydrocortisone also reduced pyolysin-induced 
cytoskeletal changes (28 ± 2 and 32 ± 9 respectively vs 88 ± 2% cells damaged, P < 
0.01, ANOVA and Dunnett’s post hoc test, n = 3, Fig 5.4). Additionally, 
glucocorticoid protection was visualized with phase-contrast microscopy and in cells 
stained with CellMask. A wider field of view highlighted the cell death caused by 
pyolysin challenge in vehicle treated cells (Fig 5.5A). Cells displayed plasma 
membrane blebs or a complete loss of shape and structure (Fig 5.5, 6). Dexamethasone 
treatment cells maintained shape, ensuring that cells maintained clearly defined edges 
(Fig 5.5B), and both glucocorticoids reduced pyolysin-induced plasma membrane 
blebbing and cell fragmentation (P < 0.001, ANOVA and Dunnett’s post hoc test, Fig 
5.6, Table 5.1). Together, these data provide evidence for glucocorticoid 
cytoprotection of HeLa cells against pyolysin. 
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Figure 5.4 Glucocorticoids prevent pyolysin-induced HeLa cytoskeletal changes 
Fluorescent microscope images of HeLa cells treated for 24 h with vehicle, 10 µM 
dexamethasone or 10 µM hydrocortisone, then challenged for 2 h with control medium 
or 100 HU pyolysin and stained with fluorescent phalloidin (white) and DAPI (red); 
images are representative from 4 independent experiments. Quantification of 
cytoskeletal changes are reported in text. 
188 
 
 
Figure 5.5 Dexamethasone protects HeLa cells against pyolysin 
Fluorescent microscope images from a (A) 10X and a (B) 40X lens of HeLa cells 
treated for 24 h with vehicle, 10 µM dexamethasone or 10 µM hydrocortisone, then 
challenged for 2 h with control medium or 100 HU pyolysin and stained with CellMask 
(white) and DAPI (red); images are representative from 3 independent experiments. 
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Figure 5.6 Glucocorticoids reduce pyolysin-induced HeLa cell blebbing 
Phase contrast microscopy of HeLa cells treated for 24 h with vehicle, 10 µM 
dexamethasone, or 10 µM hydrocortisone, then challenged for 2 h with control 
medium or 100 HU pyolysin; images are representative from 4 independent 
experiments, scale bars = 50 µm. 
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Table 5.1 Quantification of HeLa cell morphology after glucocorticoid treatment 
and pyolysin challenge 
We quantified the percentage of normal, blebbing, or fragmented HeLa cells treated 
for 24 h with vehicle, 10 µM dexamethasone, or 10 µM hydrocortisone, then 
challenged for 2 h with control medium or 100 HU. Cells were imaged by phase 
contrast microscopy and categorized as normal, blebbed or fragmented, with >100 
cells evaluated across two independent images per treatment replicate. Raw data were 
analyzed by ANOVA and Tukey’s post hoc test with superscript indicating the 
differences between vehicle and treatments (***P < 0.001),  and data are reported as 
mean ± SEM for the pyolysin challenge as a percentage of the control challenge. 
Treatment  Replicates Percentage of cells 
Normal Blebbing Fragmented 
Vehicle 10 8 ± 2  54 ± 6  38 ± 6  
Dexamethasone 7 87 ± 4 *** 8 ± 3 *** 5 ± 2 *** 
Hydrocortisone 7 67 ± 13 *** 23 ± 4 *** 10 ± 3 *** 
 
5.3.2 Glucocorticoid cytoprotection is generalized across human cells 
To explore whether glucocorticoid cytoprotection is more generalized than protecting 
HeLa cells against pyolysin, we tested protection in A549 lung epithelial cells, because 
they are often used to study cholesterol-dependent cytolysins (Statt et al., 2015, Mestre 
et al., 2010). Pyolysin challenge, optimised in Chapter 4, caused LDH and potassium 
leakage and diminished A549 cell viability (P < 0.001, two-way ANOVA and 
Dunnett’s multiple comparison test, Fig 5.7). However, treatment with 10 µM 
dexamethasone (Fig 5.7A) or 10 µM hydrocortisone (Fig 5.7B) reduced pyolysin-
induced leakage of LDH, cytolysis, and cytoskeletal changes (7 ± 4 and 16 ± 4 
respectively vs 71 ± 5% cells damaged, P < 0.01, ANOVA and Dunnett’s post hoc 
test, n = 3, Fig 5.8). Potassium ion leakage was reduced by dexamethasone treatment 
(P < 0.001) and tended to be reduced by hydrocortisone (P = 0.099, Fig. 5.7C). 
Additionally, dexamethasone protection functioned against a range of pyolysin 
challenge concentrations (Fig 5.9). 
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Figure 5.7 Glucocorticoids protect A549 cells against pyolysin damage 
(A,B) Leakage of LDH and viability of A549 cells treated for 24 h with vehicle, or the 
indicated concentration of dexamethasone or hydrocortisone, and then challenged for 
2 h with control medium or 25 HU pyolysin. Data are presented as mean (SEM) from 
3 independent experiments; statistical significance was determined using two-way 
ANOVA, and P-values reported for the effect of treatment on pyolysin challenge. (C) 
Leakage of potassium from A549 cells treated for 24 h with vehicle, 10 µM 
dexamethasone, 10 µM hydrocortisone, or 1 mM MβCD, and then challenged for 5 
min with control medium or 25 HU pyolysin. Dots represent individual values from 4 
independent experiments; statistical significance was determined using one-way 
ANOVA with Dunnett’s post hoc test; ***P < 0.001. 
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Figure 5.8 Glucocorticoids protect A549 cells against pyolysin-induced 
cytoskeletal changes 
Fluorescent microscope images of A549 cells treated for 24 h with vehicle, 10 µM 
dexamethasone or 10 µM hydrocortisone, then challenged for 2 h with control medium 
or 25 HU pyolysin and stained with fluorescent phalloidin (white) and DAPI (red); 
images are representative from 3 independent experiments. Quantification of 
cytoskeletal changes are reported in text. 
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Figure 5.9 Dexamethasone protects A549 cells against a range of pyolysin 
challenge concentrations 
(A) Leakage of LDH and (B) viability of A549 cells treated for 24 h with vehicle or 
10 µM dexamethasone, and then challenged for 2 h with control medium or the 
indicated concentrations of pyolysin. Data are presented as mean (SEM) from 4 
independent experiments; statistical significance was determined using two-way 
ANOVA and Bonferroni’s post hoc test; *P < 0.05, ***P < 0.001. 
We used Hep-G2 liver cells, NCI-H441 lung cells, and NDHF to provide additional 
validation of glucocorticoid cytoprotection. The amount of pyolysin to challenge Hep-
G2 and NC1-H441 cells was determined in Chapter 4, and we selected 25 HU pyolysin 
to challenge NDHF cells (Fig 5.10). Significantly, treatment with 10 µM 
dexamethasone reduced pyolysin-induced leakage of LDH and cytolysis in Hep-G2, 
NCI-H441, and NDHF cells (Fig 5.11).  
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Figure 5.10 The cytolytic activity of pyolysin in dermal fibroblasts 
Leakage of LDH, and cell viability determined by CyQUANT for NDHF cells 
challenged for 2 h with control medium or the indicated concentration of pyolysin. 
Data are presented as mean (SEM) with dots representing the values from 3 
independent experiments; statistical significance was determined using one-way 
ANOVA and Dunnett’s post hoc test; *P < 0.05, **P < 0.01, ***P < 0.001. 
 
Figure 5.11 Dexamethasone protects multiple cells against pyolysin 
Leakage of LDH and viability of (A) Hep-G2, (B) NCI-H441 and (C) NDHF cells 
treated for 24 h with vehicle or 10 µM dexamethasone, and then challenged for 2 h 
with control medium or pyolysin (Hep-G2, 100 HU; NC1-H441, 200 HU; NDHF, 25 
HU). Data are presented as mean (SEM) from 4 independent experiments; statistical 
significance was determined using two-way ANOVA, with Bonferroni’s post hoc test; 
*P < 0.05, **P < 0.01, ***P < 0.001. 
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To explore whether glucocorticoids protect cells against other cytolysins, we first 
challenged HeLa or A549 cells with another cholesterol-dependent cytolysin, 
streptolysin O. Dexamethasone reduced potassium and LDH leakage and cytolysis 
caused by streptolysin O in HeLa and A549 cells (Fig 5.12). However, interestingly 
hydrocortisone did not significantly reduce potassium leakage in either cell type.  
We next examined cytoprotection against a member of the hemolysin family of 
cytolysins, S. aureus α-hemolysin (Peraro and van der Goot, 2016, Mestre et al., 2010). 
Challenging with α-hemolysin caused leakage of potassium ions within 15 min, and 
leakage of LDH and cytolysis after 24 h in HeLa and A549 cells (Fig 5.13, 5.14). 
Dexamethasone reduced α-hemolysin-induced LDH and potassium ion leakage and 
cytolysis in HeLa cells (Fig 5.13A,B). Additionally, dexamethasone treatment reduced 
the cytoskeletal changes in HeLa cells caused by the α-hemolysin challenge (17 ± 4 vs 
86 ± 3% cells damaged, P < 0.01, t-test, n = 3, Fig 5.13C). Although, dexamethasone 
treatment did reduce the leakage of LDH from A549 cells, it did not protect against 
the potassium ion leakage, cytolysis, or cytoskeletal changes caused by α-hemolysin 
challenge (Fig 5.14), Collectively, these findings provide evidence that glucocorticoid 
cytoprotection extends to a range of types of cells and pore-forming toxins. 
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Figure 5.12 Glucocorticoids protect HeLa and A549 cells against streptolysin O 
Leakage of LDH and viability of HeLa (A) and A549 cells (B) treated for 24 h with 
vehicle or 10 µM dexamethasone, and then challenged for 2 h with control medium or 
the indicated concentrations of streptolysin O. Data are presented as mean (SEM) from 
4 independent experiments; statistical significance was determined using one-way 
ANOVA and Bonferroni’s post hoc test; *P < 0.05, **P < 0.01, ***P < 0.001. Leakage 
of potassium from HeLa cells (C) and A549 cells (D) treated for 24 h with vehicle, 10 
µM dexamethasone, 10 µM hydrocortisone or 1 mM MβCD, and then challenged for 
5 min with control medium or streptolysin O (HeLa, 12.5 µg; A549, 6.25 µg). Dots 
represent individual values from 4 independent experiments; statistical significance 
was determined using one-way ANOVA and Dunnett’s post hoc test; *P < 0.05, 
***P < 0.001. 
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Figure 5.13 Dexamethasone protects HeLa cells against α-hemolysin damage  
 (A) Leakage of LDH and viability of HeLa cells treated for 24 h with vehicle or 10 
µM dexamethasone, and then challenged for 24 h with control medium or the indicated 
concentration of α-hemolysin. Data are presented as mean (SEM) from 4 independent 
experiments; statistical significance was determined using two-way ANOVA and 
Bonferroni’s post hoc test; **P < 0.01, ***P < 0.001. (B) Leakage of potassium from 
HeLa cells treated for 24 h with vehicle, 10 µM dexamethasone, 10 µM hydrocortisone 
or 1 mM MβCD, then challenged for 15 min with control medium or 8 µg α-hemolysin. 
Dots represent values from 4 independent experiments; statistical significance was 
determined using one-way ANOVA with Dunnett’s post hoc test; *P < 0.05, 
**P < 0.01. (C) Fluorescent microscope images of HeLa cells treated for 24 h with 
vehicle or 10 µM dexamethasone, then challenged for 24 h with control medium or 8 
µg α-hemolysin and stained with fluorescent phalloidin (white) and DAPI (red); 
images are representative from 3 independent experiments. Quantification of 
cytoskeletal changes are reported in text. 
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Figure 5.14 Glucocorticoids do not protect A549 cells against α-hemolysin 
(A) Leakage of LDH and viability of A549 cells treated for 24 h with vehicle or 10 
µM dexamethasone, and then challenged for 24 h with control medium or the indicated 
concentration of α-hemolysin. Data are presented as mean (SEM) from 4 independent 
experiments; statistical significance was determined using two-way ANOVA and 
Bonferroni’s post hoc test; *P < 0.05. (B) Leakage of potassium from A549 cells 
treated for 24 h with vehicle, 10 µM dexamethasone, 10 µM hydrocortisone or 1 mM 
MβCD, and then challenged for 15 min with control medium or 8 µg α-hemolysin. 
Dots represent individual values from 4 independent experiments; statistical 
significance was determined using one-way ANOVA with Dunnett’s post hoc test; 
**P < 0.01.  (C) Fluorescent microscope images of A549 cells treated for 24 h with 
vehicle, 10 µM dexamethasone, then challenged for 24 h with control medium or 8 µg 
α-hemolysin and stained with fluorescent phalloidin (white) and DAPI (red); images 
are representative from 3 independent experiments. 
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5.3.3 Cytoprotection is glucocorticoid receptor dependent 
To investigate the role of the glucocorticoid receptor in cytoprotection, we first used 
fluticasone propionate, a glucocorticoid receptor agonist (Johnson, 1998). Fluticasone 
propionate is highly selective, demonstrating negligible effects on the human 
androgen, mineralocorticoid, or progesterone receptor (Johnson, 1998). Additionally, 
fluticasone is more potent than dexamethasone at activating glucocorticoid receptor 
target genes (Adcock and Barnes, 1996). Treatment with fluticasone propionate for 24 
h reduced pyolysin-induced leakage of LDH and cytolysis in HeLa (Fig 5.15A) and 
A549 (Fig 5.15B) cells.  
Secondly, we used the glucocorticoid receptor antagonist RU486, which binds to both 
the progesterone and the glucocorticoid receptor with a high affinity, (Cadepond et al., 
1997). However, we focused on the anti-glucocorticoid activity as HeLa cells do not 
express the progesterone receptor (Mac Namara and Loughrey, 1998). Treatment with 
RU486 induces glucocorticoid receptor translocation, though the bound antagonist 
cannot induce the correct conformational change in the glucocorticoid receptor, 
impairing DNA interaction (Bourgeois et al., 1984, Fryer et al., 2000, Nordeen et al., 
1995). Dexamethasone and hydrocortisone cytoprotection were impaired following 
treatment with RU486 in HeLa (Fig 5.16A,B) and in A549 (5.16C) cells, with 
pyolysin-induced reductions in cell viability and LDH leakage restored.  
Finally, we depleted the glucocorticoid receptor in HeLa cells using siRNA to target 
NR3C1 (Fig 5.17A, B). Depleting the glucocorticoid receptor impaired the 
cytoprotective effect of dexamethasone and hydrocortisone against pyolysin (Fig 
5.17C). Together these experiments provide evidence that glucocorticoid 
cytoprotection against pyolysin was dependent on the glucocorticoid receptor. 
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Figure 5.15 Fluticasone protects HeLa and A549 cells against pyolysin damage 
Leakage of LDH and viability of (A) HeLa and (B) A549 cells treated for 24 h with 
vehicle or the indicated concentrations of fluticasone propionate, and then challenged 
for 2 h with control medium or pyolysin (100 HU, HeLa; 25 HU, A549). Data are 
presented as mean (SEM) from 4 independent experiments; statistical significance was 
determined using two-way ANOVA, and P-values are reported for the effect of 
treatment on pyolysin challenge.  
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Figure 5.16 The glucocorticoid receptor contributes to cytoprotection 
Leakage of LDH and viability of (A,B) HeLa and (C) A549 cells treated for 24 h with 
vehicle, 10 µM dexamethasone, or 10 µM hydrocortisone, in the presence of vehicle 
or 10 µM RU486, and then challenged for 2 h with control medium or pyolysin (100 
HU, HeLa; 25 HU, A549). Data are presented as mean (SEM) of 4 independent 
experiments; statistical significance was determined using two-way ANOVA and 
Bonferroni’s post hoc test; *P < 0.05, **P < 0.01, ***P < 0.001. 
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Figure 5.17 Glucocorticoid cytoprotection against pyolysin is NR3C1 dependent  
(A) Representative Western blots of glucocorticoid receptor and α-tubulin for HeLa 
cells transfected with scrambled siRNA or siRNA targeting NR3C1; image 
representative from 4 independent experiments. (B) Densitometry data for 
glucocorticoid receptor were normalized to α-tubulin and presented as mean (SEM); 
statistical significance was determined using two-way ANOVA and Dunnett’s post 
hoc test; ***P < 0.001. (C) Leakage of LDH and viability of HeLa cells transfected 
for 48 h with scramble siRNA or siRNA targeting NR3C1, treated for 24 h with 
vehicle, 10 µM dexamethasone or 10 µM hydrocortisone, and then challenged for 2 h 
with control medium or 100 HU pyolysin. Data are presented as mean (SEM) from 4 
independent experiments; statistical significance was determined using two-way 
ANOVA and Bonferroni’s post hoc test; **P < 0.01. 
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5.3.4 Cytoprotection is not dependent on changes in cellular cholesterol. 
We next considered possible mechanisms for glucocorticoid cytoprotection. 
Cholesterol-dependent cytolysins bind to accessible cholesterol in plasma membranes 
(Das et al., 2013), and reducing cellular cholesterol protects against cytolysis (Statt et 
al., 2015, Amos et al., 2014). Although treatment with 1 mM MβCD for 24 h reduced 
total cellular cholesterol by 40% in HeLa (Fig 5.18A) and 52% in A549 (Fig 5.18B) 
cells, treatment with dexamethasone or hydrocortisone did not reduce cellular 
cholesterol in either cell type. In fact, dexamethasone and hydrocortisone increased 
the abundance of cholesterol in A549 cells (P < 0.01). Furthermore, even adding 30 
µg/ml cholesterol in combination with the glucocorticoid treatments did not 
significantly reduce cytoprotection against pyolysin (Fig 5.19).  
We have shown in Chapter 3 and Chapter 4 that oxysterols protect cells against 
cholesterol-dependent cytolysins partially through ACAT esterification of cholesterol 
to reduce accessible labile cholesterol in plasma membranes. However, although 
inhibiting ACAT with SZ58-035 reduced 27-hydroxycholesterol cytoprotection 
against pyolysin-induced LDH leakage and cytolysis, SZ58-035 had no significant 
effect on dexamethasone cytoprotection (Fig 5.20). This data provides some evidence 
to suggest that glucocorticoids and side-chain oxysterols protect cells against pore-
forming toxins through independent mechanisms.  
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Figure 5.18 Glucocorticoids do not reduce HeLa or A549 cell cholesterol 
Cellular cholesterol in (A) HeLa and (B) A549 cells treated for 24 h with vehicle (V), 
the indicated concentration of dexamethasone, 10 µM hydrocortisone (Hydro) or 1 
mM MβCD. Data are presented as mean (SEM) from 4 independent experiments; 
statistical significance was determined using one-way ANOVA with Dunnett’s post 
hoc test; **P < 0.01, ***P < 0.001. 
 
 
Figure 5.19 Cholesterol supplementation does not prevent glucocorticoid 
cytoprotection 
(A) Leakage of LDH and (B) viability of HeLa cells treated for 24 h with vehicle, 10 
µM dexamethasone, or 10 µM hydrocortisone in medium containing 30 µg/ml 
cholesterol, and then challenged for 2 h with control medium or 100 HU pyolysin. 
Data are presented as mean (SEM) from 4 independent experiments; statistical 
significance was determined using two-way ANOVA with Bonferroni’s multiple 
comparison test; *P < 0.05, ***P < 0.001. 
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Figure 5.20 Inhibiting ACAT does not prevent glucocorticoid cytoprotection  
(A) Leakage of LDH and (B) viability of HeLa cells cultured for 16 h with vehicle or 
10 µM SZ58-035, then treated for 24 h with vehicle, 10 µM dexamethasone, or 10 
ng/ml 27-hydroxycholesterol (27-HC), in the continuing presence of vehicle or SZ58-
035, and then challenged for 2 h with control medium or 100 HU pyolysin. Data are 
presented as mean (SEM) from 4 independent experiments; statistical significance was 
determined using two-way ANOVA with Tukey’s post hoc test; *P < 0.05, 
***P < 0.001. 
We also examined the binding of pyolysin to cells to evaluate if glucocorticoids altered 
the accessible labile cholesterol in the plasma membrane (Das et al., 2013). As 
expected, treating HeLa cells with, the LXR agonist T0901317, 27-hydroxycholesterol 
or MβCD, diminished pyolysin binding (Fig. 5.21). However, treatment with 
dexamethasone or hydrocortisone had no significant effect on pyolysin binding to 
HeLa cells, although less pyolysin bound to A549 cells (Fig 5.22). Together these 
results do not support the concept that glucocorticoid cytoprotection is mediated by 
alterations in cellular cholesterol. 
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Figure 5.21 Glucocorticoids do not reduce pyolysin binding in HeLa cells 
Representative Western blot of pyolysin binding and α-tubulin for HeLa cells treated 
for 24 h with vehicle, 10 µM dexamethasone, 10 µM hydrocortisone, 50 nM 
T0901317, 10 ng/ml 27-hydroxycholesterol (27HC), or 1 mM MβCD, and then 
challenged for 2 h with control medium or 100 HU pyolysin. Densitometry data were 
normalized to α-tubulin and presented as mean (SEM) from 4 experiments; statistical 
significance was determined using ANOVA and Dunnett’s post hoc test; *P < 0.05. 
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Figure 5.22 Glucocorticoids reduce pyolysin binding in A549 cells 
Representative Western blot of pyolysin binding and α-tubulin for A549 cells cultured 
for 24 h with vehicle, 10 µM dexamethasone, 10 µM hydrocortisone, 50 nM 
T0901317, 10 ng/ml 27-hydroxycholesterol (27-HC), or 1 mM MβCD, and then 
challenged for 2 h with control medium or 25 HU pyolysin. Densitometry data were 
normalized to α-tubulin and presented as mean (SEM) from 4 independent 
experiments; statistical significance was determined using ANOVA and Dunnett’s 
post hoc test, P-values are reported. 
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5.3.5 Serum impairs glucocorticoid cytoprotection. 
Using serum-free media avoided the potentially confounding endogenous cholesterol, 
steroids, and LDH in serum (Thomas et al., 2015). However, to determine whether 
serum affected cytoprotection, HeLa cells were treated with dexamethasone, 
hydrocortisone or fluticasone propionate in complete medium containing 10% serum, 
before challenging cells for 2 h with pyolysin in serum-free medium. The presence of 
10% serum impaired glucocorticoid cytoprotection in HeLa cells (Fig 5.23A). The 
impairment of cytoprotection by serum was concentration-dependent, but ≥ 4% serum 
prevented cytoprotection (Fig 5.23B).  
Charcoal stripping FBS can reduce the concentration of steroid hormones (such as 
oestrogens, androgens, and progesterone), growth factors, and vitamins that might 
impact glucocorticoid cytoprotection (Cao et al., 2009, Sikora et al., 2016, Tu et al., 
2018). However, using 10% steroid-depleted charcoal-stripped serum did not restore 
cytoprotection (Fig 5.23C). Additionally, the presence of serum impaired 
glucocorticoid cytoprotection in A549 cells (Fig 5.24). Intriguingly, when HeLa cells 
were treated with dexamethasone in serum-free media for 24 h, cytoprotection was 
impaired if 10% serum was added for ≥ 2 h before a pyolysin challenge (Fig 5.25A). 
Conversely, cytoprotection was restored by replacing serum-containing medium and 
dexamethasone, with serum-free medium without dexamethasone for ≥ 8 h before a 
pyolysin challenge (Fig 5.25B). Together these data provide evidence for serum 
reversibly impairing glucocorticoid cytoprotection against pyolysin. 
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Figure 5.23 Serum prevents glucocorticoid cytoprotection in HeLa cells 
(A) Viability of HeLa cells treated for 24 h with vehicle, or the indicated 
concentrations of dexamethasone, hydrocortisone, or fluticasone propionate in 
complete medium containing 10% serum, and then challenged for 2 h with control 
serum-free medium or 100 HU pyolysin. Data are presented as mean (SEM) from 4 
independent experiments; statistical significance was determined using two-way 
ANOVA and P-values are reported for the effect of treatment on pyolysin challenge. 
(B) Viability of HeLa cells treated with vehicle or 10 µM dexamethasone in serum-
free medium or complete medium containing the indicated concentration of serum, 
and then challenged for 2 h with control serum-free medium or 100 HU pyolysin. Data 
are presented as mean (SEM) percentage viable cells compared with the control 
challenge from 4 independent experiments; statistical significance was determined 
using two-way ANOVA and Bonferroni’s post hoc test; ***P < 0.001. (C) Viability 
of HeLa cells treated with vehicle or 10 µM dexamethasone in serum-free medium or 
complete medium containing 10% stripped serum, and then challenged for 2 h with 
control serum-free medium or 100 HU pyolysin. Data are presented as mean (SEM) 
from 4 independent experiments; statistical significance was determined using two-
way ANOVA with Bonferroni’s post hoc test; ***P < 0.001. 
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Figure 5.24 Serum prevents glucocorticoid cytoprotection in A549 cells  
A549 cells were treated with vehicle or the indicated concentrations of dexamethasone, 
hydrocortisone, or fluticasone propionate in complete medium containing 10% serum, 
and then challenged for 2 h with control serum-free medium or 25 HU pyolysin. Cell 
viability was assessed by MTT assay. Data are presented as mean (SEM) from 4 
independent experiments; statistical significance was determined using two-way 
ANOVA and P-values are reported for the effect of treatment on pyolysin challenge. 
 
Figure 5.25 Serum reversibly inhibits glucocorticoid cytoprotection  
(A) Viability of HeLa cells treated with vehicle or 10 µM dexamethasone for 24 h in 
control serum-free medium, and then supplemented with 10% serum at the indicated 
time prior to being challenged for 2 h with control serum-free medium or 100 HU 
pyolysin. Data are presented as percentage viability of control challenge, and dots 
represent individual values from 2 to 4 cell passages at each time point. (B) Viability 
of HeLa cells treated for 24 h with vehicle or 10 µM dexamethasone in serum-free or 
complete medium containing 10% serum, with the medium replaced with serum-free 
medium, without treatments, at the indicated time periods before the cells were 
challenged for 2 h with control serum-free medium or 100 HU pyolysin. Data are 
presented as percentage viable cells compared with the control challenge, and dots 
represent individual values from 2 to 4 cell passages at each time point. 
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5.3.6 Ion flux does not contribute to glucocorticoid cytoprotection  
When challenged with pore-forming toxins, cells activate the MAPK cell stress 
response and damage repair mechanisms, principally in response to potassium efflux 
and calcium influx (Kloft et al., 2009, Cassidy and O'Riordan, 2013, Gonzalez et al., 
2011). As expected, treatment with dexamethasone or hydrocortisone did not induce 
MAPK phosphorylation (Fig 5.26). Instead, dexamethasone and hydrocortisone 
treatment prevented pyolysin-induced phosphorylation of ERK1/2, p38 and JNK, as 
effectively as MβCD.  
Furthermore, although cells challenged with pyolysin in low-potassium medium (5 
mM KCl) leaked more LDH and were less viable than cells challenged with pyolysin 
in high-potassium high medium (140 mM KCl to prevent potassium efflux), 
dexamethasone remained cytoprotective (Fig 5.27).  
To examine the impact of calcium ion flux, HeLa cells were treated with 
dexamethasone and challenged with pyolysin in medium with and without calcium. In 
Chapter 4, HeLa cells were significantly more susceptible to pyolysin when 
challenged in calcium free medium to prevent calcium ion influx. Therefore, in the 
present chapter we used a range of pyolysin challenge conditions to ensure that 
increased cell death did not mask the role of calcium ion influx on glucocorticoid 
cytoprotection. To cause a varying degree of LDH leakage and cytolysis, we challenge 
cells for 2 h with both a low and high concentration of pyolysin in medium that was 
calcium free for 15 min or 2 h. Limiting calcium ion influx increased pyolysin-induced 
LDH leakage and cytolysis in all challenge conditions (Fig 5.28). Dexamethasone 
treatment was consistently cytoprotective (P < 0.01), however, protection was 
significantly less effective against 100 HU pyolysin in calcium free medium for 2 h, 
with cells less viable and leaking more LDH than cells challenged in calcium 
containing medium (Fig 5.28B). Together this data provide evidence to suggest that 
glucocorticoid cytoprotection against pyolysin is not dependent on the influx of 
calcium ions, the efflux of potassium ions, or MAPK phosphorylation. 
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Figure 5.26 Glucocorticoids reduce pyolysin-induced MAPK phosphorylation 
Representative Western blot of phosphorylated and total ERK1/2, p38 and JNK, and 
α-tubulin for HeLa cells treated for 24 h with vehicle, 10 µM dexamethasone, 10 µM 
hydrocortisone or 1 mM MβCD, and challenged for 10 min with control medium or 
100 HU pyolysin. Densitometry data were normalized to α-tubulin and presented as 
mean (SEM) from 3 experiments; statistical significance was determined using 
ANOVA with Tukey’s post hoc test; **P < 0.01, ***P < 0.001. 
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Figure 5.27 Potassium ion efflux does not affect dexamethasone cytoprotection 
(A) Leakage of LDH and (B) viability of HeLa cells treated for 24 h with serum-free 
medium containing vehicle or 10 µM dexamethasone and then challenged for 2 h with 
100 HU pyolysin in control medium, low-potassium medium, or high-potassium 
medium. Data are presented as mean (SEM) from 4 independent experiments; 
statistical significance was determined using two-way ANOVA and Bonferroni’s post 
hoc test; *P < 0.05. 
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Figure 5.28 Calcium ion influx does not affect glucocorticoid cytoprotection 
Hela cells were treated with control serum-free medium containing vehicle or 10 µM 
dexamethasone for 24 h and challenged for 2 h with (A) 25 HU pyolysin, or (B) 100 
HU pyolysin in medium containing calcium, in calcium-free medium for 15 min then 
supplemented with calcium for the remainder of the challenge, or in calcium-free 
medium for the full 2 h. The leakage of LDH was measured in cell supernatants and 
cell viability was assessed by MTT. Data are presented as mean (SEM) with dots 
representing the values of cells from 4 independent passages; and are analysed by two-
way ANOVA with Bonferroni’s post hoc test; **P < 0.01, ***P < 0.001.  
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5.3.7 Glucocorticoid cytoprotection is partially dependent on HMGCR 
We finally considered whether the cytoprotective action against pyolysin might 
depend on glucocorticoids activating a specific gene. Actinomycin D is a polypeptide 
antibiotic that intercalates into DNA, inhibiting transcription by preventing the 
progression of RNA polymerases (Perry and Kelley, 1970, Bensaude, 2011). 
Cycloheximide blocks the elongation phase of eukaryotic translation by binding to 
ribosomes and inhibiting enzyme II-dependent translocation (Obrig et al., 1971, 
Schneider-Poetsch et al., 2010). Using actinomycin to inhibit gene transcription or 
cycloheximide to inhibit translation in HeLa cells impaired dexamethasone 
cytoprotection (Fig 5.29).  
Glucocorticoids and serum regulate numerous genes, though a limited number are 
regulated by both (Wang et al., 2004, Iyer et al., 1999). From the literature we 
identified 22 genes regulated by both dexamethasone and serum, of which only 15 
were differentially regulated (Table 5.2A-G). This list largely contained genes that 
seemed unlikely to contribute to cytoprotection, however, one potential candidate was 
HMGCR, the rate-limiting enzyme in the mevalonate pathway. Dexamethasone 
increases and serum reduces HMGCR expression (Cavenee and Melnykovych, 1977, 
Cavenee et al., 1978, Johnston et al., 1979). Using siRNA to target HMGCR reduced 
HMGCR protein by 37% (Fig 5.30A, B), and reduced the effectiveness (but did not 
prevent) dexamethasone cytoprotection (Fig 5.30C). Thus, we conclude that that 
dexamethasone cytoprotection may be partially reliant on HMGCR. 
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Figure 5.29 Glucocorticoid cytoprotection is dependent on transcription and 
translation  
Leakage of LDH and viability of HeLa cells treated for 24 h with vehicle or 10 µM 
dexamethasone, in medium containing vehicle, (A) 1 µg/ml cycloheximide or (B) 0.25 
µg/ml actinomycin D (added 2 h prior to dexamethasone), and then challenged for 2 h 
with control medium or 100 HU pyolysin. Data are presented as mean (SEM) from 4 
independent experiments; statistical significance was determined using two-way 
ANOVA with Bonferroni’s post hoc test; **P < 0.01.  
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Table 5.2 Genes regulated by dexamethasone and serum 
Genes grouped into sub tables A - G according to function. Human Gene Organisation 
Gene Nomenclature Committee (HGNC) ID number provided for each gene.  
Key 
↑ Induced 
↓ Repressed 
 Differentially regulated 
 Similarly regulated 
References 
1. (Wang et al., 2004) 11. (Wang et al., 2007) 
2. (Iyer et al., 1999) 12. (Cavenee and 
Melnykovych, 1977) 
3. (Amano et al., 1993) 13. (Mostafa et al., 
2019) 
4. (Chang et al., 2001) 14. (Mayanagi et al., 
2008) 
5. (Kim et al., 2015) 15. (Meisinger et al., 
1996) 
6. (Dhawan et al., 2007) 16. (Chedid et al., 
1996) 
7. (Lasa et al., 2002) 17. (Yang et al., 2014) 
8. (Kemppainen and 
Behrend, 1998) 
18. (Breen et al., 2012) 
9. (Wang et al., 2017) 19. (van de Stolpe et 
al., 1993) 
10. (Obradovic et al., 
2019) 
20. (Wang et al., 2006) 
 
(A) Inflammation 
Gene Name 
(HGNC ID) 
Dexamethasone FBS 
ALOX5AP (436) ↑ (1) 
 
CCL2 (10618) ↓ (1, 6) ↓ (2) 
CCL20 (10619) ↑ (1) 
 
CXCL12 (10672) 
 
↑ (2) 
CXCL2 (4603) 
 
↓ (2) 
CXCL8 (6025) ↓ (4) ↓ (5) 
ICAM1 (5344) ↓ (19) ↑ (2) 
IL11 (5966) ↓ (1) 
 
IL1B (5992) ↓ (3) ↓ (2) 
PDE4B (8781) ↓ (1) 
 
PTGS2 (9605) ↓ (1) ↑ (2) 
THBD (11784) ↑ (1) 
 
TSC22D3 (3051) ↑ (1) 
 
 
(B) Metabolism 
Gene Name (HGNC 
ID) 
Dexamethasone FBS 
ANGPTL4 (16039) ↑ (1) 
 
B3GNT5 (15684) ↑ (1) 
 
ETNK2 (25575) ↑ (1) 
 
MGAM (7043) ↑ (1) 
 
TXNIP (16952) ↑ (20) ↓ (2) 
(C) Transport 
Gene Name (HGNC 
ID) 
Dexamethasone FBS 
MT1A (7393) ↑ (7) ↑ (2) 
MT1B (7394) 
 
↑ (2) 
MT1IP (7401) ↑ (1) ↑ (2) 
SCNN1A (10599) ↑ (1) 
 
SLC19A2 (10938) ↑ (1) 
 
SLC26A2 (10994) ↑ (1) 
 
STOM (2282) ↑ (1) 
 
 
(D) Growth and Apoptosis 
Gene Name (HGNC 
ID) 
Dexamethasone FBS 
BIRC3 (591) ↑ (1) 
 
CCNA2 (1578) 
 
↑ (2) 
CCNB1 (1579) 
 
↑ (2) 
CCND1 (1582) 
 
↑ (2) 
CDK1 (1722) 
 
↑ (2) 
CDK7 (1788) 
 
↑ (2) 
CDKN1C (1786) ↑ (1) ↓ (2) 
CENPF (1857) 
 
↑ (2) 
CKS2 (2000) 
 
↑ (2) 
CTPS1 (2519) 
 
↑ (2) 
CUL1 (2551) ↓ (1) 
 
FGFBP1 (19695) ↓ (1) 
 
GADD45B (4096) ↑ (1) 
 
ID2 (5361) 
 
↑ (2) 
ID3 (5362) 
 
↑ (2) 
LBR (6518) 
 
↓ (2) 
MAD2L1 (6763) 
 
↑ (2) 
MFGE8 (7036) ↑ (1) 
 
MKI67 (7101) 
 
↑ (2) 
PCNA (8729) 
 
↑ (2) 
RRM1 (10451) 
 
↑ (2) 
RRM2 (10452) 
 
↑ (2) 
S100P (10504) ↑ (1) 
 
SERPINB9 (8955) ↓ (1) 
 
SERTAD2 (30784) ↓ (1) 
 
SIAH1 (10857) 
 
↓ (2) 
SNAI2 (11094) ↑ (1) 
 
SPRY1 (11269) ↑ (1) 
 
TNFAIP3 (11896) ↑ (1) 
 
TOP2A (11989) 
 
↑ (2) 
WEE1 (12761) 
 
↓ (2) 
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(E) Cholesterol Biosynthesis 
Gene Name 
(HGNC ID) 
Dexamethasone FBS 
CYP51A1 (2649) 
 
↓ (2) 
FDFT1 (3629) 
 
↓ (2) 
HMGCR (5006) ↑ (12) ↓ (2, 12) 
IDI1 (5387) 
 
↓ (2) 
SQLE (11279) 
 
↓ (2) 
 
(F) Cell Signalling 
Gene Name 
(HGNC ID) 
Dexamethasone FBS 
ACKR3 (23692) ↓ (1) 
 
AKAP13 (371) ↑ (1) 
 
ANKRD1 (15819) ↑ (1) 
 
ARL8 (25192) ↓ (1) 
 
BHLHE40 (1046) ↓ (1) 
 
CDC42EP3 (16943) ↑ (1) 
 
CPEB4 (21747) ↑ (1) 
 
DNER (24456) ↑ (1) 
 
DUS1 (3064) ↑ (7) ↑ (2) 
EDN2 (3177) ↑ (1) 
 
ENC1 (3345) ↓ (1) 
 
EPB41L4B (19818) ↑ (1) 
 
FGD4 (19125) ↑ (1) 
 
FKBP5 (3721) ↑ (1, 17) ↓ (17) 
GEM (4234) ↓ (1) ↓ (2) 
IHPK3 (17269) ↑ (1) 
 
IRS2 (6126) ↑ (1) 
 
KIT (6342) 
 
↓ (2) 
PLK2 (19699) ↓ (1) ↑ (2) 
POU5F1 (9221) ↑ (1) 
 
PPP1R14C (14952) ↑ (1) 
 
RASD1 (15828) ↑ (8) ↓ (9) 
RGS2 (9998) ↑ (1) 
 
ROR1 (10256) ↑ (10) ↓ (2) 
S1PR1 (3165) 
 
↑ (2) 
SEC14L1 (10698) ↑ (1) 
 
SGK1 (10810) ↑ (11) ↓ (2) 
TGFBR3 (11774) ↑ (1) ↓ (2) 
ZIC2 (12873) ↓ (1) 
 
 
(G) Other 
Gene Name 
(HGNC ID) 
Dexamethasone FBS 
ABHD2 (18717) ↑ (1) 
 
ADGRF4 (19011) ↑ (1) 
 
AMIGO2 (24073) ↓ (1) 
 
ARRDC3 (29263) ↓ (1) 
 
CALD1 (1441) ↑ (13,14) ↓ (2) 
CAVIN2 (10690) ↑ (1) ↑ (18) 
CDH2 (1759) 
 
↑ (2) 
CFHR1 (4888) 
 
↓ (2) 
COL1A1 (2197) 
 
↓ (2) 
DNAJC15  
(20325) 
↑ (1) 
 
FBN2 (3604) 
 
↓ (2) 
FGF2 (3676) ↑ (15) ↑ (2) 
FGF3 (3681) 
 
↓ (2) 
FGF7 (3685) ↓ (16) ↑ (2) 
FHL2 (3703) 
 
↑ (2) 
FLVCR2 (20105) ↑ (1) 
 
FURIN (8568) 
 
↑ (2) 
GPR153 (23618) ↑ (1) 
 
HKDC1 (23302) ↓ (1) 
 
KTN1 (6467) ↓ (1) 
 
LAMA2 (6482) 
 
↓ (2) 
LRRC8A (19027) ↑ (1) 
 
MME (7154) 
 
↓ (2) 
NAV3 (15998) ↓ (1) 
 
OTULINL (25629) ↑ (1) 
 
PLEKHA7  
(27049) 
↑ (1) 
 
PLOD2 (9082) 
 
↑ (2) 
PMP2 (9117) ↓ (1) 
 
PNRC1 (17278) 
 
↓ (2) 
PRRG4 (30799)  ↑ (1) 
 
SERPINB2 (8584) 
 
↑ (2) 
SERPINE1 (8583) ↑ (13) ↑ (2) 
SPINK5L3 (27200) ↑ (1) 
 
SPTBN1 (11275) 
 
↓ (2) 
SRGN (9361) ↑ (1) 
 
TFPI2 (11761) ↓ (13) ↑ (2) 
TNS4 (24352) ↑ (1) 
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Figure 5.30 Glucocorticoid cytoprotection is partially dependent on HMGCR 
(A) Representative Western blot of HMGCR and α-tubulin for HeLa cells transfected 
with scrambled siRNA or siRNA targeting HMGCR; (B) densitometry data for 
HMGCR were normalized to α-tubulin and presented as mean (SEM) from 4 
independent experiments; statistical significance was determined using one-way 
ANOVA and Dunnett’s post hoc test; *P < 0.05. (C) Leakage of LDH and viability of 
HeLa cells transfected for 48 h with scramble siRNA or siRNA targeting HMGCR, 
treated for 24 h with vehicle or 10 µM dexamethasone, and then challenged for 2 h 
with control medium or 100 HU pyolysin. Data are presented as mean (SEM) from 4 
independent experiments; statistical significance was determined using two-way 
ANOVA and Bonferroni’s post hoc test; **P < 0.01, ***P < 0.001. 
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5.4 DISCUSSION 
Glucocorticoids are thought to limit the severity of disease by suppressing 
inflammation and immunity, however, in this chapter treatment with glucocorticoids 
increased the intrinsic protection of several cell types against the damage caused by 
pore-forming toxins. Glucocorticoids are ligands for the glucocorticoid receptor and 
cytoprotection was dependent on its expression, as well as being reliant on protein 
transcription and translation. Glucocorticoids did not significantly affect cellular 
cholesterol and did not appear to protect cells through cholesterol esterification or by 
preventing toxin binding, though protection may be mediated in part by HMGCR. 
Challenging cells with pyolysin, streptolysin O and α-hemolysin led to the formation 
of pores in cell plasma membranes, determined by the leakage of potassium ions and 
LDH, activation of the MAPK stress response, changes in cytoskeleton structure, and 
cell cytolysis. These are typical consequences of pore-forming toxin damage that were 
mirrored throughout the present thesis (Kloft et al., 2009, Gonzalez et al., 2011, Dal 
Peraro and van der Goot, 2016). 
The key and unexpected finding was that the glucocorticoids dexamethasone and 
hydrocortisone almost completely protected HeLa cells against cytolysis in the face of 
pyolysin, streptolysin O and α-hemolysin challenge that typically caused > 75% 
cytolysis. Treatment with 10 µM dexamethasone and hydrocortisone, reduced 
potassium ion and LDH leakage, prevented the activation of the MAPKs ERK1/2, p38 
and JNK, and prevented cytoskeletal changes. This protection extended to A549, Hep-
G2, NC1-H441, and primary dermal fibroblasts. Collectively, these findings provide 
evidence for a glucocorticoid cytoprotective effect against pore-forming toxins, which 
contradicts their inability to significantly protect bovine endometrial cells against 
pyolysin in Chapter 3. This protection has not been previously identified, possibly due 
to the cell type and context specific nature of glucocorticoid responses.  
Cytoprotection was dependent on the glucocorticoid receptor as the specific 
glucocorticoid receptor agonist fluticasone induced cytoprotection, and siRNA 
targeting NR3C1 diminished glucocorticoids cytoprotection. Glucocorticoids regulate 
gene transcription in a cell specific manner by binding to the glucocorticoid receptor, 
and associating with glucocorticoid response elements (Biddie et al., 2011, So et al., 
2007), though they can repress transcription factors and have immediate non-genomic 
221 
 
effects (Samarasinghe et al., 2012). The protective mechanism was likely genomic as 
preventing protein transcription and translation with the inhibitors actinomycin D and 
cycloheximide impaired cytoprotection, and protection required > 8 h of treatment. 
The transcriptional effects of glucocorticoid treatment vary extensively between cell 
types. This was demonstrated in a study by Franco et al. (2019) where glucocorticoid 
treatment caused differential expression of 9,457 unique genes across 9 different cell 
types, but only 25 of these were significantly differentially expressed in each cell type. 
Cell specific glucocorticoid responses might explain the varying degree of protection 
against pyolysin challenge observed across the cell types examined in this study, the 
limited protection of A549 cells against α-hemolysin damage, and the lack of 
protection in the bovine endometrium in Chapter 3.  
Reducing cellular cholesterol is an effective method for protecting cells against 
cholesterol-dependent cytolysins (Amos et al., 2014, Statt et al., 2015). Glucocorticoid 
treatment in this chapter did not decrease HeLa or A549 cellular cholesterol or prevent 
pyolysin binding, agreeing with previous observations that dexamethasone stimulates 
cholesterol synthesis and suppresses cellular cholesterol efflux (Ayaori et al., 2006). 
In Chapters 3 and 4, oxysterols protected cells against cholesterol-dependent 
cytolysins by mobilizing cell surface accessible cholesterol through ACAT-driven 
cholesterol esterification and reducing toxin binding. Glucocorticoids stimulate 
cholesteryl ester formation in human smooth muscle cells (Petrichenko et al., 1997) 
and macrophages (Cheng et al., 1995). However, in the present chapter, 
glucocorticoids did not significantly protect HeLa cells through cholesterol 
esterification. We therefore reason that alterations in cellular cholesterol are unlikely 
to be a mechanism for glucocorticoid cytoprotection.  
An unexpected finding was that the presence of serum reversibly prevented 
glucocorticoids from protecting cells against pyolysin. Serum contains a variety of 
nutritional and hormonal components and is known to have a powerful effect on 
transcriptional responses (Shaw et al., 1989, Treisman, 1986), however, attempting to 
strip some of these components away with charcoal-dextran did not restore 
cytoprotection. Cholesterol has been identified as a component of serum that 
modulates aspects of glucocorticoid action (Yang et al., 2014), but supplying 
exogenous cholesterol in the absence of serum in this study did not prevent protection  
Lipopolysaccharide binding protein (LBP) is another important component in serum 
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that has a role in the innate immune response to LPS from bacteria (Heumann et al., 
2003). Furthermore, A549 cells and macrophages express LBP that might be 
stimulated by oxysterols or glucocorticoids (Zhang et al., 2007, Sallam et al., 2014, 
Hu et al., 2021). Future work might consider whether serum containing, or serum 
stimulated proteins, such as LBP, can contribute to or interfere with cytoprotective 
mechanisms. 
The inhibitory effect of serum inspired a search for factors that are differentially 
regulated by serum and glucocorticoids. Although serum and glucocorticoids regulate 
a wide range of genes and pathways, few are differentially regulated (Wang et al., 
2004, Iyer et al., 1999). One example is that serum stimulates MAPK phosphorylation, 
whereas glucocorticoids suppress MAPK phosphorylation (Newton, 2014, Troppmair 
et al., 1994). Though the suppression of MAPK by glucocorticoids counters the 
expected role of MAPKs in damage repair in response to pore-forming toxins (Kloft 
et al., 2009, Cassidy and O'Riordan, 2013, Gonzalez et al., 2011). On the other hand, 
HMGCR is repressed by serum treatment (Iyer et al., 1999), whereas glucocorticoids 
increase HMGCR activity in HeLa cells in a protein synthesis-dependent manner 
(Cavenee and Melnykovych, 1977, Cavenee et al., 1978, Johnston et al., 1979). The 
increase in HMGCR activity might explain the slight increase in cellular cholesterol 
we noted. More striking was that siRNA targeting HMGCR diminished glucocorticoid 
cytoprotection. However, the function of HMGCR in intrinsic cell protection is 
unclear. Targeting HMGCR with statins or siRNA typically protects cells against 
cholesterol-dependent cytolysin by reducing cellular cholesterol (Statt et al., 2015, 
Griffin et al., 2017). In contrary to this, reducing HMGCR expression in the present 
chapter did not alter protection. Furthermore, dexamethasone treatment still provided 
some protection against pyolysin suggesting that HMGCR is not the sole protective 
mechanism. Using a gene array to verify the involvement of HMGCR or identify other 
potential target genes might help solve this conundrum, though this was beyond the 
scope of the present thesis.  
Reparative mechanisms that might contribute to reducing the damage caused by pore-
forming toxins include endocytosis, exocytosis, unfolded protein response, or caspase 
activity (Cassidy and O'Riordan, 2013, Gonzalez et al., 2011, Andrews and Corrotte, 
2018) . Calcium ion influx or potassium ion efflux initiate these reparative responses; 
however, glucocorticoid conferred protection did not depend on challenge medium ion 
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concentrations in the present study. Another possibility is that glucocorticoids might 
stimulate actin stress fiber formation and increased actin cytoskeleton stability 
(Mayanagi et al., 2008, Castellino et al., 1992). Dexamethasone and hydrocortisone 
stimulated actin stress fiber formation in HeLa and A549 cells, which might explain 
how glucocorticoids prevent pyolysin-induced cytoskeletal changes. However, it is 
unclear how this would prevent the leakage of potassium and LDH.  
Glucocorticoids are used as an adjunct therapy to reduce inflammation and 
immunopathology caused by bacterial infection (Cain and Cidlowski, 2017, Kadmiel 
and Cidlowski, 2013, Newton, 2014). Our findings imply that glucocorticoids might 
also protect tissues against the damage caused by bacteria that secrete pore-forming 
toxins. A future challenge will be to untangle the anti-inflammatory and protective 
roles of glucocorticoids. However, prolonged high doses of glucocorticoid treatment 
is associated with adverse endocrine or immunosuppressive effects in patients, 
potentially limiting the translation of our findings (Newton, 2014). The negative 
connotations of glucocorticoid treatment have supported the development of selective 
glucocorticoid receptor agonists, such as fluticasone propionate, with a greater affinity 
for the glucocorticoid receptor, and an improved therapeutic index (Schacke et al., 
2007, Harding, 1990, Johnson, 1998). Our findings might stimulate a search for 
selective glucocorticoid receptor agonists that also improve cytoprotection. Protecting 
cells against pore-forming toxins can help tissues better tolerate pathogens and reduce 
the dependence on immunity or antimicrobials to kill bacteria (Medzhitov et al., 2012). 
The serum-induced suppression of glucocorticoid cytoprotection raises the question of 
how the findings of the present chapter translate to physiology. Unfortunately, 
experiments demonstrating the in vivo relevance of prophylactic glucocorticoid 
treatment to protect cells against toxin-secreting pathogenic bacteria were beyond the 
scope of the thesis. Additionally, we did not investigate the effect of glucocorticoid 
treatment on cells already exposed to pore-forming toxins. Future experiments 
challenging cells with pyolysin before a subsequent treatment would investigate 
whether glucocorticoids might also contribute to tissue recovery. 
In conclusion we found that glucocorticoids protect several types of cells against pore-
forming toxins. Glucocorticoids increased HeLa and A549 cell-intrinsic protection 
against pyolysin, streptolysin O and α-hemolysin damage. The glucocorticoid 
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cytoprotection was dependent on glucocorticoid receptor mediated protein synthesis 
and partly reliant on HMGCR. Our findings imply that targeting the glucocorticoid 
receptor could be exploited to limit the severity of disease caused by pathogens that 
secrete pore-forming toxins. 
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6 GENERAL DISCUSSION 
Pore-forming toxins are secreted as virulence factors to promote bacterial invasion, 
releasing nutrients from lysed target cells and facilitating the delivery of additional 
virulence factors (Dal Peraro and van der Goot, 2016). Cholesterol-dependent 
cytolysins represent the largest family of pore-forming toxins (Tweten, 2005). 
Trueperella pyogenes, a common cause of uterine disease in postpartum cattle and 
Streptococcus pyogenes, a cause of pharyngitis and impetigo, represent examples of 
pathogens that release cholesterol-dependent cytolysins, secreting pyolysin and 
streptolysin O respectively (Jost and Billington, 2005, Bhakdi et al., 1985). 
Staphylococcus aureus, is an example of a bacteria that secretes another family of 
pore-forming toxins, causing target cell cytolysis through the release of an α-
hemolysin (Seilie and Bubeck Wardenburg, 2017). Release of pyolysin, streptolysin 
O or α-hemolysin by their respective bacteria is associated with the severity of 
pathology (Amos et al., 2014, Zhu et al., 2017, Patel et al., 1987). Resilience to 
infection by bacteria such as T. pyogenes, S. pyogenes, and S. aureus is achieved 
through a combination of resistance and tolerance mechanisms (Schneider and Ayres, 
2008). Whilst resistance mechanisms, such as innate and adaptive immunity, are well 
understood, research into tolerance mechanisms is ongoing (Sheldon et al., 2020). 
Cells can tolerate bacterial infection by repairing some of the damage caused by pore-
forming toxins through the activation of pro-survival responses following the cytosolic 
ion and molecular flux triggered by pore-formation (Gonzalez et al., 2011, Gurcel et 
al., 2006, Andrews and Corrotte, 2018). Alternatively, tolerance can be achieved by 
protecting cells against pore-forming toxin damage. It is established that depleting cell 
cholesterol with methyl-β-cyclodextrin (MβCD) and statins can provide protection 
against the cytolysis caused by cholesterol-dependent cytolysins (Statt et al., 2015, 
Giddings et al., 2003), and more specifically pyolysin (Amos et al., 2014, Griffin et 
al., 2017, Pospiech et al., 2021), but little is known beyond this. Hence, this thesis 
aimed to explore other methods of protecting eukaryotic cells against the damage 
caused by pore-forming toxins.  
Oxysterol and steroids impact the severity of disease caused by bacteria that secrete 
pore-forming toxins (Abrams et al., 2020, Stern et al., 2017, Lewis, 2003). Therefore, 
we began with the hypothesis that side-chain oxysterols and steroids alter the intrinsic 
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protection of eukaryotic cells against pore-forming toxins. To challenge this 
hypothesis, we first screened the ability of progesterone, oestradiol, glucocorticoids, 
or 27-hydroxycholesterol to reduce the cytolytic impact of pyolysin on the target 
epithelial and stromal cells of the bovine endometrium. This model represented an 
important biological problem, as parturition in cattle is accompanied by infection with 
bacteria such as T. pyogenes and S. aureus and results in the disruption of the 
protective epithelium in the endometrium exposing underlying sensitive stromal cells 
(Sheldon et al., 2019). Uterine disease is a common outcome, leading to the reduced 
fertility in many animals (Ribeiro et al., 2016). We found that the protection afforded 
by 27-hydroxycholesterol was striking. Cytoprotection was also afforded by 25-
hydroxycholesterol and against α-hemolysin from S. aureus providing evidence to 
show that side-chain oxysterols can help protect bovine endometrial cells against pore-
forming toxins. Furthermore, Chapter 4 established that side-chain oxysterols also 
protected human epithelial cells against pore-forming toxins. Collectively these 
findings suggest that side-chain oxysterols may help defend tissues against pore-
forming toxins from pathogenic bacteria.   
Treatment with the steroids progesterone and estradiol did not protect bovine 
endometrial cells against pyolysin at the concentrations and treatment durations 
explored in this study and so were not examined further. Hydrocortisone or 
dexamethasone treatment did not significantly affect the pyolysin-induced cytolysis of 
bovine endometrial cells (though there was a trend for reduced cell death in 
dexamethasone treated epithelial cells); however, glucocorticoid effects vary 
significantly between cells and tissues. Therefore, Chapter 5 tested the hypothesis that 
glucocorticoids increase the protection of human tissue cells against pore-forming 
toxins. Strikingly, hydrocortisone and dexamethasone protected cells against pyolysin, 
streptolysin O and α-hemolysin, implying that glucocorticoids could be exploited to 
limit the damage caused by bacteria that secrete pore-forming toxins. 
Utilising a range of cell types and pore-forming toxins throughout the thesis helped to 
determine if protective mechanisms were generic, and the main findings are 
summarised in Table 6.1.  
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Table 6.1 Summarised cytoprotective findings 
(25-HC, 25-hydroxycholesterol; 27-HC, 27-hydroxycholesterol; Dex, 
Dexamethasone; Hydro, Hydrocortisone; FP, Fluticasone propionate; -, not tested; ●, 
cytoprotective; ●, some protection noted; ●, not cytoprotective) 
Cell type Toxin Side-chain oxysterols LXR agonists Glucocorticoids 
25-HC 27-HC T0901317 GW3965 Dex Hydro FP 
Bovine 
endometrial 
epithelial cells 
Pyolysin ● ● ● ● ● ● - 
α-hemolysin ● ● ● - - - - 
Bovine 
endometrial 
stromal cells 
Pyolysin ● ● ● ● ● ● - 
α-hemolysin ● ● ● - - - - 
HeLa cervical 
cells 
Pyolysin ● ● ● ● ● ● ● 
α-hemolysin ● ● - - ● ● - 
Streptolysin O  - - - - ● ● - 
A549 lung 
cells 
Pyolysin ● ● ● ● ● ● ● 
α-hemolysin ● ● - - ● ● - 
Streptolysin O - - - - ● - - 
Hep-G2 liver 
cells 
Pyolysin - ● - - ● - - 
NC1-H441 
lung cells 
Pyolysin - ● - - ● - - 
Normal human 
dermal 
fibroblasts 
Pyolysin - - - - ● - - 
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6.1 SIDE-CHAIN OXYSTEROL CYTOPROTECTION 
The cytoprotection afforded by side-chain oxysterols was the first notable finding of 
the present thesis, and reduced cytolysis in every examined cell type. Treatment with 
27-hydroxycholesterol reduced pyolysin binding without decreasing total cellular 
cholesterol. Side-chain oxysterols remodel plasma membrane cholesterol through 
acetyl-coenzyme A acetyltransferase (ACAT)-dependent cholesterol esterification 
(Lange et al., 1999), and the ACAT inhibitor Sandoz 58-035 (SZ58-035) reduced 
cytoprotection in bovine endometrial and HeLa cells. Oxysterols are also ligands for 
the liver X receptors (LXRs) (Wang and Tontonoz, 2018). The synthetic LXRs 
T0901317 and GW3965 provided protection against pyolysin in bovine endometrial 
cells, HeLa cells, and A549 cells. Additionally, reducing the expression of the LXR 
genes NR1H2 and NR1H3 reduced cytoprotection in bovine endometrial cells. 
However, it is unlikely that these are the sole cytoprotective mechanisms. Inhibiting 
ACAT or reducing the expression of NR1H2 and NR1H3 only provided moderate 
reductions in cytoprotection, and it is unlikely that experiments combining the two 
would completely prevent protection. Oxysterols also inhibit cholesterol synthesis by 
blocking sterol responsive element binding protein (SREBP) activation and triggering 
3-hydroxy 3-methylglutaryl coenzyme A reductase (HMGCR) degradation 
(Radhakrishnan et al., 2007, Lange et al., 2008). It is likely that these mechanisms also 
contribute to cytoprotection, and future in vitro studies might verify their involvement. 
We propose that oxysterol cytoprotection is derived from a combination of multiple 
protective pathways, stemming from their ability to regulate cholesterol homeostasis.   
Side-chain oxysterol cytoprotection appeared generalized, however, a few key 
differences were noted when comparing protection in bovine endometrial cells to 
protection in human HeLa cervical cells. Firstly, the relationship between 27-
hydroxycholesterol treatment duration and the degree of protection was linear up to 24 
h in bovine endometrial cells, with protection evident after > 8 h treatment and 
maximal at ~ 24 h. However, cytoprotection was evident after 4 h in HeLa cells and 
maximal with > 12 h of treatment. Additionally, reducing the expression of NR1H2 
and NR1H3 impaired 27-hydroxycholesterol cytoprotection in bovine endometrial 
cells but not in HeLa cells. It is possible that oxysterol cytoprotective mechanisms are 
tissue and cell type specific, with the involvement of individual protective pathways 
depending on gene expression and oxysterol sensitivity. This suggestion is supported 
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by the inability of oxysterols to protect bone marrow-derived macrophages against 
Listeria monocytogenes infection and the delay in 25-hydroxycholesterol driven 
mobilization of accessible cholesterol in Chinese hamster ovary cells that 
constitutively express the transcriptionally active fragment of SREBP2 (Abrams et al., 
2020, Yang et al., 1994). 
At the time of discovery, the ability of side-chain oxysterols to provide complete 
protection against pore-forming toxin damage appeared novel. However, in a recent 
study by Zhou et al. (2020) interferon stimulated mouse bone marrow-derived 
macrophages were protected against perfringolysin O, streptolysin O, and anthrolysin 
O in a 25-hydroxycholesterol-dependent mechanism, and the protective effects of the 
LXR agonist GW3965 were noted. However, the findings of the present thesis are still 
impactful, demonstrating protection in additional cell types and against α-hemolysin, 
though cytoprotection against other classes of pore-forming toxins warrants further 
investigation.  
Prior to this study, oxysterols in the bovine uterus had not been previously examined. 
We found novel data demonstrating the presence of a large range of oxysterols, 
significantly including 25-hydroxycholesterol and 27-hydroxycholesterol, in both 
uterine and ovarian follicular fluid. Additionally, 25-hydroxycholesterol was released 
by bovine endometrial epithelial cells. Although it was known that the innate immune 
system triggers the secretion of 25-hydroxycholesterol from macrophages (Baumann 
et al., 2005, Reboldi et al., 2014), we unexpectedly found that both LPS and pyolysin 
stimulated the release of further 25-hydroxycholesterol. Although 27-
hydroxycholesterol was detected in uterine fluid, it was not released from endometrial 
cells, indicating that endometrial cells were not the origin of this oxysterol in the 
biological fluids. Ovarian steroid hormones regulate the function of the bovine 
endometrium, preparing the uterus for pregnancy (Wira et al., 2005, Lewis, 2003). It 
is possible that the ovaries might also produce oxysterols to help protect cells against 
pore-forming toxins.  Collectively, our data informs the proposal that oxysterols are 
produced in the ovaries and released from endometrial epithelial cells to contribute to 
uterine protection against invading pathogens (Fig 6.1). Future research might verify 
the significance of oxysterols in uterine disease by comparing concentrations in 
healthy and diseased animals and exploring cytoprotection afforded by a wider range 
of oxysterols, however, this was beyond the scope of the present thesis.  
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Figure 6.1 Oxysterol cytoprotection in the bovine endometrium  
The oxysterols 25-hydroxycholesterol and 27-hydroxycholesterol help protect 
endometrial cells against damage by the cholesterol-dependent cytolysin pyolysin 
from T. pyogenes and α-hemolysin from S. aureus. Both oxysterols are present in 
uterine fluid; and endometrial epithelial, but not stromal cells, release 25-
hydroxycholesterol, and this is further increased in response to pyolysin or 
lipopolysaccharide from Gram-negative pathogens, such as Escherichia coli. We 
propose that oxysterols from the ovary and 25-hydroxycholesterol from endometrial 
epithelial cells help protect the underlying sensitive stromal cells against pore-forming 
toxins. Created with BioRender.com. 
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6.2 GLUCOCORTICOID CYTOPROTECTION 
Another novel finding in the present thesis was that glucocorticoids increase the 
intrinsic protection of cells against the damage caused by pore-forming toxins. 
Glucocorticoids are thought to limit the severity of disease by suppressing 
inflammation and immunity (Kadmiel and Cidlowski, 2013), however, our findings 
suggest that glucocorticoids may also increase the tolerance of tissues to pathogenic 
bacteria by protect cells against pore-forming toxins. Dexamethasone and 
hydrocortisone protected HeLa cells against the damage caused by pyolysin, 
streptolysin O and α-hemolysin, preventing the leakage of cytosolic molecules, cell 
cytolysis, cytoskeletal changes, and mitogen-activated protein kinase (MAPK) 
activation. Protection extended to A549, Hep-G2, NC1-H441 cells and to dermal 
fibroblasts. Unsurprisingly, cytoprotection was dependent on the glucocorticoid 
receptor. Although the glucocorticoid receptor can mediate fast-acting non-genomic 
effects (Buttgereit and Scheffold, 2002), cytoprotection is likely a genomic mechanism 
as protection requires > 8 h treatment and inhibiting transcription and translation 
diminished cytoprotection.  
The resulting transcriptional response following glucocorticoid treatment depends on 
a range of elements including cell type and glucocorticoid target gene expression, 
chromatin accessibility, interactions with other transcription factors, and the presence 
of other cells and extracellular molecules (Quatrini and Ugolini, 2021, John et al., 
2011). Collectively, these factors contribute to the cell and context specific nature of 
glucocorticoid responses. Therefore, it is not surprising that the cytoprotection 
afforded by glucocorticoids varied across the cell types examined in this study. 
Specifically, this might explain the inability of hydrocortisone or dexamethasone to 
significantly protect bovine endometrial cells against pyolysin and the limited 
protection of A549 cells against α-hemolysin.  
The mechanisms contributing to glucocorticoid cytoprotection appear unrelated to 
those utilised by oxysterols. Glucocorticoid treatment increases the accumulation of 
cholesterol esters in human macrophages and smooth muscle cells cultured without 
serum (Petrichenko et al., 1997, Cheng et al., 1995). However, glucocorticoids did not 
appear to protect HeLa cells through cholesterol esterification as the ACAT inhibitor 
SZ58-035 did not diminish glucocorticoid cytoprotection despite reducing the 
effectiveness of 27-hydroxycholesterol cytoprotection. Additionally, glucocorticoids 
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did not prevent HeLa cell pyolysin binding, suggesting that accessible cholesterol is 
not reduced. However, evaluating pyolysin binding in A549 cells did not provide such 
clear-cut results and further experiments might explore the involvement of ACAT in 
glucocorticoid cytoprotection in additional cell types. 
Uncovering the precise mechanisms involved in glucocorticoid cytoprotection proved 
elusive. Glucocorticoids stimulate actin stress fibre formation which might help 
stabilize the cytoskeleton (Mayanagi et al., 2008, Castellino et al., 1992), but it is 
unlikely that this would prevent LDH and potassium leakage. Experiments targeting 
HMGCR with short-interfering ribonucleic acid (siRNA), impaired glucocorticoid 
protection. Statins can also be used to inhibit HMGCR activity, however, as they also 
provide protection against cholesterol-dependent cytolysins it was not possible to use 
them to explore the role of HMGCR in glucocorticoid cytoprotection. Dexamethasone 
increases HMGCR activity in HeLa cells (Cavenee and Melnykovych, 1977), and this 
might explain the slight increase in cellular cholesterol, but it is not clear how this 
would contribute to protection. Perhaps this excess cholesterol is continually 
compartmentalized and/or removed from the cell via efflux, providing a dynamic pool 
of accessible cholesterol that makes pyolysin oligomerization and pore formation 
challenging. It is also important to consider whether the involvement of HMGCR in 
HeLa cell glucocorticoid cytoprotection is part of the generalized glucocorticoid 
cytoprotective mechanism or is a product of the cell type specific nature of 
glucocorticoid responses. Future experiments might use siRNA to verify the 
involvement of HMGCR in glucocorticoid cytoprotection in the other cell types used 
in the present thesis. 
6.3 SERUM AND CYTOPROTECTION 
An unexpected finding was the fact that serum, reversibly diminished glucocorticoid 
cytoprotection. Serum contains a variety of nutritional and signalling components and 
has powerful effects on transcriptional responses (Treisman, 1986). A bioassay has 
previously identified the ability of serum to impair glucocorticoid activity 
(Perogamvros et al., 2011). Corticosteroid-binding globulins in serum bind to 
endogenous glucocorticoids, controlling their transport and bioavailability 
(Hammond, 1990). However, it is unlikely that corticosteroid-binding globulins are 
responsible for the inhibitory effect, as the synthetic glucocorticoids dexamethasone 
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and fluticasone propionate demonstrate negligible corticosteroid-binding globulin 
binding affinity (Maitra et al., 1993, Bodor et al., 2016). 
Yang et al. (2014) aimed to uncover the components of serum that control 
glucocorticoid sensitivity using HeLa cells and synthetic reporter assays. The serum 
effect on glucocorticoid signalling required c-Jun (N)-terminal kinase (JNK)/ 
activating protein-1 activation and was modulated by serum cholesterol content.  
However, experiments examined the inhibitory effect of 50% serum compared to 10% 
serum and so the findings do not necessarily translate to the present thesis. 
Furthermore, charcoal stripping serum restored some glucocorticoid sensitivity and 
supplementing cholesterol impaired glucocorticoid action (Yang et al., 2014), whereas 
in the present study charcoal stripping serum did not restore glucocorticoid 
cytoprotection and glucocorticoid treatment in serum-free medium containing 30 
µg/ml cholesterol still protected cells against pyolysin. Future experiments using 
lipoprotein deficient serum might provide more insight into the role of lipids in the 
inhibitory effect of serum on glucocorticoid cytoprotection. 
Serum and glucocorticoids both regulate a wide range of genes and pathways (Iyer et 
al., 1999, Wang et al., 2004). Ideally a gene array would be used to thoroughly screen 
genes differentially regulated by serum and glucocorticoids to help uncover specific 
protective pathways activated in the cell types used in the present thesis. However, as 
this was beyond the scope of our project, we examined existing data available in the 
literature to identify possible targets. This helped identify the involvement of HMGCR 
as described above (section 6.2). Mitogen-activated protein kinase phosphorylation is 
also differentially regulated by glucocorticoids and serum. Glucocorticoids suppress 
MAPK activation whereas serum stimulates MAPK phosphorylation (Troppmair et 
al., 1994, Newton, 2014). Suppressing MAPK phosphorylation is at odds with the 
protective role of MAPK against damage by pore-forming toxins and so we did not 
consider its involvement in cytoprotection (Gonzalez et al., 2011, Kloft et al., 2009, 
Cassidy and O'Riordan, 2013). However, glucocorticoid receptor transcriptional 
activation can be selectively impaired by JNK and extracellular signal-regulated 
kinase 1 and 2 (ERK1/2) activation (Newton, 2014, Yang et al., 2014, Rogatsky et al., 
1998).  Therefore, future experiments might use inhibitors to explore whether serum-
induced MAPK phosphorylation impairs glucocorticoid cytoprotection.   
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Additionally, incubating cells in serum-free medium for 24 h is likely to cause a wide-
range of starvation-related phenotypes. It is unclear if glucocorticoid treatment just 
alters starvation responses, instead of serum activating transcriptional pathways that 
counteract the function of the glucocorticoid cytoprotective mechanism. Animal 
studies would be required to determine whether glucocorticoid cytoprotection would 
be relevant to non-starved cells in vivo. 
Although the presence of serum did not prevent side-chain oxysterol cytoprotection, it 
increased the concentration of 25-hydroxycholesterol required to completely protect 
bovine endometrial and HeLa cells against pyolysin. Furthermore, in a separate study 
the effective concentration of 25-hydroxycholesterol required to mobilize cellular 
cholesterol in CHO-7 was approximately 40-fold higher in the presence of serum 
(Abrams et al., 2020). Culturing cells in the presence of serum alters cholesterol 
homeostasis and is likely to interfere with the ability of treatments to adjust cholesterol 
accessibility (Brown and Goldstein, 1986). However, as oxysterol treatment still 
provided protection in the presence of serum it seems likely that this protection would 
translate to in vivo studies. Indeed, in the recent study by Zhou et al. (2020), pre-
injecting the dermis of mice with 25-hydroxycholesterol reduced the tissue damage 
induced by anthrolysin. 
6.4 CELL REPAIR AND CYTOPROTECTION 
Little is known about the intrinsic protection of cells against pore-forming toxins; 
however, cell repair is well documented. Several reparative processes were outlined in 
Chapter 1, such as membrane remodelling, MAPK activationand inflammasome 
activation (Andrews and Corrotte, 2018, Gurcel et al., 2006, Gonzalez et al., 2011), 
and these pathways are largely triggered by the changes to cytosolic ion concentrations 
caused by pore formation (Gekara et al., 2007, Kloft et al., 2009, Cabezas et al., 2017).  
Manipulating the concentration of calcium and potassium ions in the challenge 
medium effected the susceptibility of HeLa cells to pyolysin challenge. Cells were 
more susceptible to pyolysin when challenged in calcium free medium, possibly 
because a lack of calcium ion influx prevented the activation of repair pathways. On 
the other hand, impairing potassium ion efflux by challenging cells with pyolysin in 
high potassium medium appeared to reduce the susceptibility of cells to damage. This 
contradicts the belief that potassium efflux activates reparative pathways to reduce cell 
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damage (Kloft et al., 2009, Gonzalez et al., 2011). However, cholesterol-dependent 
cytolysins form large diameter pores and the high concentrations of pyolysin used in 
our experiments facilitate the rapid and excessive loss of cytosolic contents. Perhaps 
increasing extracellular potassium concentrations mediates the loss of intracellular ion 
concentrations. Nevertheless, side-chain oxysterols and glucocorticoid cytoprotection 
against pyolysin in HeLa cells was not dependent on ion concentrations in the 
challenge medium. 
Side-chain oxysterol and glucocorticoid treatment also appeared to prevent pyolysin 
pore formation, as demonstrated by reduced LDH and potassium ion leakage, 
suggesting that the cellular cytosolic contents remain stable. Additionally, both side-
chain oxysterols and glucocorticoids prevented MAPK phosphorylation, highlighting 
an absence of cell stress. Collectively, these findings suggest that the mechanisms of 
side-chain oxysterol and glucocorticoid cytoprotection are likely to be independent 
from cell repair mechanisms that are triggered by toxin-induced changes to cytosolic 
ion concentrations. However, it is possible that treatments could alter cytosolic ion 
concentrations and activate pro-survival pathways in advance of the pore-forming 
toxin challenge. Indeed, oxysterol treatment can trigger immediate calcium ion 
oscillations and this might help prepare the cell for the upcoming membrane 
perforation and increase the chance of survival (Mackrill, 2011).  
Cells can recover from pore-forming toxin damage by repairing damaged membrane. 
Plasma membrane blebs are typically generated by plasma membrane damage 
(Bischofberger et al., 2009). Blebbing human embryonic kidney cells are more likely 
to recover from streptolysin O damage (Babiychuk et al., 2011, Babiychuk et al., 
2009), however, their contribution to repair is contentious (Andrews and Corrotte, 
2018). It was assumed that pore-containing blebs are released from the injured 
membrane, allowing cells to reseal the plasma membrane, though they might just 
reflect reversible membrane remodelling. In the present thesis we quantified plasma 
membrane blebs to assess cell damage and examine whether blebbing contribute to 
side-chain oxysterol and glucocorticoid cytoprotection. Unfortunately, blebbing was 
not consistently visible in bovine endometrial epithelial and stromal cells.  Pyolysin 
challenge induced the formation of large plasma membrane blebs in HeLa cells. 
Challenges containing higher concentrations of pyolysin fragmented cells, and 
blebbing was no longer visible. The fact that dead cells do not produce blebs suggests 
236 
 
that it is an active process that might contribute repairing the membrane damage 
caused by lower pyolysin concentrations. However, treatment with side-chain 
oxysterols and glucocorticoids reduced blebbing and protected against cell 
fragmentation, indicating an absence of membrane damage, and suggesting that 
blebbing does not contribute to cytoprotection.  
6.5 LIMITATIONS 
Though the present thesis provided clear evidence that demonstrated the ability of side-
chain oxysterols and glucocorticoids to protect cells against pore-forming toxins, there 
were several key limitations to our findings. Firstly, we only examined protection 
against isolated pore-forming toxins, but this does not accurately represent bacterial 
infection. Bacteria secrete several additional virulence factors that also contribute to 
pathology (Jost and Billington, 2005, Chen et al., 2005). Experiments challenging cells 
with bacteria should be used to confirm whether side-chain oxysterol or glucocorticoid 
treatment can increase the tolerance of tissues to pathogenic bacteria. Examples of 
isolates that could be used to complement the bovine endometrial cell model include 
live T. pyogenes (MS249) and a plo-inactivated T. pyogenes mutant of the same strain. 
Alternatively, should cytoprotection extend to pneumolysin, Streptococcus 
pneumoniae (D39) could be utilised in a model alongside the lung cells from the 
present thesis. Furthermore, resilience to infection is achieved by resisting as well as 
tolerating pathogenic bacteria (Medzhitov et al., 2012, Schneider and Ayres, 2008). 
Although it seems likely that protection against toxins will increase tissue tolerance 
and reduce pathology, in vivo studies are required to determine how cellular protection 
interacts with other tolerance and resistance mechanisms to contribute to infection 
resilience.   
Secondly, although our experiments utilised two families of pore-forming toxins, 
protection remains to be explored against many other families (listed in Table 1.1). 
Critically, α-pore-forming toxins perforate plasma membranes in a different manner 
to β-pore-forming toxins (Cosentino et al., 2016). Future experiments challenging cells 
with a broader range of toxins would uncover the true extent of side-chain oxysterol 
and glucocorticoid cytoprotection.  
Although using mass spectrometry provided a novel insight into the presence of 
oxysterols in the bovine endometrium, we were limited by the number of replicates we 
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could analyse. Unfortunately, without additional replicates, our data is not sufficient 
to provide a reliable estimate for typical bovine ovarian follicular and uterine fluid 
oxysterol concentrations and simply highlights their presence. It is also possible that 
ovarian cycle stage and the presence of infection might alter oxysterol abundance, and 
both present possible avenues of future research.  
Additionally, Western blot is not the optimal method for measuring pyolysin binding. 
Though side-chain oxysterol treatment demonstrates a clear reduction in binding, 
experiments using glucocorticoids do not provide such clear results. The variability of 
the assay impairs the detection of more sensitive changes in binding. Furthermore, it 
does not provide any information with regards to the state and location of bound toxin. 
Perhaps glucocorticoid treatments cause the rapid internalization of pyolysin or 
prevent bound monomers from permeabilizing the membrane. Surface labelling cells 
with mutant pyolysin would allow more detailed observations and might be a focus of 
future studies.  
Finally, the concentrations of dexamethasone and hydrocortisone used throughout this 
thesis are unusually high and might limit their therapeutic potential. The EC50 of 
dexamethasone and hydrocortisone to the glucocorticoid receptor is typically as ~5 
nM and ~70 nM respectively (Novotna et al., 2012, Sedlak et al., 2011), but 10 µM 
dexamethasone or hydrocortisone was required to provide maximal protection in our 
studies. However, protection was still afforded by 0.1 µM dexamethasone or 
hydrocortisone in HeLa cells. Additionally, fluticasone propionate was protective at 
much lower concentrations (≥ 0.5 nM). Furthermore, throughout infection cells many 
cells are exposed to lower concentrations of toxin than those used to challenge cells in 
our in vitro experiments and lower concentrations of glucocorticoid treatment might 
still provide protection against these lower toxin concentrations. This variation in toxin 
concentrations during infection, along with other confounding factors located in the 
biological fluids that surround infected tissues, limits the relevance of the effective 
treatment concentrations determined in the present thesis of side-chain oxysterols as 
well as glucocorticoids. Therapeutic concentrations must be informed from future in 
vivo studies.  
238 
 
6.6 FUTURE APPLICATIONS  
The increased consumption and improper prescription of antimicrobials results in 
selective pressure that drives drug resistance in exposed bacteria (Fair and Tor, 2014). 
This drug resistance is an increasing global concern that compromises our ability to 
treat common infections, resulting in enduring illness and increased mortality (O'Neill, 
2016).   Antimicrobial therapy is the recommended course of treatment for most 
Staphylococcus and Streptococcus skin and soft tissue infections (Stevens et al., 2014). 
Horizontal gene transfer of antimicrobial genes between organisms has driven the 
development of S. aureus strains that are resistant to multiple antimicrobial 
compounds (Jensen and Lyon, 2009). Though S. pyogenes has remained susceptible to 
almost all classes of antibiotics (Blondeau et al., 1999, Alves-Barroco et al., 2020), 
there are reports of increased resistance to macrolides (Richter et al., 2005, Abraham 
and Sistla, 2018). Very few novel classes of antibiotics have been introduced in recent 
years, highlighting the requirement for alternative therapeutic options (Silver, 2011). 
Future research might examine the therapeutic potential of side-chain oxysterols, LXR 
agonists, and glucocorticoids. By protecting cells against streptolysin O and α-
hemolysin, side-chain oxysterols, LXR agonists, and glucocorticoids might increase 
the tolerance of tissues to S. aureus and S. pyogenes (and potentially other pathogenic 
bacteria that secrete pore-forming toxins), reduce disease severity, and decrease the 
reliance on antimicrobials.  
Glucocorticoids are regularly administered therapeutically to suppress inflammation; 
however, treatment is associated with complex adverse endocrine and 
immunosuppressive side-effects, spurring the development of selective glucocorticoid 
receptor agonists (Newton, 2014). As glucocorticoid cytoprotection was dependent on 
the glucocorticoid receptor, our work might guide drug design through the 
development of novel selective glucocorticoid receptor agonists that would also 
protect cells against pore-forming toxins, possibly providing another alternative to 
antimicrobials.  
Uterine disease remains a concern in cattle, causing pain, decreased milk yields, 
reduced fertility, and an annual global cost of over $2 billion (Fourichon et al., 2000, 
Haimerl and Heuwieser, 2014, Sheldon et al., 2009). The current use of antibiotics 
needs re-thinking as it does not resolve fertility issues (Haimerl and Heuwieser, 2014). 
Furthermore, several governments advise against the use of antibiotics in food 
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producing animals because of the threat of antimicrobial resistance (Rochford et al., 
2018). Uterine infections can be treated with the topical application of pharmaceutical 
molecules via an intrauterine infusion (Sheldon et al., 2009). Intrauterine infusion of 
side-chain oxysterols or synthetic LXR agonists could be used to limit the severity of 
uterine disease in postpartum animals by increasing the tolerance of the compromised 
endometrium to pathogenic bacteria that secrete pore-forming toxins. Alternatively, 
an attempt could be made to target the pre-existing abundance of oxysterols in the 
bovine endometrium. Alongside the enzymatic and nonenzymatic transformation of 
endogenous sterols, oxysterols can be derived from diet (Brzeska et al., 2016). 
Oxysterol concentrations are particularly high in processed or thermal treated food 
products. The most common dietary oxysterols are oxidative ring modifications (7-
hydroxycholesterol and 7-ketocholesterol), though side-chain oxidation products (19-
hydroxycholesterol, 20-hydroxycholesterol, 24-hydroxycholesterol, and 25-
hydroxycholesterol) are present in a smaller amount (Linseisen and Wolfram, 1998, 
Otaegui-Arrazola et al., 2010). Controlling the diet of cattle to adjust oxysterol 
concentrations in vivo might present a straightforward and economical method of 
reducing the severity of uterine disease. However, it is not clear whether manipulating 
dietary oxysterols would affect the concentration of oxysterols in the endometrium, or 
whether this might have other negative side-effects that compromise the health of the 
animal. Should targeting oxysterols to reduce the severity of uterine disease in cattle 
prove successful, then there is a potential for these principles to be applied to reduce 
the severity of disease caused by bacteria that secrete pore-forming toxins in other 
areas of the agricultural sector. 
6.7 CONCLUSION 
In summary, the present thesis aimed to explore methods of protecting eukaryotic cells 
against the damage caused by pore-forming toxins. The side-chain oxysterols 25-
hydroxycholesterol and 27-hydroxycholesterol protected bovine endometrial and 
human epithelial cells against pyolysin damage through a partially ACAT-dependent 
mechanism. Protection also extended to S. aureus α-hemolysin. Interestingly, the 
protective concentrations of 25-hydroxycholesterol and 27-hydroxycholesterol were 
similar to concentrations in the bovine uterus and ovary. Though the involvement of 
the liver X receptors in oxysterol cytoprotection was inconsistent, the synthetic LXR 
agonists T0901317 and GW3965 provided both bovine and human tissue cells with 
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moderate protection against pyolysin damage. Despite the fact that progesterone, 
oestradiol, and glucocorticoids did provide bovine endometrial cells with significant 
protection against pyolysin damage, glucocorticoids did increase the protection of 
human cells against pyolysin, streptolysin O and S. aureus α-hemolysin. This 
protection was dependent on the glucocorticoid receptor, de novo protein synthesis, 
and partially reliant on the expression of HMGCR. In conclusion, side-chain oxysterols 
and glucocorticoids increase the intrinsic protection of eukaryotic cells against pore-
forming toxins. These findings might be exploited to limit the severity of disease 
caused by pathogenic bacteria that secrete pore-forming toxins.  
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Médecine et Maladies Infectieuses, 39, 531-8. 
 
 
275 
 
VAN DE STOLPE, A., CALDENHOVEN, E., RAAIJMAKERS, J. A., VAN DER 
SAAG, P. T. & KOENDERMAN, L. 1993. Glucocorticoid-mediated 
repression of intercellular adhesion molecule-1 expression in human 
monocytic and bronchial epithelial cell lines. American Journal of Respiratory 
Cell and Molecular Biology, 8, 340-347. 
VAN MEER, G., VOELKER, D. R. & FEIGENSON, G. W. 2008. Membrane lipids: 
where they are and how they behave. Nature Reviews. Molecular Cell Biology, 
9, 112-124. 
VON LANGEN, J., FRITZEMEIER, K. H., DIEKMANN, S. & HILLISCH, A. 2005. 
Molecular basis of the interaction specificity between the human 
glucocorticoid receptor and its endogenous steroid ligand cortisol. 
ChemBioChem: A European Journal of Chemical Biology, 6, 1110-1118. 
WADA, T., KANG, H. S., JETTEN, A. M. & XIE, W. 2008. The emerging role of 
nuclear receptor RORα and its crosstalk with LXR in xeno- and endobiotic 
gene regulation. Experimental Biology and Medicine, 233, 1191-1201. 
WALEV, I., BHAKDI, S. C., HOFMANN, F., DJONDER, N., VALEVA, A., 
AKTORIES, K. & BHAKDI, S. 2001. Delivery of proteins into living cells by 
reversible membrane permeabilization with streptolysin-O. Proceedings of the 
National Academy of Sciences of the United States of America, 98, 3185-3190. 
WALEV, I., MARTIN, E., JONAS, D., MOHAMADZADEH, M., MULLER-
KLIESER, W., KUNZ, L. & BHAKDI, S. 1993. Staphylococcal alpha-toxin 
kills human keratinocytes by permeabilizing the plasma membrane for 
monovalent ions. Infection and Immunity, 61, 4972-4979. 
WALEV, I., RESKE, K., PALMER, M., VALEVA, A. & BHAKDI, S. 1995. 
Potassium-inhibited processing of IL-1β in human monocytes. The EMBO 
Journal 14, 1607-1614. 
WANG, B. & TONTONOZ, P. 2018. Liver X receptors in lipid signalling and 
membrane homeostasis. Nature Reviews. Endocrinology, 14, 452-463. 
WANG, D., ZHANG, H., LANG, F. & YUN, C. C. 2007. Acute activation of NHE3 
by dexamethasone correlates with activation of SGK1 and requires a functional 
glucocorticoid receptor. American Journal of Physiology. Cell Physiology, 
292, C396-404. 
WANG, J. C., DERYNCK, M. K., NONAKA, D. F., KHODABAKHSH, D. B., 
HAQQ, C. & YAMAMOTO, K. R. 2004. Chromatin immunoprecipitation 
(ChIP) scanning identifies primary glucocorticoid receptor target genes. 
Proceedings of the National Academy of Sciences of the United States of 
America, 101, 15603-15608. 
WANG, L., MITSUI, T., ISHIDA, M., IZAWA, M. & ARITA, J. 2017. Rasd1 is an 
estrogen-responsive immediate early gene and modulates expression of late 
genes in rat anterior pituitary cells. Endocrine Journal, 64, 1063-1071. 
 
276 
 
WANG, S., LI, W., HUI, H., TIWARI, S. K., ZHANG, Q., CROKER, B. A., 
RAWLINGS, S., SMITH, D., CARLIN, A. F. & RANA, T. M. 2020. 
Cholesterol 25-Hydroxylase inhibits SARS-CoV-2 and other coronaviruses by 
depleting membrane cholesterol. The EMBO Journal, 39, e106057. 
WANG, Y., KUMAR, N., CRUMBLEY, C., GRIFFIN, P. R. & BURRIS, T. P. 2010. 
A second class of nuclear receptors for oxysterols: Regulation of RORα and 
RORγ activity by 24S-hydroxycholesterol (cerebrosterol). Biochimica et 
Biophysica Acta, 1801, 917-923. 
WANG, Z., RONG, Y. P., MALONE, M. H., DAVIS, M. C., ZHONG, F. & 
DISTELHORST, C. W. 2006. Thioredoxin-interacting protein (txnip) is a 
glucocorticoid-regulated primary response gene involved in mediating 
glucocorticoid-induced apoptosis. Oncogene, 25, 1903-1913. 
WANNAMAKER, L. 1970. Medical progress: Differences between streptococcal 
infections of the throat and of the skin. The New England Journal of Medicine, 
282, 23-31. 
WEI, P., INAMDAR, N. & VEDECKIS, W. V. 1998. Transrepression of c-jun gene 
expression by the glucocorticoid receptor requires both AP-1 sites in the c-jun 
promoter. Molecular Endocrinology, 12, 1322-1333. 
WEIKUM, E. R., KNUESEL, M. T., ORTLUND, E. A. & YAMAMOTO, K. R. 2017. 
Glucocorticoid receptor control of transcription: precision and plasticity via 
allostery. Nature Reviews. Molecular Cell Biology, 18, 159-174. 
WESTERMANN, S., DRILLICH, M., KAUFMANN, T. B., MADOZ, L. V. & 
HEUWIESER, W. 2010. A clinical approach to determine false positive 
findings of clinical endometritis by vaginoscopy by the use of uterine 
bacteriology and cytology in dairy cows. Theriogenology, 74, 1248-1255. 
WILKE, G. A. & BUBECK WARDENBURG, J. 2010. Role of a disintegrin and 
metalloprotease 10 in Staphylococcus aureus alpha-hemolysin-mediated 
cellular injury. Proceedings of the National Academy of Sciences of the United 
States of America, 107, 13473-13478. 
WILLY, P. J., UMESONO, K., ONG, E. S., EVANS, R. M., HEYMAN, R. A. & 
MANGELSDORF, D. J. 1995. LXR, a nuclear receptor that defines a distinct 
retinoid response pathway. Genes and Development, 9, 1033-1045. 
WIPPEL, C., FORTSCH, C., HUPP, S., MAIER, E., BENZ, R., MA, J., MITCHELL, 
T. J. & ILIEV, A. I. 2011. Extracellular calcium reduction strongly increases 
the lytic capacity of pneumolysin from Streptococcus pneumoniae in brain 
tissue. The Journal of Infectious Diseases, 204, 930-936. 
WIRA, C. R., FAHEY, J. V., SENTMAN, C. L., PIOLI, P. A. & SHEN, L. 2005. 
Innate and adaptive immunity in female genital tract: cellular responses and 
interactions. Immunological Reviews, 206, 306-335. 
WIRA, C. R., RODRIGUEZ-GARCIA, M. & PATEL, M. V. 2015. The role of sex 
hormones in immune protection of the female reproductive tract. Nature 
Reviews. Immunology, 15, 217-230. 
277 
 
WITZENRATH, M., PACHE, F., LORENZ, D., KOPPE, U., GUTBIER, B., 
TABELING, C., REPPE, K., MEIXENBERGER, K., DORHOI, A., MA, J., 
HOLMES, A., TRENDELENBURG, G., HEIMESAAT, M. M., 
BERESWILL, S., VAN DER LINDEN, M., TSCHOPP, J., MITCHELL, T. J., 
SUTTORP, N. & OPITZ, B. 2011. The NLRP3 inflammasome is differentially 
activated by pneumolysin variants and contributes to host defense in 
pneumococcal pneumonia. Journal of Immunology, 187, 434-440. 
WOLFMEIER, H., RADECKE, J., SCHOENAUER, R., KOEFFEL, R., 
BABIYCHUK, V. S., DRUCKER, P., HATHAWAY, L. J., MITCHELL, T. 
J., ZUBER, B., DRAEGER, A. & BABIYCHUK, E. B. 2016. Active release 
of pneumolysin prepores and pores by mammalian cells undergoing a 
Streptococcus pneumoniae attack. Biochimica et Biophysica Acta, 1860, 2498-
2509. 
WU, Q., ISHIKAWA, T., SIRIANNI, R., TANG, H., MCDONALD, J. G., 
YUHANNA, I. S., THOMPSON, B., GIRARD, L., MINEO, C., BREKKEN, 
R. A., UMETANI, M., EUHUS, D. M., XIE, Y. & SHAUL, P. W. 2013. 27-
Hydroxycholesterol promotes cell-autonomous, ER-positive breast cancer 
growth. Cell Reports, 5, 637-645. 
WULF, M. & VOSS, A. 2008. MRSA in livestock animals-an epidemic waiting to 
happen? Clinical Microbiology and Infection, 14, 519-521. 
YAMAKAWA, T. & NAGAI, Y. 1978. Glycolipids at the cell surface and their 
biological functions. Trends in Biochemical Sciences, 3, 128-131. 
YAMAMOTO, K. R. 1985. Steroid receptor regulated transcription of specific genes 
and gene networks. Annual Review of Genetics, 19, 209-252. 
YANG-YEN, H. F., CHAMBARD, J. C., SUN, Y. L., SMEAL, T., SCHMIDT, T. J., 
DROUIN, J. & KARIN, M. 1990. Transcriptional interference between c-Jun 
and the glucocorticoid receptor: mutual inhibition of DNA binding due to 
direct protein-protein interaction. Cell, 62, 1205-1215. 
YANG, J., SATO, R., GOLDSTEIN, J. L. & BROWN, M. S. 1994. Sterol-resistant 
transcription in CHO cells caused by gene rearrangement that truncates 
SREBP-2. Genes and Development, 8, 1910-1919. 
YANG, N., CARATTI, G., INCE, L. M., POOLMAN, T. M., TREBBLE, P. J., HOLT, 
C. M., RAY, D. W. & MATTHEWS, L. C. 2014. Serum cholesterol selectively 
regulates glucocorticoid sensitivity through activation of JNK. The Journal of 
Endocrinology, 223, 155-166. 
YASIR, M., GOYAL, A., BANSAL, P. & SONTHALIA, S. 2018. Corticosteroid 
adverse effects, StatPearls Publishing, Treasure Island (FL). 
YEAGLE, P. L. 1985. Cholesterol and the cell membrane. Biochimica et Biophysica 
Acta, 822, 267-287. 
ZELCER, N., HONG, C., BOYADJIAN, R. & TONTONOZ, P. 2009. LXR regulates 
cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor. 
Science, 325, 100-104. 
278 
 
ZERBINATI, C. & IULIANO, L. 2017. Cholesterol and related sterols autoxidation. 
Free Radical Biology and Medicine, 111, 151-155. 
ZHANG, N., TRUONG-TRAN, Q. A., TANCOWNY, B., HARRIS, K. E. & 
SCHLEIMER, R. P. 2007. Glucocorticoids enhance or spare innate immunity: 
effects in airway epithelium are mediated by CCAAT/enhancer binding 
proteins. Journal of Immunology, 179, 578-589. 
ZHAO, X., LI, H., WANG, J., GUO, Y., LIU, B., DENG, X. & NIU, X. 2016. 
Verbascoside alleviates pneumococcal pneumonia by reducing pneumolysin 
oligomers. Molecular Pharmacology, 89, 376-387. 
ZHAO, X., LIU, B., LIU, S., WANG, L. & WANG, J. 2017. Anticytotoxin effects of 
amentoflavone to pneumolysin. Biological and Pharmaceutical Bulletin, 40, 
61-67. 
ZHOU, Q. D., CHI, X., LEE, M. S., HSIEH, W. Y., MKRTCHYAN, J. J., FENG, A. 
C., HE, C., YORK, A. G., BUI, V. L., KRONENBERGER, E. B., FERRARI, 
A., XIAO, X., DALY, A. E., TARLING, E. J., DAMOISEAUX, R., 
SCUMPIA, P. O., SMALE, S. T., WILLIAMS, K. J., TONTONOZ, P. & 
BENSINGER, S. J. 2020. Interferon-mediated reprogramming of membrane 
cholesterol to evade bacterial toxins. Nature Immunology, 21, 746-755. 
ZHU, L., OLSEN, R. J., LEE, J. D., PORTER, A. R., DELEO, F. R. & MUSSER, J. 
M. 2017. Contribution of secreted NADase and streptolysin O to the 
pathogenesis of epidemic serotype M1 Streptococcus pyogenes infections. The 
American Journal of Pathology, 187, 605-613. 
 
